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In industrialised countries age-related macular disease (ARMD) is the leading cause of visual 
loss in older people. Because oxidative stress is purported to be associated with an increased 
risk of disease development the role of antioxidant supplementation is of interest. Lutein is a 
carotenoid antioxidant that accumulates within the retina and is thought to filter blue light. 
Increased levels of lutein have been associated with reduced risk of developing ARMD and 
improvements in visual and retinal function in eyes with ARMD.  
The aim of this randomised controlled trial (RCT) was to investigate the effect of a lutein-based 
nutritional supplement on subjective and objective measures of visual function in healthy eyes 
and in eyes with age-related maculopathy (ARM) – an early form of ARMD. Supplement 
withdrawal effects were also investigated.  
A sample size of 66 healthy older (HO), healthy younger (HY), and ARM eyes were randomly 
allocated to receive a lutein-based supplement or no treatment for 40 weeks. The supplemented 
group then stopped supplementation to look at the effects of withdrawal over a further 20 
weeks. The primary outcome measure was multifocal electroretinogram (mfERG) N1P1 
amplitude. Secondary outcome measures were mfERG N1, P1 and N2 latency, contrast 
sensitivity (CS), Visual acuity (VA) and macular pigment optical density (MPOD).  
Sample sizes were sufficient for the RCT to have an 80% power to detect a significant clinical 
effect at the 5% significance level for all outcome measures when the healthy eye groups were 
combined, and CS, VA and mfERG in the ARM group. 
This RCT demonstrates significant improvements in MPOD in HY and HO supplemented eyes. 
When HY and HO supplemented groups were combined, MPOD improvements were 
maintained, and mfERG ring 2 P1 latency became shorter. On withdrawal of the supplement 
mfERG ring 1 N1P1 amplitude reduced in HO eyes. When HO and HY groups were combined, 
mfERG ring 1 and ring 2 N1P1 amplitudes were reduced.  In ARM eyes, ring 3 N2 latency and 
ring 4 P1 latency became longer. These statistically significant changes may not be clinically 
significant.  
The finding that a lutein-based supplement increases MPOD in healthy eyes, but does not 
increase mfERG amplitudes contrasts with the CARMIS study and contributes to the debate on 
the use of  nutritional supplementation in ARM.  
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The effect of nutritional supplementation on subjective and objective measures of visual 
function – a randomised controlled trial 
 
Chapter 1: Background 
1.1 Prevalence and incidence of age-related macular disease 
Age-related macular disease (ARMD) is the leading cause of visual loss in developed countries 
[1-4]. In Britain ARMD is a growing public health concern. Blind and partial sight registrations 
have increased in by approximately 30-40% over 40 years whereas registrations for cataract, 
glaucoma and optic atrophy have decreased [4]. The prevalence of ARMD will continue to 
increase as life expectancy increases [1, 5-7]. New ARMD treatments such as ranibizumab for 
slowing cell proliferation and reducing neovascularisation in ‘wet’ age-related macular 
degeneration (AMD), are costly to the National Health Service [8-10]. Government expenditure 
will also increase for managing ARMD as blind and partial sight registration, and years of lost 
working life rises. The psychological impact [11, 12] and reduced quality of life [13, 14]  that 
occur during the later stages of the disease are devastating to individuals and their relatives, 
giving greater impetus for the need to examine systems for earlier diagnosis and monitoring of 
ARMD, and investigate potential preventative ARMD measures.  
 
1.2 Retinal anatomy 
Age-related macular disease affects the retinal pigment epithelium (RPE), Bruch’s membrane, 
choriocapillaris and the photoreceptors which are located in the outer retina. The retina is a 
highly differentiated neuroectodermal tissue consisting of two distinct regions: the central retina 
(the macula) which is specialised for detailed vision, and the peripheral retina. The human retina 
is comprised of three layers of nerve cell bodies and two layers of synapses [15] (figure 1.1). 
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Figure 1.1: Section through the human eye with a schematic enlargement of the retina (Source - 
Webvision, http://webvision.med.utah.edu/imageswv/Sagschem.jpeg with permission). 
 
The outer nuclear layer contains photoreceptor cell bodies. The inner nuclear layer contains 
bipolar, horizontal and amacrine cell bodies. The ganglion cell layer contains ganglion cells and 
displaced amacrine cells [15].  
 
1.3 Structure and function of the photoreceptors 
Within the human retina there are two types of photoreceptors – rods and cones. There are 
approximately 92 million rods, predominantly found at the periphery of the retina, which 
contain the visual pigment rhodopsin and are required for night vision. There are approximately 
4.6 million cones found predominantly in the macula which contain the red, green or blue opsin 
pigments necessary for colour vision and sharp visual acuity [16]. These visual pigments are 
located within the outer segment discs (figure 1.2) of the photoreceptors and are essential for 
light absorption. Photoreceptors are continually exposed to oxygen, and when they are exposed 
to light, free radicals are produced which over time cause injury to the photoreceptor discs. 
Photoreceptor outer segment discs consist of approximately 50% of polyunsaturated fatty acids 
(docosahexaenoic acid or DHA) with the remaining 50% comprising of proteins [17]. 
Photoreceptors selectively uptake DHA which is used to make new disc membranes [18]. 
Photoreceptor inner segments contain mitochondria and the necessary processes for transport of 
molecules to the outer segment and axonal parts of the cell. The inner segments form junctions 
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with the Müller cells and together comprise the outer limiting membrane. Photoreceptor basal 
axonal processes synapse with bipolar and horizontal cells (figure 1.1).  
Figure 1.2: Schematic diagram of a cone photoreceptor (source - author’s own). 
 
1.4 The RPE, Bruch’s membrane and choriocapillaris 
The RPE plays a central role in regulating the environment surrounding the photoreceptors 
where phototransduction occurs [19]. Each RPE cell underlies approximately 30 photoreceptor 
cells. The RPE cell apical processes diurnally phagocytose the shed outer segments of 
photoreceptors allowing for constant turnover of photoreceptor membrane discs [20].  The RPE 
consists of a non-renewing monolayer of cuboidal-shaped cells, of which the apical surface is 
positioned next to the photoreceptors and the basal surface is situated adjacent to the collagen-
rich Bruch’s membrane. The correctly functioning RPE provides an outer blood-retinal barrier 
as RPE cell plasma membranes, linked by tight junctions, selectively allow nutrient and waste 
product exchange between the ocular vascular beds and retinal tissues, and prevents leakage of 
macromolecules and other potentially harmful products into the retina [21].  
 
An abundance of melanosomes give the RPE its pigment which allows for the absorption of 
stray light – essential for image sharpness by minimising light scatter [22]. Within the visual 
cycle the RPE is involved in the retinoid processing cycle in the renewal of 11-cis retinal as all-
Plasma membrane 
Disc
s Cytoplasmic space 
Cilium 
Mitochondria 
Nucleus 
Synaptic vesicles 
Outer segment 
Inner segment 
Synaptic terminal 
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trans retinal is transported to the RPE and re-isomerized into 11-cis retinal which is transported 
back to the photoreceptors and combined with opsin. Retinal pigment epithelial cells reduce 
uniformly over time with increasing age within the retina, at a greater rate equatorially 
compared to centrally [23]. Melanosome number also consistently decreases with increasing 
age, possibly through the damaging effects of blue light irradiation [24].  
 
Bruch’s membrane lies between the RPE and choriocapillaris. It provides a semi-permeable 
filtration barrier through which major metabolic transfer occurs [25]. It consists of five layers – 
the basement membrane, inner collagen fibre layer, elastic fibre sheet, collagen fibre layer and 
the basement membrane of the capillary endothelial cells of the choriocapillaris [26].  
 
The choriocapillaris is directly adjacent to Bruch’s membrane and comprises of an intricate 
network of blood vessels which provide oxygen and nutrients to the RPE. It is among the most 
highly perfused tissues in the body [27]. Choriocapillaris density decreases and Bruch’s 
membrane thickens with increasing age [28] and an ageing Bruch’s membrane has been shown 
to decrease RPE phagocytosis [29]. 
 
1.5 The macula 
The macula is defined as the portion of the posterior retina that contains xanthophyll and two or 
more layers of ganglion cells [30]. This region is approximately 6 mm in diameter and consists 
of two areas. The cone-dominated fovea is a depression in the inner retinal surface in the centre 
of the macula measuring 0.8mm in diameter. The parafovea encircles the fovea and is 
dominated by rod photoreceptors thus the macula overall has a larger cone concentration 
compared to the remainder of the eye but is not cone-dominant [16]. The central floor of the 
fovea is called the foveola and this is 0.35 mm thick. The foveola lies within a capillary free 
zone and thus has no retinal circulation [30]. The rod to cone ratio in the macula is 9:1 
compared to the overall retina where it is 20:1[16].   
 
The macula contains the xanthophyll carotenoids lutein (L), zeaxanthin (Z) and meso-
zeaxanthin (MZ) which give the macula its characteristic yellow colour when observed on 
fundoscopy. Together, these carotenoids are termed macular pigment (MP) [31]. The ratio of L 
to Z is 1:2.4 in the central 0-0.25mm of the retina, to over 2:1 in the peripheral 8.7-12.2 mm of 
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the retina which is linearly correlated with the rod:cone ratio [32]. Meso-zeaxanthin is thought 
to be converted in the retina from L [33].  
 
1.6 Age-related macular disease (ARMD) 
Age-related macular disease is a degenerative disease of the macula, most common over the age 
of 50 years [34]. It is the leading cause of visual loss within western industrialised countries [1, 
2, 4]. The number of blind registrations attributable to the disease increased by 30-40% between 
1950-1990 in Britain [4] and cases each year are continuing to rise [1, 6, 7] as these populations 
have an increasing longevity. The RPE, Bruch’s membrane, photoreceptors and choriocapillaris 
are affected in ARMD.  
     
1.7 Definition of ARMD 
The international age-related maculopathy group has defined an international classification 
system for quantifying and defining the different subgroups of ARMD in an attempt to permit 
easier comparison of research findings between groups [34]. 
 
Age-related maculopathy (ARM) as defined by the international age-related maculopathy group 
is a disorder of the macular area, most apparent after age 50 and is characterised by areas of: 
 Drusen which are external to the neuroretina and RPE. They are soft and distinct or soft 
and indistinct. Hard drusen are not characteristic of ARM.   
 Hyperpigmentation in the outer retina or choroid with drusen. 
 Hypopigmentation of the RPE with drusen. 
 
This early stage of the condition may not affect vision, but can predispose patients to visual loss 
(see figure 1.3 below).  
 
Later stages of the condition are classified by the international age-related maculopathy group 
age-related macular degeneration (AMD). This form of the disease can occur with or without 
the involvement of new blood vessel growth. If new vessels are not involved, (non-exudative or 
dry AMD), clinical presentation is a sharply defined round or oval area of hypopigmentation 
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where choroidal vessels are more visible than the surrounding area, with a diameter greater than 
175μm [34] (figure 1.4). This is also known as geographic atrophy (GA).  
 
The term ‘wet AMD’, also termed disciform AMD, exudative AMD or neovascular AMD refers 
to the involvement of neovascularisation (figure 1.5) and has numerous manifestations: 
 Choroidal neovascularisation (CNV) 
 RPE detachment(s) 
 Subretinal or sub-RPE neovascular membrane(s) 
 Deposition of scarring, glial tissue or fibrin-like material within the epiretinal, 
intraretinal, subretinal or sub-RPE layers 
 Subretinal haemorrhages (without other retinal vascular cause) 
 Hard exudates (formed from lipid) associated with the above manifestations (without 
other retinal vascular cause).  
 
 
Figure 1.3: ARM showing drusen.             Figure 1.4: AMD with GA. 
                 
      Figure 1.5: Exudative AMD. 
 
(Source – figures 1.3, 1.4 author’s own photos, figure 1.5 Webvision with permission). 
In accordance with the international classification system the term ARMD will be used to 
encompass both ARM and AMD for the purposes of this thesis. 
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1.8 Physiology of ARMD 
The RPE rests on Bruch’s membrane and separates the neural retina from the choriocapillaris. 
The RPE phagocytoses the outer segment discs of the photoreceptors and is a point of 
metabolite and waste exchange, which is considered crucial to retinal function [21]. The initial 
signs of ARMD are variations within and below the RPE, seen as alterations in the pigmentation 
of the RPE, with or without the occurrence of drusen [35]. Drusen are discrete white-yellow 
spots containing abnormal extracellular lipoprotein deposits which accumulate between the RPE 
basal lamina and the inner collagenous layer of Bruch’s membrane [36]. Within the ageing eye 
a build up of lipofuscin granules can be seen in the RPE [37], possibly caused by a reduced 
ability of the RPE’s phagocytic-lysosomal system to efficiently digest photoreceptor outer 
segment membranes [38], leading to an accumulation of lipids from this material in Bruch’s 
membrane reducing membrane permeability. This in turn may interrupt the supply of nutrients 
from the choroid to the retina ultimately leading to photoreceptor atrophy [39]. Oxidative stress 
causes injury and inflammation to the RPE and choriocapillaris affecting nutrient supply to the 
RPE and retina, possibly thus further damaging the RPE and retina, leading to the retinal 
atrophy seen in the later stages of ARMD [40].  
 
1.9 Aetiology of ARMD 
Although the precise aetiology of ARMD is currently unknown there are several hypotheses that 
have been postulated:  
 
Oxidative stress 
Ageing is associated with cumulative oxidative damage [41]. The retina is constantly under high 
oxygen tension and is thus susceptible to this damage.  Reactive oxygen intermediates (ROI), a 
term used to describe hydrogen peroxide, singlet oxygen and free radicals, are synthesized as 
by-products of phototransduction and cell metabolism [42]. Phagocytosis of photoreceptor outer 
segments by the RPE produces ROIs, increasing oxidative stress. Outer segments of 
photoreceptors contain polyunsaturated fatty acids (PUFA) and vitamin A. Under high oxygen 
tension and light irradiation the outer segments undergo lipid peroxidation, especially within the 
macular area [43]. Light irradiation induces photoreceptor damage [44]. It has been suggested 
that lipid peroxidation may be involved in the cause of light induced retinal degeneration [45]. 
A healthy RPE is required for the correct functioning of the retina [46] but RPE changes occur 
with age as lipofuscin granules accumulate within RPE cells. Lipofuscin is composed of vitamin 
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A metabolites and lipid peroxides, and is constantly exposed to visible light (400-700nm) and 
high oxygen tension (~70mmHg) which cause reactive oxygen species synthesis and possible 
RPE membrane damage [47]. Lipofuscin accumulates in the human RPE from approximately 20 
years of age and continues throughout life [48]. Lipofuscin is a photosensitizer that may 
increase the risk of retinal photodamage and contribute to the development of ARMD [49]. 
There are differing thoughts as to whether RPE melanosomes provide a protective effect to the 
RPE by scavenging reactive free radicals [50].Therefore their decline within the RPE with 
increasing age [24] may reduce free radical scavenging by these cells. However an increase in 
phototoxic melanin-lipofuscin complexes (melanolipofuscin) also occur with increasing age and 
may have a detrimental effect to the RPE as their accumulation more closely reflects the onset 
of AMD than lipofuscin accumulation alone [51].  
 
Genetics 
Several genes have been associated with an increased risk of developing ARMD and have been 
verified in further studies [52]. The LOC387715 variant [53] and complement factor H gene 
polymorphisms (Y402H) predispose individuals to an increased risk of developing ARMD [54]. 
Protective genes have also been identified such as the complement factor B and complement 
component 2 gene, although current knowledge is rudimentary and continued genetic research 
may yield further information [55]. Although the extent of heritability and the number of genes 
involved in ARMD is presently unknown [56] there has been evidence to suggest increased risk 
of disease development with a positive family history of the disease [57-60]. It appears likely 
that a combination of exposure to environmental stimuli and genetic predisposition to ARMD 
are implicated in the pathogenesis of the disease [4, 61].  
 
Deterioration of Ruysch’s complex 
Ruysch’s complex consists of the RPE, Bruch’s membrane and choriocapillaris. The hydraulic 
conductivity of Bruch’s membrane reduces with increasing age [35, 62, 63]. Bruch’s membrane 
collagen solubility decreases with increasing age, particularly at the posterior pole, and is 
thought to interfere with the function of the RPE [64] whose cell attachment rates are decreased 
on an aged Bruch’s membrane [65]. Cross-linking of collagen fibres within Bruch’s membrane 
increases with increasing age and a rise in UV absorbance and fluorescence also occurs within 
the membrane [66].  
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In ARMD deposition of long-space collagen and basement membrane proteins can be observed 
between the RPE plasma membrane and RPE basement membrane [67]. These deposits are 
termed basal laminar deposits (BlamD). Basal linear deposits (BlinD) are found between the 
basement membrane of RPE cells and Bruch’s membrane mostly comprising of membranous 
debris [68]. Histopathologically ARMD is characterized by occurrence of both deposits [68, 
69]. The presence of BlamD is strongly associated with the presence of AMD [70] which 
compromises photoreceptor cell function [71] and BlinD are also specific for AMD [68]. 
Histopathological studies have correlated BlamD with CNV [72, 73] and a severely 
compromised RPE [67].  
 
With increasing age Bruch’s membrane progressively accumulates lipid content [25, 74] and 
fluid diffusion is slowed [62]. It is thought that the debris within Bruch’s membrane is derived 
from RPE metabolic activity [25] and this rise in lipid and protein quantity within Bruch’s 
membrane reduces permeability, thus impeding flow of macromolecules between the RPE and 
choroid [75]. This may lead to slowed regeneration of photopigment due to retinoid deficiency, 
ultimately causing photoreceptor loss [76]. Bruch’s membrane thickens with increasing age, 
[77] which is associated with a decline in phagocytosis of photoreceptor outer segments by RPE 
cells [78] and increases the distance for oxygen transport between the choriocapillaris and outer 
retina, reducing the oxygen to the outer retina [79]. In the normally functioning RPE, vascular 
endothelial growth factor (VEGF) and pigment-epithelium derived factor (PEDF) proteins are 
optimally balanced within the RPE, with PEDF being an antagonist of VEGF. Oxidative stress 
and the accumulation of deposits within the RPE and Bruch’s membrane may disrupt this 
balance [80, 81] contributing to the development of CNV [82-84]. The build up of debris within 
the RPE and Bruch’s membrane is thought to trigger a chronic inflammatory response within 
the area and activation of the complement system which can result in chronic cellular damage 
[40]. 
 
There is evidence to suggest that choroidal circulation attenuation may play a role in the 
development of ARMD. Ninety percent of the oxygen requirement of the photoreceptors is 
provided by the choroidal circulation [85] and reduced choroidal blood flow has been associated 
with ARMD [86, 87]. Choriocapillaris density and lumen diameter reduce with age [28], which 
may decrease oxygen to the RPE and photoreceptors, and reduce clearance of waste products 
from Bruch’s membrane, leading to its thickening with age [40]. Retinal hypoxia increases the 
release of VEGF within Ruysch’s complex leading to CNV [88]. Vascular deficits are further 
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advanced in AMD [89] with a linear relationship between reduced choroidal blood flow and 
increased risk for development of CNV [90]. Retinal hypoxia drives the synthesis of VEGF 
which gives rise to the angiogenesis seen in CNV [91]. 
 
1.10 Risk Factors for ARMD 
Although the pathogenesis of ARMD is still not fully understood genetic predilection together 
with environmental factors are implicated. Epidemiological studies have found conflicting 
findings between ARMD development and many potential risk factors. An in-depth account of 
all modifiable and non-modifiable risk factors associated with ARMD development has been 
accepted for publication and can be found in appendix 1.  
 
Age, smoking and genetic factors appear to be consistently associated with an increased risk of 
developing ARMD. However, ageing and genetic disposition cannot be currently modified, 
leading to increased interest as to how other modifiable factors may reduce the risk of ARMD.  
 
Nutrition as a risk factor for developing ARMD 
Some research has found an association between certain nutrients and reduced risk for ARMD 
development (table 1.1). The first National Health and Nutrition Examination Study (NHANES) 
found dietary vitamin A provides a protective effect against AMD with no beneficial effect 
shown with vitamin C [92]. The Beaver Dam eye study found no association between vitamins 
A, C and E and reduced risk of developing ARM [93]. Another study of serum lycopene in the 
Beaver Dam eye study showed an increased risk of ARMD with reduced lycopene levels [94]. 
However, lower levels of L, Z and vitamin E were not related to an increased risk for ARMD 
development in this study. Conversely higher serum alpha tocopherol (a form of vitamin E) and 
an antioxidant index including ascorbic acid (a form of vitamin C), alpha tocopherol and beta 
carotene (a form of vitamin A), were found to be conducive to lower ARMD risk in the 
Baltimore longitudinal study [95]. The Physicians Health study and the Blue Mountains eye 
study did not find a protective effect for vitamin C, E and multivitamins [96], and vitamin E and 
beta carotene [97] against ARMD respectively. The Eye Disease Case Control Study (EDCCS) 
found a reduced risk of neovascular AMD with higher serum and dietary carotenoid levels [98]. 
An antioxidant index combining selenium, vitamin C, vitamin E and carotenoids also showed 
reductions in risk in this study. A further study from the EDCCS reported that spinach and 
collards, high in the carotenoids lutein (L) and zeaxanthin (Z), were most strongly associated 
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with a reduced risk for AMD (p<0.001) [99]. The carotenoids L and Z together make up 
macular pigment (MP). They are lipid soluble antioxidants, not produced within the body and 
only obtained through diet [31]. Collard greens are various loose-leafed vegetables of Brassica 
oleracea, the same species that produces cabbage and broccoli. They are genetically similar to 
kale and spring greens. High-dose vitamins C, E beta carotene and zinc were found to be 
effective in lowering the odds ratio of developing advanced AMD in eyes with intermediate 
drusen, large drusen and non-central GA in a large trial undertaken by the AREDS group [100]. 
Improvements in visual function in eyes with ARM or non-exudative AMD were reported in 
several studies involving carotenoids [101-104]. 
 
High levels of omega-3 fatty acid consumption (>75 percentile) have been shown to provide a 
protective effect against progression to AMD [105]. Lowering the dietary glycaemic index with 
higher omega-3 intake also showed a reduction in AMD progression in this study. The benefits 
of a low glycaemic diet in reducing ARM risk have been identified in other studies [105-107]. 
The Blue Mountains eye study found a lower risk of developing ARM when consuming omega-
3 fatty acids in the form of one serving of fish per week [108]. Consumption of linoleic acid in 
the form of 1 to 2 servings of nuts per week was also associated with reduced ARM risk in this 
study. The AREDS study found a reduction in risk of progression from drusen to geographic 
atrophy in those with the highest dietary intake of omega-3 fatty acid [109] and reduced risk of 
developing neovascular AMD [110, 111]. It is thought that omega-3 provides a protective role 
within the retina by inhibiting oxidative stress and reducing inflammation within the retina 
[112].  
 
Association between higher trans-unsaturated fat intake and increased prevalence of AMD was 
reported in a large study of 6734 participants [113]. Omega-3 fatty acids and olive oil were 
associated with a reduced prevalence of ARM and AMD in this study. However, the third 
NHANES results showed no association between dietary fat intake and ARM risk in 7883 
participants [114] and this was echoed in 3654 participants from the Blue Mountains eye study 
[115]. Studies of mouse retinae have shown an increase in the accumulation of basal laminar 
deposits when consuming a high fat and cholesterol diet [116]. Some studies have shown that 
diets higher in fats have a propensity to be lower in essential nutrients and antioxidants [93, 
117]. 
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Table 1.1: Dietary supplementation and ARMD risk 
Study Cohort sizes Study design Dietary component 
assessed  
 Outcome 
Beaver Dam eye 
study [118] 
n = 1968 Retrospective longitudinal 
cohort design 
Zinc, carotenoids, 
vitamin C, E 
Higher zinc = lower ARM risk (odds ratio 
0.6) 
Mares-Perlman et 
al.,[94] 
n = 127 ARM, 9 GA, 
31 AMD, 167 controls 
Nested case-control study 
within a population-based 
cohort 
Carotenoids, tocopherols  Low lycopene = higher ARMD risk (odds 
ratio 2.2) 
Baltimore 
longitudinal study 
[95] 
n = 976 Retrospective and 
prospective longitudinal 
design 
α-tocopherol, β-carotene, 
ascorbic acid 
Protective effect of combined plasma levels 
of α-tocopherol, β-carotene, ascorbic acid 
against ARMD. Protective effect for ARMD 
with high plasma α-tocopherol levels (no odds 
ratio given) 
Blue Mountains eye 
study [97] 
n = 156 Case-controlled design α-tocopherol, β-carotene No protective effect of α-tocopherol or β-
carotene against ARM 
Eye disease case 
control study [98] 
n = 421 AMD, 615 
controls 
Case-control design Vitamin C, E, 
carotenoids, selenium 
Protective effect of combined nutrients 
against AMD (no odds ratio given) 
Seddon et al., [99] n = 356 AMD, 520 
controls 
Case-control design Carotenoids, vitamin 
A,C,E 
Higher carotenoids = lower risk of AMD 
(odds ratio 0.57)  
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Table 1.1 continued 
Study Cohort sizes Study design Dietary component 
assessed  
 Outcome 
Age-related eye 
disease study [100] 
n = 3640 Double-masked, 
prospective, clinical trial 
Vitamin C, E, β-carotene, 
zinc 
Vitamin C, E, β-carotene, zinc = reduced 
progression from ARM (and non-central GA) 
to AMD (odds ratio 0.72) 
Chiu et al., [105] n = 2924 Observational study Docosahexaenoic acid 
(DHA), eicosapentaenoic 
acid (EPA) 
 Higher DHA = lower progression of ARM to 
AMD (hazard ratio 0.73) 
Blue Mountains eye 
study [108] 
n = 2454 Observational study Omega-3, linoleic acid Higher omega-3 = reduced risk of incident 
ARM (relative risk 0.69), higher linoleic acid 
= reduced risk of incident ARM (relative risk 
0.65) 
Age-related eye 
disease study [109] 
n = 2132 Prospective cohort study DHA, EPA Higher DHA and EPA = reduced risk of 
progression from ARM to GA (odds ratio 
0.45) 
Age-related eye 
disease study [110] 
n = 4519 Cohort study Omega-3 Omega-3 inversely associated with CNV 
(odds ratio 0.61) 
Chong et al., [113] n = 6734 Cohort study Omega-3, olive oil Omega-3 (odds ratio 0.85) and olive oil (odds 
ratio 0.48) associated with reduced risk of 
progression to AMD  
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Table 1.1 continued 
Study Cohort sizes Study design Dietary component 
assessed  
 Outcome 
Mares-Perlman et al., 
[119] 
n = 8222 Prospective cohort study Lutein and zeaxanthin Higher levels of lutein and zeaxanthin = 
lower odds for pigmentary changes (odds 
ratio 0.1) 
Age-related eye 
disease study [120] 
n = 4159 Prospective cohort study Lutein and zeaxanthin, 
vitamin A,C,E 
Lutein and zeaxanthin intake was inversely 
associated with CNV (odds ratio 0.65), GA 
(odds ratio 0.45) and large or extensive 
drusen (odds ratio 0.73) 
Pathologies oculaires 
liees a l’age [121] 
n = 2584 Prospective cohort study Retinol, ascorbic acid, α-
tocopherol 
Higher α-tocopherol = decreased risk for 
ARM (odds ratio 0.72) 
Van Leeuwen et al., 
[122] 
n = 4170 Prospective cohort study Vitamin C, E, β-carotene 
and zinc 
Vitamin C E, β-carotene and zinc levels  
associated with a 35% reduced risk of ARMD 
hazard ratio 0.65)  
 
34 
 
1.11 The role of nutritional supplementation in ARMD 
Currently there are limited treatments available for delaying the course of ARMD and these are 
discussed in appendix 2. Because oxidative stress may be a factor in the pathogenesis of 
ARMD, the function of antioxidant supplementation in this disease is of interest. Current 
recommendation for the treatment of ARMD includes nutritional supplementation with 
antioxidants, vitamins and zinc in eyes with extensive intermediate drusen,  one large druse or 
noncentral GA in one or both eyes, or if one eye has AMD [100].  
 
The carotenoids L and Z together make up MP. They are lipid soluble antioxidants, not 
produced within the body and only obtained through diet [31]. Within the central fovea, MP is 
most concentrated within the photoreceptor axons and is also found in the inner plexiform 
layers external to the foveola [123]. It is also located in the fibres of Henle which largely consist 
of cone axons (Henle f.l. in figure 1.6) the fovea, the inner nuclear layer at the parafoveal area 
[124] in the RPE and choroid [125]. Tubulin is a protein located in cone photoreceptor 
cytoskeletons, which selectively binds to L and Z [126]. Macular pigment reduces with 
eccentricity to optically undetectable levels at six to eight degrees [127]. Zeaxanthin is more 
concentrated than L at the centre of the fovea with the situation reversed towards the peripheral 
retina [128]. Lutein and Z, and hence MP, are thought to reduce oxidative damage by filtering 
short wavelength blue light within the macula [123] and by quenching light-induced singlet 
oxygen and related free radicals [129]. 
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Figure 1.6: A cross section through the monkey fovea demonstrating anatomy of the central 
retina – source Webvision, http://webvision.med.utah.edu/imageswv/monkfov.jpeg (with 
permission).GCL = ganglion cell layer, IPL = inner plexiform layer, INL = inner nuclear layer, 
OPL = outer plexiform layer, Henle f.l. = Henle fibre layer. 
 
 
Relationships between AMD and low levels of L and Z concentrations within the body have 
been discovered [99, 130] and high intake of foods rich in L and Z are associated with a 
decreased likelihood of developing ARMD [119, 120]. Lutein supplementation has been 
correlated with improved visual function in healthy eyes and eyes with ARMD [101, 102, 104, 
131-134].  Indeed, it has been suggested that increasing retinal antioxidants may improve the 
function of damaged photoreceptors [135].  
 
Vitamin E, another antioxidant, is located in the photoreceptor outer segments [136] which may 
also provide some protective effect on the retina [137]. Alpha-tocopherol is the form of vitamin 
E that is preferentially absorbed and accumulated in humans [138]. Its deficiency is linked with 
damage of the retina [139], an increase in RPE accumulation of lipofuscin [140] and an increase 
in lipid peroxidation [136]. Vitamin E supplementation has improved the survival of 
photoreceptor cell nuclei in the retinae of a rat strain developed by the Royal College of 
Surgeons [141]. Rats deficient in vitamin E showed attenuation of the flash electroretinogram 
with reduced a- and b-wave amplitudes and delayed latencies [142]. A significant protective 
effect of alpha-tocopherol against the risk of developing ARMD was shown in a study of 226 
cases of ARMD [143] and in the Pathologies Oculaires Liees a l'Age (POLA) study, although 
36 
 
this association was not found in other studies [94, 97]. Lipofuscin formation has been shown to 
decrease in rabbit and bovine RPE cells when supplemented with vitamin E [144]. Mice fed on 
a vitamin E deficient diet had accelerated degenerative changes in the retina compared to mice 
on vitamin E supplemented diets [145].  
 
Vitamin C or L-ascorbic acid was found to reduce oxidative stress within rat retinae by 
inhibiting oxidation of rod outer segment membrane lipids during intense light which reduced 
photoreceptor cell loss [146].  Reduced phototoxic injury was also demonstrated in rat retinae in 
a more recent study when vitamin C was administered [147]. Ascorbic acid deficiency was also 
shown to increase oxidative stress in guinea pig retinae [148]. Vitamin C combined with 
vitamin E, carotenoids and selenium showed a significant association with a decreased 
likelihood of neovascular AMD in the EDCCS [130]. Another study assessing supplementation 
with vitamin C, vitamin E, zinc and beta-carotene found a 35% reduced risk of developing 
ARMD [122]. The POLA study found no association between vitamin C serum levels and 
reduced risk for ARMD development [121].Vitamin C was shown to protect against hypoxia 
induced cell apoptosis in bovine RPE cells [149].  
 
Beta-carotene, a precursor to vitamin A has been linked with an increased risk of lung cancer in 
smokers [150] and is not included in the nutritional supplementation used for this study. 
However it has been found to provide a reduced risk in the progression of AMD when 
combined with zinc, vitamin C and vitamin E in a randomised controlled trial undertaken by the 
Age-related Eye Disease Study (AREDS) group [100]. This large scale study of 3640 
participants showed that those with extensive intermediate drusen, large druse or non-central 
GA in 1 or both eyes, or advanced AMD in 1 eye should consider taking a high-dose 
supplement with vitamin C and E, beta carotene and zinc. A protective effect of beta-carotene, 
ascorbic acid and alpha-tocopherol against risk of developing ARMD was found in another 
study of 226 cases of ARMD [143]. However a protective effect of beta-carotene was not 
demonstrated in a further study [97]. The Blue Mountains eye study reported an increased risk 
of incident neovascular AMD associated with higher beta-carotene intake [151].  
 
Docosahexaenoic acid (DHA) is a dietary omega-3 long chain polyunsaturated fatty acid 
(LCPUFA) from fish oil that cannot be made by the body but can only be obtained through the 
diet. It is located in the outer segment membranes of retinal photoreceptors [112] and is 
important for maintaining photoreceptor outer segment membrane fluidity [152]. Rod and cone 
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photoreceptors uptake DHA which is used as a building block for producing outer segment 
discs [18]. Increased intake of polyunsaturated fatty acids has been linked with a reduced 
incidence of ARM and reduced risk of progression from ARM to advanced AMD [108-111, 
113, 115]. It is thought that omega–3 LCPUFAs may protect the retina against damage from 
ischaemia, light, oxygen, age and inflammation [111]. Neuroprotectin D1 is a bioactive product 
of DHA which protects RPE cells from oxidative stress [153]. Deficiency in DHA may lead to 
reduction in rod sensitivity and recovery with age [154]. Rhesus monkey retinas deficient in 
essential fatty acids have been shown to have abnormal full field electroretinograms (ffERG) 
with delayed rod implicit times and rod recovery [154]. The Inuit population have a diet high in 
fish oil, although paradoxically, the incidence of ARM and AMD was found to be higher in this 
population than in most other populations studied [155]. The authors did not provide possible 
mechanisms for the higher incidence of ARM and AMD in this study. The Inuit diet has been 
shown to have low fruit and vegetable consumption, giving rise to dietary deficiencies in 
antioxidants [156], which as already discussed, may be linked with an increased risk for 
developing ARMD. 
 
Copper and zinc are trace minerals that are essential for retinal health. Oral supplementation of 
zinc oxide and copper was shown to reduce the risk of progression to advanced AMD in eyes 
with extensive intermediate drusen, large drusen, non-central GA and in fellow eyes of 
participants with AMD in one eye (p = 0.009) [100]. Zinc content in the macular RPE is 
reduced in ageing and ARMD [157]. It is found throughout the retina [158] and in the synaptic 
terminals of the photoreceptors which when released from the synapse, may modulate 
photoreceptor activity in vertebrates [159, 160]. Reduced zinc serum levels have been 
associated with AMD [161]. In the rat retina reduced zinc has been associated with increased 
oxidative stress [162] which, in the human retina, is associated with an increased risk for 
ARMD development. Excessive zinc consumption can lead to copper deficiency and thus 
copper is often found in supplements containing zinc. Copper is found in photoreceptor inner 
segments. Mouse retinae with copper, zinc superoxide dismutase deficiency show features of 
AMD [163] and a reduction of copper and zinc has been identified in human eyes with AMD 
[164].  
 
The fact that nutrition is a modifiable risk factor in the pathogenesis of ARMD means that there 
are active steps that can be taken to potentially reduce the risk of developing the disease or to 
slow the progression of disease.  
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1.12 Measures of visual function in ARMD  
In the majority of clinical studies of ARMD visual acuity (VA) is used as a measure of macular 
function. However this is far from ideal as it assesses one small area of the retina, does not 
provide an overall measure of macular function and relies on subjective patient responses. It 
may be preferable to undertake a combination of objective and subjective testing to assess how 
the disease affects other measures of visual and retinal function.  
 
Subjective measures of visual function 
Subjective cone-mediated tests that have shown attenuation in ARM include reduced distance 
and near VA, contrast sensitivity (CS), visual field loss, slowed cone adaptation dynamics, 
reduced microperimetry sensitivity, decreased foveal sensitivity and colour vision deficiency 
[165-181]. Administration of a lutein-based (L-based) supplement has shown some 
improvements in subjective measures of visual performance in eyes with AMD but not ARM 
[101, 102, 104] and effects of supplement withdrawal were not assessed in these studies. 
Slowed rod adaptation kinetics have been shown to be affected at least as much as (some say 
more than) cone adaptation kinetics [76, 182]. Contrast sensitivity and VA are cone-mediated 
measures and the functional status of cone photoreceptors can provide information about 
changes in the RPE and Bruch’s membrane  [183] as is seen in ARMD. 
 
Objective measures of visual function 
Objective measures of cone function have shown sensitivity to abnormality in ARMD, 
including the focal electroretinogram (fERG) which measures single areas of retinal function 
and the multifocal electroretinogram (mfERG) which measures many single areas of outer 
retinal function simultaneously. A review of the literature demonstrates that both tests provide a 
direct measure of retinal function and are a useful means to diagnose and monitor disease 
progression [184] (see full review published in Documenta Ophthalmologica – appendix 3). The 
RPE, Bruch’s membrane, choriocapillaris and photoreceptor layer are affected in ARMD, and 
are all situated prior to the bipolar cell layer. Any damage to or before the bipolar cell layer as 
occurs in ARMD, will reduce the amplitude of the first order kernel of the conventional cone-
driven mfERG [185]. The mfERG is a technique that can distinguish between inner and outer 
retinal disease such as ARMD, as inner retinal disturbance to amacrine and ganglion cells has 
shown no effect on mfERG amplitude with only a small effect on the mfERG waveform [185]. 
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Improvements in central retinal function as determined by increased fERG and mfERG 
amplitudes have been witnessed in eyes with ARM when L-based supplementation was 
administered [103, 134], suggesting that antioxidant therapy may reduce outer retinal 
dysfunction in ARM. However, in these studies the amount of dietary L and Z, self-
supplemented L and Z or retinal accumulation of L and Z (macular pigment optical density, or 
MPOD) were not quantified. Intervention with supplemented and dietary increases in L and Z 
have shown increases in MPOD in eyes with ARM [186, 187] in some studies but not in others 
[188].  
 
1.13 Research rationale 
Age-related macular degeneration is the leading cause of irreversible blindness in the western 
world [4], with the number of cases expected to increase as the population ages. Age-related 
maculopathy is an earlier stage of the condition that predisposes patients to visual loss, 
characterised by drusen (≥63μm) with or without RPE changes [34]. Age related macular 
disease is a term used to encompass both early and late stages of the disease (ARM and AMD). 
Although the pathogenesis of ARM is still not fully understood, genetic predilection together 
with environmental factors are implicated.  
 
There are many modifiable and non-modifiable factors that have been inconsistently linked with 
increased risk for developing ARMD. Age, smoking and genetic susceptibility are largely 
consistent factors associated with an increased risk for developing the disease. Because it is 
purported that oxidative stress is a feature in the aetiology of the disease, research into the role 
of antioxidants such as L and Z may provide important answers for reducing risk of disease 
development and progression.   
 
The potential benefits of L and Z supplementation on visual function require further 
investigation. Randomised-controlled trials (RCTs) are the most stringent methods to evaluate 
whether a cause-effect relationship exists between intervention with L and Z supplementation 
and non-intervention [189].  
 
As subjective measures of visual function are prone to participant inconsistencies, objective 
measures of visual function may provide additional information when assessing ARMD.  
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Review of the literature provides evidence that the mfERG is an objective, sensitive tool for 
assessing retinal changes in ARMD and for monitoring effectiveness of clinical intervention in 
this disease. Indeed, mfERG measures were improved with lutein-based supplementation in 
eyes with ARM in a previous study, although retinal or dietary levels of L and Z were not 
quantified [103].  
 
The limited treatments available for ARMD give greater impetus for the need to identify the 
disease earlier and assess treatments to slow disease progression. Improvements in visual 
function in ARM eyes taking a L-based supplement may imply a purpose for nutritional 
supplementation for delaying the onset and progression of the disease, and even remission of 
symptoms. Improvements in healthy eyes may be suggestive of a preventative or disease-
delaying therapy, especially pertinent to those with a family history of ARMD or vulnerable to 
additional risk factors. 
 
The aim of this study was to assess the effects of a L-based nutritional supplement on objective 
and subjective measures of visual function, and compare these to untreated eyes. The effects of 
supplement withdrawal were also assessed. This was undertaken in HY, HO and ARM-affected 
eyes.  
  
The primary outcome measure for the trial was the N1P1 amplitude of first order kernel of the 
conventional mfERG. The rationale for this trial was to expand on the work done by the 
Carotenoids and antioxidants in age-related maculopathy study (CARMIS) investigators [103], 
who found that an L-based supplement increased central ring 1 and 2 mfERG N1P1 amplitudes 
after 6 and 12 months in 15 eyes with ARMD compared with 12 eyes of non-treated 
participants. Because the CARMIS investigators found improvements at 26 weeks of 
supplementation with 10 mg daily dose of lutein, a 12 mg daily dose of lutein was assessed over 
20 weeks and 40 weeks for this study.  
 
L-based supplement on mfERG N1P1 amplitude for healthy eyes or for different ages were not 
assessed by the CARMIS investigators. Modifiable and possible preventative strategies for 
reducing the risk of ARMD development and progression are of importance, hence the rationale 
for inclusion of healthy eyes in this trial.  
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The CARMIS investigators did not report whether mfERG N1, P1 and N2 latencies or other 
measures of visual function were affected by nutritional supplementation. Participant dietary 
levels of L and Z were also not quantified and may have contributed to the improvement in 
mfERG amplitudes rather than the supplement alone. Furthermore, retinal levels of L and Z 
(MPOD) were not measured throughout their study to determine whether increases in retinal L 
and Z were associated with the increases in mfERG amplitude.  
 
Therefore, for this trial, secondary measures were first order mfERG N1, P1 and N2 latencies, 
retinal levels of L and Z (MPOD), VA and CS. Also, dietary analysis of the components found 
within the nutritional supplement were assessed over the study period to determine whether 
changes in visual function were due to dietary changes or could be attributed to the L-based 
supplement.  
 
The hypothesis is that a lutein-based supplement may provide improvements in objective and 
subjective measures of visual and retinal function in healthy eyes and in eyes with early ARMD 
(ARM). Also, withdrawal of the supplement may show decreases in these measures. 
 
1.14 Chapter one summary 
The aim of this thesis is to extend on previous work by undertaking a RCT (study design 
methods discussed in chapter 3) investigating the effects of a L-based nutritional supplement on 
mfERG, CS, VA and MPOD in ARM eyes and healthy eyes (results in chapter 6), and to 
investigate the effects of withdrawal of the supplement on these measures in ARM and healthy 
eyes (results in chapter 7). Dietary levels of L and Z were also investigated so any findings 
could be clearly delineated as being due to the L-based supplement rather than dietary changes 
of L and Z. A literature review established the pertinence of the mfERG as a sensitive tool for 
objectively assessing ARMD and for demonstrating improvement with clinical intervention. A 
research rational for the study was put forward. Chapter 2 describes the literature review of the 
use of differing electroretinogram modalities as tools for diagnosing, monitoring and assessing 
treatment effects in ARMD.  
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Chapter 2: The role of electroretinography in ARMD 
 
2.1 Introduction 
In the majority of clinical studies of ARMD, visual acuity is used as a measure of macular 
function. However this is far from ideal as it does not provide an overall measure of macular 
function and relies on subjective patient responses. It is important to identify individuals who 
are at most risk of developing the ARMD, so that interventions and lifestyle modifications can 
be targeted appropriately. In asymptomatic eyes, sensitive, reproducible measures of macular 
function are important to highlight the earliest signs of ARM. The objectivity and the 
topographical mapping that multifocal electroretinography (mfERG) provides allows for 
assessment of localised retinal cell function deficits in ARM over time. Evidence also suggests 
that mfERG can be used to monitor effectiveness of surgical and clinical intervention. This 
review enumerates the efficacy of various types of electroretinogram (ERG) for assessing 
retinal function in ARMD.  
 
2.2 Full field electroretinogram (ERG) 
The full-field or flash ERG (ffERG) generally consists of a negative deflection, called the a-
wave, which is mainly associated with the photoreceptors and a positive b-wave, thought to be 
produced by ON bipolar cell depolarisation. Scotopic ffERGs elicit rod–dominated 
photoreceptor function responses and photopic conditions elicit cone function responses. A 30 
hertz light stimulus ERG also provides information about cone function, whilst oscillatory 
potentials reflect amacrine cell function [190]. 
The ffERG gives a massed retinal electrical response to a light stimulus but does not provide 
spatial retinal information. Thus small retinal lesions such as those seen in ARM may be missed 
by ffERG and so there have been contradictory findings reported for the appropriateness of 
using ffERG in the assessment of the condition [191-194] Holopigian et al., examined the effect 
of normal aging, ARM and AMD on the ffERG. They demonstrated reduction of amplitudes 
and increase in implicit times of the ffERG over time with increasing age for normal subjects, as 
well as those with ARM and AMD under photopic and scotopic conditions [194]. Similarities 
between older normal subjects and those with ARM highlight the importance of using age-
matched normals for comparison when observing older subjects with ARMD. These results 
correlated with the findings of other studies showing a decrease in rod and cone ERG 
amplitudes with age [195] and a slowed inactivation of phototransduction in rod photoreceptors 
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with age when measuring the recovery of the a-wave using a paired flash ERG technique [191].  
Marcus et al., [193] studied the b-wave of the ERG in 24 eyes of 12 subjects with ARMD and 
found low to normal b-wave amplitudes in diseased eyes and no correlation with clinical 
morphology. However, there was no control group comparison.  
 
Along with reduced and delayed photopic cone-dominated a-wave responses, scotopic rod-
dominated a- and b-wave responses have been examined in ARMD using the ffERG. These 
were also reduced and delayed, suggesting that ARMD affects rod as well as cone 
photoreceptors [192]. A review by Scullica and Falsini [196] identified that studies of retinal 
function in ARM and AMD have found substantial impairment of rod photoreceptor function. 
Inconsistency exists in the literature about the value of ffERG in ARMD. As the ffERG is a 
massed response the sensitivity of the test is limited when trying to assess small lesions as 
observed in ARM  [197]. 
 
2.3 Pattern ERG 
The pattern ERG (PERG) occurs with pattern reversal stimulation, typically a checkerboard 
pattern of mean overall luminance which isolates nonlinear retinal responses while cancelling 
linear responses [198]. This gives a direct measure of ganglion cell function and allows 
discrimination between optic nerve and macular disease [199]. Pattern ERG abnormalities have 
been seen in AMD and reduced PERG P50 amplitudes have been observed in maculopathies 
[199]. The PERG has been shown to be abnormal in macular dysfunction when there is  no 
detectable change in the ffERG [200]. Since the PERG measures ganglion cell function [199] 
and ganglion cell function remains relatively preserved in AMD [201] it may be argued that 
PERG does not provide sufficient information about retinal function in ARMD, especially in 
ARM when only small areas of drusen are seen. The PERG elicits an inner retinal response 
whereas ARMD is a retinal degeneration primarily affecting the RPE and the choriocapilliaris 
[194].  
 
The PERG has been effective at assessing retinal function in AMD when clinical interventions 
are undertaken. Neveu et al., [202] demonstrated that a detectable PERG prior to photodynamic 
therapy (PDT) in eyes with choroidal neovascularisation (CNV) was the single best indicator for 
improvement in visual acuity following treatment. However in ARM the area of retinal lesion is 
usually smaller than the area of PERG recording making the PERG less effective at monitoring 
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ARM compared to angiography. The PERG fails to provide any spatial retinal information.  
Another study examining PERG at the early stages of PDT for CNV showed a reduction in 
amplitudes and delay in latencies of the P50 and N95 soon after PDT which resolved at one 
month [203]. Mackay et al., [201] assessed longer term changes to the PERG over twelve 
months and found that the P50 and N95 amplitude reduced over the twelve months, without 
recovery. The P50 latency reduced over the year but then increased at twelve months. However 
this finding was not statistically significant. 
 
2.4 Focal ERG 
Unlike the ffERG, the focal ERG (fERG) has the ability to specifically stimulate the fovea - 
useful when evaluating macular disease [204, 205]. A flickering light stimulus is utilised to 
stimulate the macular region and measures macular cone photoreceptor and bipolar cell function 
[206]. Although there is no international procedural standard set for undertaking this ERG 
technique, a number of varying techniques for recording fERG have been described in the 
literature. Differing field sizes (3° to 18°) and light stimulus frequencies have been used. Seiple 
et al., [207] examined retinal function in ARMD using a range of stimulus frequencies (10-60 
Hertz). This work showed fERG amplitude losses at high and low frequencies in patients with 
macular disease, but relative sparing of the mid-temporal frequencies although the type and 
severity of ARMD was not noted within the results or separated out from other macular 
diseases. 
 
Research on fellow eyes of patients with unilateral CNV has suggested that these eyes have a 
normal foveal cone number but abnormal cone function, indicated by delayed implicit times. 
Results were adjusted for age, gender, iris pigmentation and spherical equivalent. [208] Another 
study confirmed these findings and is postulated to be due outer retinal ischaemia [209]. Normal 
fERG phase but decreasing amplitudes have been documented with increasing severity of non-
exudative AMD [210].  
 
Nutritional supplementation and its effects on macular function have been investigated in 
subjects with ARM and age-matched normals. Falsini and colleagues [134] found that at 180 
days, normal and ARM eyes showed an increase in fERG amplitudes after lutein, vitamin E and 
nicotinamide supplementation. At 360 days amplitudes were maintained.  
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Binns and Margrain [211] proposed a fERG photostress modality to examine retinal function in 
ARM, using intense light adaptation to bleach the retina, followed by periodical fERG to 
examine the recoverability of retinal function and determine the rate of photopigment 
regeneration. Retinal function recovery rate was slower in those with ARM compared to 
controls suggesting impairment in the ability of the outer retina to regenerate cone 
photopigment. 
 
The effect of age on the fERG has been detailed, showing decreasing amplitude with increasing 
age [205, 208]  and increasing fERG implicit times [208], stressing the need for age-matched 
controls when investigating ARM and AMD with fERG.  
 
Focal ERG is useful for assessing retinal function in ARM and AMD. However, good fixation is 
required and it is limited to a single area, thus giving no information about multiple areas of 
retinal function. Also, no international procedural standard has yet been determined.  
 
2.5 Multifocal ERG 
The multifocal ERG (mfERG), developed by Sutter and Tran [212] is based on a pseudorandom 
M-sequence stimulation technique that allows simultaneous recording of ERGs from many 
retinal areas at once [213]. Like PERG, fERG and ffERG it is an objective measurement of 
retinal function but in contrast to these tests the mfERG allows simultaneous measurements of 
multiple responses at different retinal locations [214, 215]. The first order kernel of the mfERG 
waveform comprises of a negative N1 component, a positive P1 component and a negative N2 
component. Hood’s very comprehensive literature on mfERG suggests that mfERG responses 
are similar to the ffERG in that the N1 of the first order kernel of the mfERG is cone-driven (as 
in a photopic ffERG) and that the P1 contains responses from the bipolar cells [216]. The 
mfERG is dominated by bipolar cell activity and so a disease that substantially decreases the 
mfERG amplitude must therefore be acting at or before the bipolar response [190]. The first 
order kernel is the most commonly measured parameter of the mfERG. The mfERG also 
contains a second order kernel which originates from induced components of the inner retina, 
more details of which can be understood in the work of Sutter. [217-219]. The mfERG maps 
retinal function within the central 30-50º of the retina and good fixation is required for accurate 
results, suggesting it may be better suited to assessment of retinal function in ARM where 
central vision is preserved. 
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Various studies have reported the efficacy of the mfERG in the assessment of ARMD [103, 134, 
169, 201, 202, 214, 220-238]. Eyes with ARM have been found to have reduced foveal mfERG 
P1 amplitudes and increased N1 latencies when compared with age-matched normal controls 
[227]. Interestingly, asymptomatic fellow eyes of the ARM eyes in this study also exhibited the 
same findings, suggesting that the mfERG may be a sensitive means of detecting early ARM 
changes. Feigl et al., [239] in contrast, found no such correlation, possibly attributable to non-
uniform use of grading and classification systems and varying age range of the participants used 
in the different studies. 
 
Research comparing the mfERG between exudative AMD, non-exudative ARM and normal 
controls has been undertaken [225] demonstrating reduction in the P1 and N1 amplitudes of 
both CNV and  ARM eyes when compared with controls. However, although the average age of 
the CNV and ARM groups were similar in this study (64.4 years and 66.5 years respectively), 
the control group was younger (57.7 years). This may account for some amplitude reduction due 
to aging influence on the mfERG [240, 241]. Seiple et al., demonstrated a significant linear 
relationship of 10.5% reduction in the N1 to P1 amplitude per decade [242], emphasizing the 
importance of using age-matched controls when interpreting mfERG results. 
 
The mfERG guidelines described by the International Society for Clinical Electrophysiology of 
Vision (ISCEV) [243], measures cone-function. However rod-mediated mfERG can be recorded 
after dark adaptation. It is time consuming with poorer signal-to-noise ratios than cone mfERGs 
[244]. A study to compare rod- and cone-mediated mfERG in ARM showed reduced N1 and P1 
amplitudes in ARM when compared to controls in both rod- and cone-mediated mfERGs [228]. 
Delayed rod-mediated mfERG P1 implicit times in ARM eyes were reported when compared 
with age-matched normal controls [230, 233, 234], implying that both rod and cone-function is 
affected in ARM. However further work using larger sample sizes would provide more 
definitive rod mfERG information, as to date conflicting results have been demonstrated. 
 
Interesting work has been undertaken on the use mfERG to investigate the role of ischaemia in 
ARM. Hypoxia has been experimentally induced in younger and older healthy eyes resulting in 
a reduction in central and peripheral neuroretinal function indicated by reduced mfERG 
response densities [222, 245, 246]. This supports the hypothesis that post-receptoral 
vulnerability occurs during reduced oxygenation and ischaemia [233, 247]. 
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Differing mfERG paradigms have been used to evaluate rod and cone systems in ARM. Global-
flash mfERGs have been used in an attempt to overcome some of the conflicting findings that 
have been observed with the conventional mfERG and to better reflect adaptation deficits in 
ARM [231]. The findings indicate that the global-flash mfERG detects reduced adaptation 
responses before the conventional mfERG. Thus, it could be argued that global-flash mfERG 
may be more beneficial in identifying ARM sooner than the standard mfERG. More research is 
necessary to consolidate this hypothesis.  
 
The slow flash mfERG is another paradigm that has been subtracted from the conventional fast 
flicker mfERG to assess nonlinear adaptive components within the retina in ARM [229]. 
Interestingly, neither conventional mfERG nor slow flash mfERGs discriminated between the 
ARM group and age-similar controls. However, the difference between the two paradigms 
showed a reduced late component waveform in the ARM group compared to the control group 
suggesting postreceptoral adaptation abnormalities in the ARM group. 
 
Comparison between the conventional cone-mediated mfERG response and morphological 
changes in ARM have been examined [169, 221, 248], with outcomes suggesting slight increase 
in delayed implicit time with drusen progression, drusen regression with increasing RPE 
changes and in stable drusen. After more than two years the responses became more delayed 
with reduced response density. The mfERG changes were not limited to the drusen areas in 
these studies, suggesting retinal function does not correlate directly with morphology in ARM  
 
The objectivity of the mfERG in assessing retinal function correlates well with subjective 
macular function tests in ARM and AMD [220], such as colour vision and microperimetry 
testing [169] and suggests they may be significantly related to retinal function in the cone-
mediated mfERG in ARM.  
 
2.6 Multifocal ERG in clinical intervention studies 
mfERG has been investigated as a tool for assessing retinal function before and after PDT, a 
widespread treatment for predominant classic CNV prior to the introduction of intravitreal 
ranibizumab and bevacizumab. 
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Palmowski et al., [237] compared retinal function pre- and post-PDT in 16 eyes and found that 
after PDT the mfERG showed focal improvements in 13 eyes. In 10 eyes focal retinal function 
deteriorated in some locations. At fifteen weeks some areas of the mfERG did not demonstrate 
any improvement when compared with mfERGs obtained at three weeks post-PDT. They 
concluded that improvement in parafoveal function can be seen with mfERG and deemed it a 
suitable tool in assessing retinal function in AMD.  
 
Short-term mfERG changes were assessed in 17 eyes with CNV before and after PDT with 
verteporfin by Jiang et al., [236] The mfERG latencies and response amplitude densities 
remained largely unchanged within three days, and at one week post-PDT with verteporfin 
when compared with pre-PDT mfERG. Their data suggests that verteporfin therapy may not 
result in adverse effects within the outer retina, in contrast to other histopathological studies 
assessing verteporfin and PDT in the monkey retina [249].  
 
Multifocal ERG recordings were performed before PDT, and at four days, two weeks and one 
month after PDT with verteporfin in a study by Lai et al., [223]. Their research showed a 
transient impairment in retinal function that resolved after one month. In contrast to the work by 
Jiang et al., there was a change at four days post-PDT with reduced N1 and P1 response 
amplitude densities and increased P1 latencies. However Lai’s study contained only three AMD 
eyes with CNV, the other fourteen eyes being a mixture of myopic CNV, idiopathic CNV, 
polypoidal choroidal vasculopathy and central serous chorioretinopathy.  
 
Studies at baseline and six weeks post-PDT were assessed with mfERG by Ruether et al., 
showing a trend towards reduced P1 amplitudes and delayed latency, although these effects 
were not statistically significant and comparison to a non-treated group did not occur [250].  
 
Catala-Mora et al., [251] observed mfERG changes over a longer period post-PDT in twenty-
three eyes. At two and six months after treatment the N1 and P1 amplitudes did not change and 
even improved in the more peripheral areas tested. They concluded that mfERG offers 
interesting non-subjective information about retinal sensitivity in macular diseases treated with 
PDT.  
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Mackay et al., [238] examined the use of mfERG as a predictor of vision maintenance post-PDT 
in neovascular AMD using logistic regression models. Patients with an average of 6/30 vision 
were less likely to respond to PDT than those with poor vision. Relatively good contrast 
sensitivity and large central mfERGs increased the probability of a response to PDT. In a further 
study, mfERG was assessed in pre- and post-PDT in CNV. They found P1 response amplitude 
density increased at six months and then returned to baseline at twelve months [201]. Work 
undertaken by Moschos et al., demonstrated that although at six months post-PDT seventy 
percent of vision remained stable, there was a demonstrable reduction of mfERG response 
amplitude density, highlighting the need for objective measures of retinal integrity when 
monitoring the efficacy of clinical intervention [252]. 
 
Feigl et al., used the rod-mfERG and cone-mfERG to determine the effects of multiple PDT 
treatments in a case report of five eyes showing transient reduction in cone-mfERG waveforms 
and then recovery over time in all eyes and similar findings for rod-mfERG in four out of five 
eyes. However baseline rod-mfERG responses were poor, very small and the test demanding for 
patients [253]. 
 
With the recent implementation of costly intravitreal ranibizumab treatment for AMD with 
CNV, greater impetus has been given to looking at ways of diagnosing, monitoring and treating 
AMD earlier to preserve vision. In a study of nine patients who received intravitreal 
bevacizumab for the treatment of exudative AMD, mfERGs were performed pre- and post-
treatment [235]. A linear relationship was found between visual acuity and P1 response 
amplitudes, suggesting that bevacizumab improved retinal function. mfERG parafoveal retinal 
response density improvement three months post-bevacizumab has been demonstrated in 
research by Moschos et al., [254] when studying eighteen eyes with CNV. Correlation between 
mfERG retinal response density in the central 15 degrees and retinal thickness has been 
demonstrated in four eyes post-bevacizumab treatment, resulting in improvement of mfERG 
macular function responses with reduction in retinal thickness as measured by optical coherence 
tomography, although in this study ISCEV mfERG guidelines were replaced with a customised 
experimental  m-sequence technique [255]. Ranibizumab efficacy has been investigated in a 
small study of three eyes using mfERG with a reduction in central and peripheral amplitudes 
being evident after three treatments when compared to age-matched normal eyes [256]. Further 
studies are required in the area of anti-vascular endothelial growth factor (anti-VEGF) agents, 
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both singularly and in combination treatments, to test the efficacy of different dosing regimens 
and the mfERG could have an important role for assessing retinal function within this area. 
 
The role of nutrition in retinal health may prove to become an integral part in the management 
of ARM. Parisi et al., [103] looked at the influence of short-term carotenoid and antioxidant 
supplementation on retinal function in ARM. They demonstrated that in the central five degrees, 
ARM subjects treated with nutritional supplementation showed an increase in mfERG 
amplitudes after six months when compared with controls.  
 
2.7 Chapter two summary 
Sensitive but reproducible tests of macular function will become more important to detect the 
earliest signs of ARM. The objectivity and the topographical mapping of the mfERG allows 
localised retinal functional deficits in ARM to be observed over time. Evidence also suggests 
that mfERG can be used to monitor effectiveness of surgical and clinical intervention. Chapter 3 
describes the randomised controlled trial clinical intervention design, using mfERG as the 
primary outcome measure. 
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Chapter 3: Study design   
 
3.1 Randomised controlled trial design 
Randomised controlled trials are the gold standard for detecting associations between 
interventions and outcomes [189]. The aim of this thesis is to investigate the effect of a L-based 
nutritional supplement on subjective and objective measures of visual function in healthy eyes 
and those with ARM, and to assess the effects of supplement withdrawal on these measures. A 
RCT was designed to investigate this research question and to attempt to make an original 
contribution to the literature in this area. The trial followed the Consolidated Standards of 
Reporting Trials (CONSORT) statement [257]. The CONSORT statement is designed to 
improve the reporting of RCTs and provides a 25 point checklist of required pieces of 
information when reporting randomised controlled trials (see table 3.1). 
 
The study was a longitudinal, prospective, single-masked RCT. The principle investigator (EB) 
was masked from intervention and non-intervention assignment of participants. Aston university 
reception staff allocated participants to intervention or non-intervention groups depending on a 
randomly allocated number given by EB to the participants. The number was randomly 
generated using Microsoft (Microsoft Corporation, One Microsoft Way, Redmond, WA 98052-
6399 USA) excel random number generation.  
 
This study compared the effect of a nutritional supplement on retinal function in 3 subgroups:  
1) Under 50 years with healthy eyes (healthy younger, HY) 
2) 50 years and over with healthy eyes (healthy older, HO) 
3) 50 years and over with ARM (ARM). 
  
For each group, participants were randomly allocated to an intervention or non-intervention 
group. The intervention group received a L-based nutritional supplement for 40 weeks, the 
remainder acting as controls. After 40 weeks, supplementation ceased. At 60 weeks only 
participants who were in the intervention group returned for assessment of the effects of 
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withdrawal of the supplement on visual function. Outcome measures were assessed at baseline 
(visit one), 20 weeks (visit two), 40 weeks (visit three) and 60 weeks (visit four – withdrawal). 
Participants were asked to not discuss intervention with EB and were provided with another 
contact (HB) for contact to discuss concerns about supplementation. Tablets were provided free 
of charge by Bausch and Lomb (Bausch & Lomb House106-114, London Road, Kingston-
Upon-Thames, Surrey KT2 6QJ, England). The study was also funded by Bausch and Lomb. 
 
3.2 Participant recruitment 
The study required the recruitment of people with and without ARM. Systems of recruitment 
included: 
1. Leaflets for patients attending Aston Vision Sciences Department (appendix 4) 
2. Leaflets for patients attending Aston University Day Hospital (appendix 4) 
3. Information posters in Aston University and Solihull libraries (appendix 5) 
4. Information poster at the Midland Eye Institute (appendix 5) 
5. A research database composed comprising patients wishing to part in research from 
 Aston University Optometry Clinic 
6. Leaflets given to Professor Jonathan Gibson to hand to patients during a weekly clinical 
session at Aston University (appendix 4) 
 
3.3 Research centre 
The trial took place at a single research centre in the Vision Sciences department at Aston 
University. Enrolment, randomisation and data collection were carried out by EB. EB was 
masked to group assignment. HB provided the key code for randomisation. EB is a research 
ophthalmic physiologist and HB an optometrist and senior lecturer. 
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Table 3.1: CONSORT Statement 2010 25 item checklist.     
Section/Topic Item No Checklist item Reported on page/s 
Title and abstract 
 1a Identification as a randomised trial in the title 2 
1b Structured summary of trial design, methods, results, and conclusions  2 
Introduction 
Background 
and objectives 
2a Scientific background and explanation of rationale 39 
2b Specific objectives or hypotheses 40, 41 
Methods 
Trial design 3a Description of trial design 41 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons Not applicable 
Participants 4a Eligibility criteria for participants 58-60 
4b Settings and locations where the data were collected 52 
Interventions 5 Interventions for each group with sufficient details to allow replication 51,58 
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Table 3.1 continued. 
Section/Topic Item No Checklist item Reported on page/s 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when 
they were assessed 
40,41,79-84 
6b Any changes to trial outcomes after the trial commenced, with reasons Not applicable 
Sample size 7a How sample size was determined 85-87 
7b When applicable, explanation of any interim analyses and stopping guidelines Not applicable 
Randomisation:    
Sequence 
generation 
8a Method used to generate the random allocation sequence 51 
8b Type of randomisation 51 
Allocation 
Concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence                                                                                                 51-52 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants 
to interventions 
52 
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Table 3.1 continued. 
Section/Topic Item 
No 
Checklist item Reported on page/s 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
51-52 
11b If relevant, description of the similarity of interventions Not applicable 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 113 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses Not applicable 
Results 
Participant flow 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
114,118,121,124 
13b For each group, losses and exclusions after randomisation, together with reasons 66 
Recruitment 14a Dates defining the periods of recruitment and follow-up 62-64 
14b Why the trial ended or was stopped Not applicable 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 114,118,121,124 
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Table 3.1 continued. 
Section/Topic Item 
No 
Checklist item Reported on page/s 
Numbers analysed 16 For each group, number of participants included in each analysis and whether the analysis was by original 
assigned groups 
114,118,121,124 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
113-131,86,87 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Not applicable 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
124-125 
Harms 19 All important harms or unintended effects in each group  Not applicable 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 142-143 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 145-146 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 145-146 
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Table 3.1 continued. 
Section/Topic Item 
No 
Checklist item Reported on page/s 
Other information 
 
Registration 23 Registration number and name of trial registry 67 
Protocol 24 Where the full trial protocol can be accessed, if available This thesis 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 52 
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3.4 Supplement composition  
The supplement name was Ocuvite Duo, provided by Bausch and Lomb, Kingston-Upon-
Thames, Surrey, UK. The author has no proprietary interest in the supplement or company. The 
supplement was in tablet and capsule form. Participants took one capsule and one tablet 
together, once in the morning with water and this was repeated in the evening. The tablets and 
capsules were boxed and in blister packs. The nutrients contained within the supplement have 
been discussed in chapter 1 and are shown in table 3.2. All of the nutrients were within the safe 
upper levels as defined by the food standards agency [258].  
 
Table 3.2: Supplement composition. All constituents were contained within the tablets except 
for omega 3 which was provided by the capsules. 
Ingredient Safe upper levels per day [258] Dosage per day  
Vitamin C  1000 mg (guidance only) 150 mg  (per two tablets) 
Copper  10 mg 400 µg (per two tablets) 
Vitamin E 540 mg 15 mg (per two tablets) 
Zinc  25 mg 20mg (per two tablets) 
Lutein  Non established 12 mg (per two tablets) 
Zeaxanthin  non established 0.6 mg (per two tablets) 
Omega-3 non established 1080 mg (per two capsules) 
 
 
3.5 Inclusion criteria 
Suitability for inclusion was evaluated by questionnaire, fundus photographs and visual acuity. 
For inclusion participants had to provide written informed consent (see appendix 6) and were 
required to have: 
For the early ARM, HO and HY groups in either eye or both eyes: 
Best corrected visual acuity (VA) of 6/9.5 (Logarithm of the minimum angle of resolution, or 
LogMAR 0.2) or better (for good mfERG central fixation) 
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Clear optical media (as determined by fundal photography)  
No signs of retinal or optic nerve disease other than ARM in the ARM group (as determined by 
fundal photography and questionnaire) 
Good general health (as determined by health questionnaire) 
No medication that affects the retina (as determined by health questionnaire) 
 
For the ARM group in either eye or both eyes as defined by the international classification 
system described in chapter 1: 
Drusen which are external to the neuroretina and RPE. They are soft and distinct or soft and 
indistinct. Hard drusen are not characteristic of ARM; 
Or drusen with hyperpigmentation; 
Or drusen with hypopigmentation 
 
Rationale for ARM criteria 
Without good central fixation mfERG results are prone to inaccuracies (as described in chapter 
4). Thus eyes with AMD may be more susceptible to variable mfERG responses due to poor 
fixation. Therefore eyes with ARM were chosen for this trial. None of the participants 
progressed from ARM to AMD throughout the trial.   
 
3.6 Exclusion criteria 
Moderate to dense lens opacities 
Intraocular lens 
Corneal opacities 
Glaucoma or ocular hypertension 
Previous history of intraocular inflammation (e.g. uveitis) 
Previous history of retinal detachment 
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Retinal disease (other than ARM in the ARM group) 
Previous retinal laser 
Diabetes 
Systemic hypertension 
History of ocular trauma 
Neurological disease 
Advanced AMD (CNV or GA) in the studied eye 
Drugs causing retinal toxicity (chloroquine, cisplatin, oxazepam, vigabatrin) 
Previous ocular surgery (excluding LASIK/EK) 
Epilepsy 
 
Intraocular lenses (IOLs) post-cataract surgery would not have necessarily affected the mfERG 
as it provides clarity where there was previous opacity. However as cataract occurrence 
increases with age, pseudophakic individuals were likely to be older participants which could 
not then be compared with younger phakic participants for baseline data (chapter 5).  
 
Although mfERG has been undertaken to assess the use of vigabatrin on retinal function in 
participants with epilepsy [259], epilepsy was an exclusion criteria for this trial due to the 
flickering of the mfERG stimulus which may elicit an epileptic seizure, and due to some 
epileptic medication affecting the mfERG [259]. All other exclusion criteria were chosen as 
they may affect visual function or the mfERG.  
 
Although unclear optical media can affect the interpretation of mfERG results [260] some 
participants for this study were over 50, thus it was not possible to completely exclude these 
effects. Therefore moderate to dense lens opacities were classed as an exclusion criterion. 
Participants with minimal nuclear sclerosis (N2 or less according to the lens opacities 
classification system II system [261]) were included in the trial, of which none progressed 
during the trial. 
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Food diaries (as described in chapter 4) were administered during the baseline visit and repeated 
at visit three to assess the dietary intake of L and Z of both the intervention and non-intervention 
groups. Health questionnaires were administered during the baseline visit (appendix 7) to assess 
smoking habits, past medical and past ophthalmic history, and again at visits 3 and 4 to assess 
whether smoking habits or health status had changed. Any participant changes in ocular or 
general health as per the exclusion criteria over the course of the study were excluded. 
 
3.7 Data collection schedule 
The participant schedule was composed, tested and modified to reduce participant visit time to 
increase efficiency and the likelihood that participants would return for further visits throughout 
the study: 
1. Greet, call in and explain tests to participants, medical history, ophthalmic history, 
medication, cross check against inclusion / exclusion criteria. Obtain informed consent. 
2. LogMAR VA – right and left (at first visit, then for the chosen study eye for subsequent 
visits)  
3. Choose the eye with best corrected VA (at first visit and continue with the chosen study eye 
for subsequent visits) 
Then on the inclusion eye only: 
4. Macular pigment optical density measurement (MPS 9000, Tinsley Precision Instruments 
Ltd, Croydon, Essex, UK) 
5. Check intra-ocular pressure (CT-80, Topcon, Newbury, Berkshire, UK) 
6. Auto-refraction (NVision-K 5001, Shin-Nippon, Fukuyama, Hiroshima, Japan)  
7. Contrast sensitivity at 1 metre (Pelli-Robson, Clement Clarke, Harlow, Essex, UK) 
8. Dilate with Minims® 1% tropicamide (Bausch and Lomb, Kingston-Upon-Thames, Surrey, 
UK) 
9. Wait for a minimum of 20 minutes 
10. Minims® Proxymetacaine 0.5% (Bausch and Lomb, Kingston-Upon-Thames, Surrey, UK) 
11. Multifocal ERG (Visual evoked response imaging system (VERIS) science 6.1, Electro-
diagnostic Imaging inc, Redwood City, California, USA) 
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12. Check intraocular pressure post dilation 
13. Slit lamp check for corneal and scleral integrity, and lens check 
14. 45º Fundal photograph (TRC-NW8, Topcon, Newbury, Berkshire, UK) 
15. Axial length measurement at visit three only (IOL master, Carl Zeiss, Welwyn Garden City 
Hertfordshire, UK) 
16. Debrief and safety information regarding dilation  
 
3.8 Recruitment and visit schedule  
WEEKS EVENTS 
1-16 Preparation and organisation of resources 
17-57 Recruitment and baseline measures  
37-77 Participant second visits 
57-108 Participant third visits. Unmasking occurs. Supplementation ceases 
77-130 Participant fourth visits. Intervention groups only 
130-156 Data analysis and thesis writing 
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Figure 3.1: Research timeline. 
 
 
 
 
 
 
PhD Timeline Year 2 (2010)  
JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC 
3 rd visit  - weeks 57 - 108 (for all) 
2 nd visit  - weeks 37 - 77 
(for all) 
4th visit  - weeks  77  -  130  
(intervention group only) 
   
  
PhD Timeline Year 1 (2009)  
 
JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC 
Preparation  
weeks 1 - 16 
Recruitment weeks 17 - 57 
2 nd visits weeks 37 - 77 
(for all) 
Last date for recruitment at  
week 57 
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Figure 3.1: Research timeline continued. 
 
 
3.9 Intervention compliance assessment 
At visit 3 unmasking occurred. Participants were asked to return any boxes of the supplement 
that were not taken. Those who forgot to bring back the tablets were asked to contact EB after 
counting tablets at home. Patient compliance was elicited using supportive language to 
minimise the number of participants concealing supplement non-adherence [262], and reporting 
lower levels of remaining tablets than was actually the case. The sole reason for non-adherence 
was forgetfulness.  
 
3.10 Adverse effects of intervention 
Participants were contacted by telephone within the first month of receiving the intervention by 
HB to encourage compliance and ask if there were any problems taking the supplements. 
Participants were provided with a contact number (HB) to communicate any problems with the 
supplement. No adverse effects were reported with regards to the lutein-based supplement 
throughout the course of the trial or after the trial had ceased.   
 
PhD Timeline Year 3 (2011)  
JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC 
Data analysis and writing up  
On time 
4 th visit weeks 77 - 130 
Intervention group only 
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3.11 Enrolment and follow-up 
Of the 112 that were assessed for enrolment, 81 met the inclusion criteria and underwent testing 
at visit 1. At visit 2 there were 69 participants remaining. At visit 3 there were 66 participants 
remaining (table 3.3). The study at visit 4 was designed to assess the effects of supplement 
withdrawal. Thus only those who were taking the supplement for visits 1,2 and 3 were required 
to attend for visit 4, of which there were 30 participants.  Reasons for participant exclusion and 
withdrawal are laid out on table 3.4. 
 
Table 3.3 Enrolment and follow-up numbers. 
 HY HO ARM 
Visit 1 (baseline) 37 27 17 
Visit 2 32 23 14 
Visit 3 30 22 14 
Visit 4 (previously supplemented eyes 
only)  
12  10 8 
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Table 3.4: Numbers and reasons for participant exclusion and withdrawal. 
 HY HO ARM 
Excluded    
Visit 1 - visit 2 1  Hypertension 
1 Ocular hypertension 
1 LASEK 0 
Visit 2 - visit 3  0 0 0 
Visit 3 – visit 4  1 Ocular hypertension 0 0 
Withdrew       
Visit 1 – visit 2 1 Illness (from the 
treated group) 
1 Migraine post mfERG 
(from the non-treated 
group) 
1 Participant to contact 
(from the treated group) 
 3 Participant wanted 
to call back when 
appropriate for them 
and did not (2 from the 
non-treated group, 1 
from the treated group) 
1 No reason given 
(from the treated 
group) 
2 Participant to contact 
(from the non-treated 
group) 
Visit 2 – visit 3 2 Moved away (1 from 
the non-treated and 1 
from the treated group) 
 1 Illness (from the 
non-treated group) 
0 
Visit 3 – visit 4 1 Illness   1 Illness 0 
 
 
3.12 Resources   
Ongoing technical difficulties with the VERIS mfERG system delayed the study by 3 months. 
Technical support was not available in the UK. The computer was remotely accessed by 
Electrodiagnostic imaging (EDI), San Mateo, California, USA, who managed to solve issues as 
they arose. These included ‘slow error messages’ and the VERIS software quitting when data 
analysis was undertaken. Due to differing time zones between UK and California, USA, prompt 
assistance was not always available. A fault not able to be rectified via remote access in March 
2010 led to the computer being sent to the USA as per EDI request. The computer was not 
usable from March 2010 to May 2010. On return the fault remained. Thus due to technical 
difficulties mfERG parameters were not measured for all participants for each visit. After 
various new components were tried including a new switchbox, cabling and motherboard, the 
VERIS resumed operation.  
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3.13 Ethics 
The research was approved by Aston University Human Sciences Ethical Committee (reference 
300608/PF1 - see appendix 8).  The tenets of the declaration of Helsinki and [263] the 
CONSORT checklist [257] were followed. The study was registered with International Standard 
Randomised Controlled Trial (ISRCTN) register (number 17842302). 
  
3.14 Research Training 
Refresher skills in electrophysiology were undertaken at the Birmingham and Midland Eye 
Centre with Dr Peter Good. Definitive mfERG techniques were observed at Nottingham Queens 
Medical Centre with guidance from Dr Yaqin Wen.  Electrode insertion techniques were 
observed at Aston University and through online study.  
 
3.15 Chapter three summary 
This chapter described the RCT design used for assessing the effects of a L-based nutritional 
supplement on objective and subjective measures of visual function for this trial. The 
CONSORT reporting standards were met and described in conjunction with this trial.  In the 
next chapter the protocol for obtaining primary and secondary outcome measures will be 
outlined, and factors affecting the primary outcome measure will be described.  
 
 
 
 
 
 
 
 
 
 
68 
 
Chapter 4: Outcome measures  
4.1 Primary outcome measure - the mfERG 
The mfERG was introduced almost two decades ago by Sutter and Tran [212]. As previously 
discussed the mfERG allows for simultaneous recording of electrical responses from many 
retinal areas at once. This provides a better understanding of the focal effects of disease 
processes on the outer retina and allows retinal areas to be grouped together for analysis, 
depending upon the disease of interest.  
 
4.2 The mfERG stimulus 
When undertaking the conventional cone-mediated mfERG, the retina is stimulated using a 
number of hexagons in photopic conditions. The hexagons are inversely scaled with cone 
density [16] in order to obtain an approximately uniform retinal response across the visual field 
being stimulated.  The hexagons are commonly presented on a cathode ray tube (CRT) monitor. 
The drawbacks of CRT monitors include signal artefacts due to the time required for completion 
of raster scanning for each frame and time lags in phosphor decay [264]. Other stimulus 
presentation methods such as liquid crystal displays (LCD) and light emitting diode (LED) 
displays have been researched in an attempt to reduce some of these shortcomings but have their 
own limitations that need to be assessed before these methods are introduced [265, 266].  
 
Each hexagon within the group of hexagons is independently controlled by a mathematical 
sequence called a binary m-sequence [213], where each hexagon independently has a 50% 
chance of being black or white in each frame. These sequences are computer-generated. A 
different, pre-determined sequence drives each hexagon within the group of hexagons. The 
sequences consist of a group of 0’s and 1’s which switch the hexagons to black or white for 
each frame. Each retinal response is derived from cross-correlating the raw signal data from the 
m-sequence controlling that hexagon sequence. Because the waveforms are very small, many 
signals are averaged together. Responses are obtained by adding all signals for when each 
hexagon is white (on) for that retinal area and subtracting all signals for when the hexagon is 
black (off) for the same area. Thus the resulting retinal response is a mathematical extraction 
rather than an immediate retinal response to the stimulus. Each frame is typically changed every 
13.33 ms (75Hz) and appears as a random flickering of hexagons. A higher spatial resolution is 
obtained by increasing the number of hexagons stimulating the same area of the retina. This can 
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produce finer detail but at a cost of a poorer signal to noise ratio and longer testing times for 
patients [226]. 
 
4.3 The mfERG response 
Because the magnitude of mfERG responses are very small (in the order of nanovolts), they 
have to be amplified. The waveform of the first-order kernel of the cone-mediated mfERG is 
comprised of an initial negative (N1), a positive (P1) and a second negative (N2) deflection 
(figure 4.1). Work undertaken by Hood et al. using pharmacological dissection of the retinae of 
rhesus monkeys and comparison with human retinae demonstrated that N1 is generated by 
hyperpolarisation of OFF-bipolar cells with a lesser contribution attributable to photoreceptor 
hyperpolarisation [267]. ON-bipolar cell depolarisation with OFF-bipolar and photoreceptor cell 
recovery forms the leading edge of P1 with the trailing edge demonstrating ON-bipolar cell 
recovery [267].  Although there is paucity in the literature as to the cellular derivation of the N2, 
one study suggested it to be a composite response dominated by the interaction between two 
successive stimuli and the P1 component of a second stimulus delayed one frame from the first 
stimulus [268]. Another mfERG study, on porcine retinae found that the N2 is dominated by 
ON-bipolar cell activity and also shaped by OFF-bipolar cell activity although this needs to be 
interpreted with caution as there are retinal differences between primate and porcine retinas 
[269]. Hood et al. stated that the N1, P1 and N2 of human mfERG components are largely 
influenced by the different states of the bipolar cells [185]. 
 
Figure 4.1: A normal mfERG response. The double ended arrow demonstrates N1P1 amplitude 
(source - authors own drawing). 
 
                                                                                                  
 
 
 
 
 
N1 
P1 
N2 
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The second-order kernel is thought to be associated with inner retinal cell contributions [270, 
271] with lesser outer retinal contributions [269, 272]. However, Hood et al. highlighted that 
these responses are non-linear, i.e. second-order and higher-order responses are influenced by 
retinal adaptation to successive hexagon flashes and thus cannot be linked directly to cellular 
responses but only to adaptive circuitry within the retina [185].  Sutter gives a more in-depth 
analysis of mfERG second-order kernels in his literature [218]. For the purposes of the L-based 
supplement study, and for the supplement withdrawal study, first-order kernel waveforms were 
assessed due to their ability to detect retinal dysfunction in ARMD.  
 
The International society for clinical electrophysiology of vision (ISCEV) has published 
guidelines for recording cone-mediated mfERG in an attempt to reduce inconsistencies between 
laboratories [243]. These have been adhered to for the trial as described within the text of this 
chapter.  
 
4.4 The mfERG analysis  
Because mfERG signals are so small they are very susceptible to noise. Some studies have 
analysed retinal areas stimulated by a single hexagonal element [221, 273] although each 
waveform (trace array) from each retinal area stimulated by each hexagon is usually too noisy to 
reveal data of significance. Thus it is usual to group together traces from areas where the 
responses are considered to be similar, presenting accurate waveform estimates for different 
retinal regions. Traces can be grouped together in a variety of ways depending on the pathology 
of interest, for example a concentric ring analysis to examine ARMD due to the circinate nature 
of the disease. Once mfERG signals have been recorded the groups of averages can then be 
analysed by the computer software in several ways: 
 
Normalised – Waveform amplitudes for each stimulus element (hexagon) in a chosen group are 
combined and then divided by the root mean square, providing the same SD and amplitude 
(approximately) for each group. This simplifies waveform comparisons for each group and is 
useful for latency comparisons between groups. 
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Sum of groups – Waveform amplitudes are added together providing a cumulative response for 
that group, allowing comparison of equal areas or for comparing the total retinal response of 
one eye to another (unit = nV). 
 
Root Mean Squared (RMS) – The RMS is composed from the sum of squares, making this 
measure consistently positive. It compares each trace with its own template which reduces 
biasing but is sensitive to noise and can lead to overestimation of amplitude due to inability to 
discriminate between signal and noise. Any noise makes a positive contribution, falsely making 
amplitude larger.  
 
Scalar product – This is a correlation between a template and an individual waveform and not a 
direct measure of amplitude or latency and this can be seen as a 3D topography. Waveforms are 
averaged over groups chosen to create templates. Then a calculation of the average of individual 
traces and the group template traces are correlated. This is less susceptible to noise than the root 
mean squared (RMS) method [274]. 
 
Response density scaled - is the scalar product divided by the area of the element or hexagon 
(units = nV/deg
2
). Each trace is scaled to compensate for stimulus size and is an accurate 
representation of response amplitudes of hexagon group averages. Each hexagon is inversely 
scaled with the concentration of cone photoreceptors throughout the retina (response density 
scaled) to give similar amplitudes for each area stimulated [212]. The amplitudes of each 
waveform in a chosen group are added together and then divided by the hexagons within that 
group. This gives a scaled average group response to compensate for stimulus (hexagon) size, 
allowing a precise analysis of the response amplitude for each group. Values are unit area of 
stimulus per degree squared (nV/deg
2
).This gives an accurate view of actual response 
amplitudes. Due to its accuracy this method of analysis was chosen for the purposes of our 
studies. This was also the method of analysis chosen in the CARMIS study [103].  
 
5.5 Factors affecting the mfERG response  
There are numerous technical and biological factors that have been shown to affect mfERG 
amplitude and latency [274, 275]. It is essential that when reporting mfERG findings in research 
and clinical settings these factors are controlled where possible or adjusted for when 
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uncontrollable. The use of stringent inclusion and exclusion criteria can minimise biological 
discrepancy but may reduce sample sizes and thus the power of research findings.  
 
Electrode type and position 
The type of electrode used has an impact on the size of the mfERG response with the largest 
amplitudes being recorded from contact lens electrodes [276], although these electrodes can 
give rise to corneal and conjunctival abrasion, especially when used for long periods.  
 
For this trial Dawson Trick Litzkow (DTL) electrodes were used as they do not impede the 
optics of the eye unlike contact lens electrodes, and provide greater participant comfort while 
providing reproducible results [277, 278]. They are silver-impregnated microfiber corneal 
electrodes with small adhesive sponge pads at each end that are secured to the nasal and 
temporal canthi while the microfiber thread is positioned either along the lower lid, or draped 
into the lower fornix. The DTL electrodes used in this study were placed along the upper margin 
of this lower lid as per the ISCEV guidelines, which state that positioning the fibre into the 
fornix may reduce variability but results in smaller amplitudes [279].  
 
Amplifiers and filters 
Filtering is required to eliminate unwanted electrical noise from the mfERG signal but can 
attenuate the mfERG signal. Han et al. found that mfERG signal filtering restricted between 10 
and 100 Hz contained less noise, a higher signal to noise ratio and less intersubject variability 
than signals filtered at 10-300 Hz. However Keating et al. recommend a bandwidth as wide as 
possible [274]. The mfERG first order kernel waveform is concentrated at around 19 and 47 Hz 
[280].  However, ISCEV guidelines recommend a high pass filter between 3 and10 Hz and a 
low pass filter of between 100 and 300 Hz. Our filters were set in line with the ISCEV 
guidelines and VERIS manufacturer (Electrodiagnostic imaging, Redwood City, California, 
USA) recommendation at 10-300Hz [243]. The CARMIS study used a 1-100 Hz bandpass filter 
in their study assessing mfERG amplitudes with a lutein-based supplement [103]. Amplifiers 
amplify mfERG signals prior to their conversion from analogue to digital. Although ISCEV do 
not provide a figure for amplifier gain they state that the amplifier should produce recognisable 
signals without saturation. Our amplifier setting was set at 100,000 as per the CARMIS study 
[103]. Our amplifier and filter settings remained constant for all participant visits.  
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Stimulus and background luminance 
Stimulus type has already been described but the luminance level of the stimulus also affects 
mfERG waveforms. Therefore it is vital to periodically check the calibration of the stimulus 
luminance as per the ISCEV calibration guidelines when assessing differences in mfERG 
waveforms between groups and over time [281]. A study assessing different mfERG stimulus 
luminance at 150, 300 and 500 candelas per meter squared (cd/m
2
) found that there was a 20% 
increase in mfERG amplitude when luminance increased from 150 to 500 cd/m
2
 and latency 
decreased by 1.5ms [282]. This was reproduced in another study demonstrating a linear increase 
in P1 latency and reduction in N1P1 amplitude with decreases in mean luminance of the mfERG 
stimulus [283]. Guidelines for mfERG luminance as per ISCEV should be 100-200cd/m
2
 for the 
white hexagon stimulus and the black hexagon should have low enough luminance to provide 
≥90% contrast. Our equipment was calibrated as per the VERIS manufacturer’s guidelines at 
monthly intervals using the VERIS autocalibration software/hardware system. A photometric 
sensor, mounted in casing was placed over the refractor camera and screen luminance was 
automatically calibrated by the VERIS system. Because monitor brightness can change 
considerably during warm-up this was done at least 20 minutes after the equipment was 
switched on. Equally, all participants were not tested until at least 20 minutes after the mfERG 
had been switched on for this trial. The luminance (L) and contrast settings were:  
 
White hexagons (Lmax) = 200 cd/m² 
Black hexagons (Lmin) = 1 cd/m² 
 
ISCEV calibration guidelines  
Mean luminance = (Lmax + Lmin) = 100.5 cd/m² 
      2 
Contrast = (Lmax-Lmin)    x   100 = 99.0   % 
      (Lmax+Lmin) 
 
Brightness of background room lighting has also been shown to affect mfERG amplitude and 
latency with reduced amplitudes and shorter P1 latencies occurring as room lighting was 
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increased from darkness [284]. Therefore it is necessary for the eye to be light adapted for at 
least 15 minutes prior to testing [243]. The mfERG recordings were undertaken in the same 
room for all participant visits, with each participant being light adapted in this room for at least 
20 minutes during pupil dilation prior to mfERG testing.  
 
Stimulus size 
There are various stimulus hexagon sizes that can be used to provide varying degrees of spatial 
resolution when recording the mfERG, usually ranging from 19 to 241 hexagons. However 
there are trade-offs when deciding on stimulus hexagon size. Decreasing the size of the stimulus 
hexagons over the same field will yield greater resolution, good for highlighting small defects 
that may otherwise be missed. However the signal to noise ratio will be decreased, requiring 
longer testing times and greater discomfort for the patient. Lower spatial resolution (larger 
stimulus hexagon size) increases the signal to noise ratio, therefore less recording time is 
necessary for the patient although small areas of attenuation of retinal function may be missed. 
In a study by Heinemann-Vernaleken et al. [226] different resolutions of mfERG were assessed 
in 20 eyes of 14 patients with ARM. They found that 16 of the 20 eyes showed focal retinal 
dysfunction at both 103 and 241 stimulus element spatial resolution. However in the higher 
resolution recordings, a reduced signal to noise ratio meant that 3 recordings could not be 
analysed. They concluded that although higher resolution provides greater sensitivity for 
detecting focal abnormality, the lower resolution recordings provided better signal to noise 
ratios and were more appropriate in the clinical setting.  We used a 61 hexagon stimulus as 
recommended by ISCEV mfERG guidelines to balance the necessity for participant comfort 
while providing adequate assessment of macular function [243]. This also replicates the 
CARMIS study stimulus type [103]. 
 
Areas of analysis 
Studies have shown that mfERG waveforms change with retinal area. In healthy eyes 
conventional cone-mediated mfERG amplitudes are greatest at the centre and decrease with 
eccentricity [285] due to the high density of cone photoreceptors in the fovea which decline 
with eccentricity [16]. Asymmetry has been found between the inferior versus superior, and 
nasal versus temporal retinal areas in some studies but not others. Larger mfERG amplitudes 
and shorter N1 and P1 latencies in the superior retina compared to the inferior retina were 
recorded in one study [285] but no significant differences were seen between nasal and temporal 
areas in this study. Conversely, another study found larger amplitudes in the temporal retina 
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compared to the nasal retina but no difference between superior and inferior areas [286]. Other 
work has shown no difference between inferior and superior, or temporal and nasal areas for 
mfERG measures in healthy eyes, eyes with ARM, or when comparing healthy eyes to ARM 
eyes [227]. However, when concentric ring analysis was used, attenuation of central mfERG 
waveforms were found in ARM eyes when compared to healthy eyes [221, 287].  
 
Concentric ring analysis was used for the L-based supplementation study and the supplement 
withdrawal study, based on its appropriateness in detecting ARM and its ability to detect 
changes in retinal function in ARM with nutritional supplementation in the CARMIS study 
[103].  
 
Indeed, baseline differences of the participants were found in the mfERG measures between 
ARM eyes and healthy age-matched eyes using concentric ring analysis as described in chapter 
five. Single retinal areas stimulated by individual localised hexagons were not assessed  because 
of poor signal to noise ratios as previously described, lack of correlation with drusen 
morphology [169, 221, 287] and the subtle nature of ARM.  
 
Participant cooperation 
Any deviation in fixation during recording of the mfERG has an effect on the spatial accuracy 
of the mfERG waveforms because as the eye moves, different areas of the retinal field will be 
stimulated by different hexagons rather than 1 fixed hexagon per retinal area when the eye is 
stationary. One study by Chisholm et al. demonstrated that around 51% of participants fixation 
fell within 1.2 degrees from the point of fixation suggesting fixation quality was adequate when 
the central element subtended 2.4 degrees or greater (typically a 61 hexagon stimulus pattern or 
less). Greater resolution (smaller, greater numbers of hexagons) means that any deviation in 
fixation will have a greater effect on mfERG waveforms as any eye movement will cause the 
retina to be stimulated by a larger number of hexagonal stimulus elements [274, 288]. Another 
study demonstrated that central mfERG amplitudes were most affected by fixation deviation, 
showing reduced amplitudes. These amplitudes became increasingly affected the further from 
the centre the fixation deviation occurred [289]. The investigators also suggested that mfERG 
amplitude was not greatly attenuated if fixation remained within the central hexagon. However 
they used a 103 hexagon stimulus pattern in contrast to Chisholm et al’s study [288], although 
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stimulus distance was adjusted so the central hexagon subtended 2.4 degrees as per Chisholm et 
al’s work.  
 
Poor visual acuity can limit the ability to focus on the central fixation marker throughout a 
mfERG recording. This can lead to reduction in central mfERG amplitudes [289, 290]. Because 
fixation has such an impact on mfERG waveforms one of the inclusion criteria for this study 
was for all participants to have a logarithmic minimum angle of resolution (logMAR) distance 
visual acuity of 0.2 or better in order to see the fixation cross throughout mfERG recordings. 
This was required for HO, HY and ARM eyes. The mfERG system had a refractor camera, used 
to monitor fixation throughout the recording process. Any recordings affected by loss of 
fixation or blink artefact were eliminated and repeated. All participants positively responded 
when asked if they could see the fixation cross before mfERG recordings commenced.  
 
Age 
Age is a significant factor that affects the mfERG. This is described further in chapter five 
where a baseline study was undertaken to obtain normative values for the laboratory and to 
compare the effects of age and disease on retinal function using the mfERG. This was done 
prior to participants being allocated to treated and non-treated groups for the L and Z 
supplementation trial. 
 
Pupil size 
Pupil size controls the amount of light reaching the retina and therefore has a significant effect 
on the size of the mfERG response. Studies have shown that when pupil size is reduced mfERG 
N1P1 amplitude is significantly reduced and P1 latency delayed [274, 291].Therefore ISCEV 
mfERG guidelines recommend that pupils are dilated prior to mfERG recording [243]. For this 
study each participant at each visit was dilated with tropicamide 1% (Bausch and Lomb, 
Kingston-Upon-Thames, UK) for consistent pupil dilation for each visit.  
 
Media opacity and Intraocular lenses (IOLs) 
Any disturbance to the passage of light through to the retina will have an impact on mfERG 
waveforms. Therefore when assessing retinal responses with the mfERG it is important to 
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exclude participants with significant cataract or intraocular lenses as these factors affect the 
transmission of light through to the retina. Increasing severity of cataract has been associated 
with reduced mfERG amplitudes in the central retina [292]. Studies have compared mfERG 
responses before and after cataract surgery, and have found that mfERG N1P1 amplitudes 
significantly increased centrally after cataract surgery when compared with amplitudes prior to 
surgery [293, 294]. The effects of differing strengths of light scattering acrylic filters on mfERG 
waveforms have been studied, again largely showing central reduction in amplitude [295] 
although this was not statistically significant. Other work using a liquid crystal light diffuser 
also showed a statistically significant reduction in macular mfERG amplitudes [260]. Another 
study found that mfERG amplitudes were significantly reduced peripherally as well as centrally 
in eyes with cataract when compared to post-operative amplitudes [296].  
 
Eyes with IOLs were excluded from this study because we wanted to obtain normative values 
for our laboratory and assess baseline differences between healthy younger, healthy older and 
ARM eyes. Because young eyes do not routinely require IOLs, exclusion of any eyes with IOLs 
meant that any mfERG differences between young and old eyes, or young and ARM eyes could 
be attributed to age or macular disease rather than a change of optics caused by the IOLs.  
 
Axial length and refractive error 
Increasing severity of myopia has been associated with reduced mfERG amplitudes and delayed 
latencies. One study found a reduction in central mfERG N1 amplitude and both central and 
paracentral mfERG P1 amplitudes with increasing degrees of myopia and axial length. 
Refractive error was correlated with axial length in this study [297]. Other work assessing the 
effects of myopia in adults and children found that central and peripheral mfERG N1, P1 and 
N2 amplitudes reduced and N1, P1 and N2 latencies increased in adults with myopia. However, 
this relationship was not demonstrated in children with myopia except for P1 latency. This 
increased with myopia in children for all areas analysed together but not when peripheral and 
central areas were analysed separately [298]. The authors attributed mfERG differences in the 
adult group to changes in retinal function over time with long-term myopia. A study by Chen et 
al found prolonged P1 latencies for all areas in myopic eyes when compared to emmetropic 
eyes [299]. They found that axial length accounted for 15% of the latency variance while 
refractive error was responsible for 27% of the variation in latency between groups. They 
suggested the remainder of the variance may be caused by other effects such as inter-subject 
variability. The authors suggested that this may have accounted for the lack of amplitude 
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difference between myopes compared to emmetropes in their study. Greater loss of peripheral 
mfERG P1 amplitudes were seen in another study of myopes when compared to an 
emmetropic/low myopic group [300] which the authors suggested may be due to a coarser 
distribution of cones in the periphery of the retina in eyes with an increased axial length. Some 
studies have attributed attenuated mfERG responses in myopia to reduced cone and outer retinal 
function [299, 300]. However, other non-conventional mfERG protocols [301], and 
conventional mfERG protocols combined with structural retinal tests [302] have also shown 
inner retinal function attenuation in myopia.  
 
As described in the results chapter there was no statistically significant difference between 
treated and non-treated groups for axial length or spherical equivalent. Therefore we did not 
need to adjust for this in our analysis. All participants’ refractive error was corrected throughout 
mfERG recordings using the refractor camera that accompanies the VERIS system. 
 
Drugs and diseases affecting retinal function  
The mfERG has been successfully used as a tool to assess the effects of drug toxicity on retinal 
function. Mercury toxicity in the retinas of 10 patients gave reduced P1, N1 and N2 amplitudes 
for all areas, with faster N1 latencies and delayed P1 latencies centrally in mfERG recordings 
[303]. Ethambutol is used as an effective treatment for treating tuberculosis. Its retinal toxicity 
has been demonstrated with central mfERG N1 amplitudes being reduced in these eyes when 
compared to a control group in one study [304] and N1 and P1 central amplitudes reductions 
seen in a case study [305]. The case study demonstrated that after 3 months of ceasing 
ethambutol treatment mfERG amplitudes recovered, providing supporting evidence of the 
usefulness of mfERG as a tool for assessing the effects of systemic drugs on retinal function. 
Hydroxychloroquine and chloroquine are anti-malarial medications but are also used to treat 
rheumatoid arthritis, systemic lupus erythematosus and Sjögren's Syndrome. Significant 
correlations between hydroxychloroquine dosage and central and/or paracentral mfERG 
amplitudes have been demonstrated with reductions in amplitude with increasing dosage of the 
drug [306-310]. The mfERG was also shown to be useful in demonstrating the reversal of toxic 
retinal effects when the medication was ceased [311]. Vigabatrin is an anti-epileptic drug that 
has been associated with attenuated retinal function as shown by mfERG testing [312]. 
Peripheral (8-23 degrees) mfERG amplitude reductions were demonstrated in one study in 6 of 
12 patients taking vigabatrin [313]. Other studies have also shown mfERG abnormalities which 
persist after cessation of vigabatrin [314].  
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There are systemic diseases that can affect retinal function as assessed by the mfERG. Diabetic 
and hypertensive participants were excluded from our studies due to the effects of diabetic [315-
319] and hypertensive retinopathy [320] on mfERG waveforms. As mfERG measures retinal 
function, retinal disease or damage will have an impact on mfERG amplitudes and/or latencies 
(see table 4.1) [216, 321-324]. 
 
Hence any participants taking medications that affect retinal function, or who had retinal disease 
(other than ARM in the ARM group) were excluded from this study. 
 
Table 4.1: Site and mechanism of retinal damage and effects on mfERG waveforms (adapted 
from Hood et al., 2000 [216]). 
Damage Mechanism mfERG P1 amplitude mfERG P1 latency 
Cone photoreceptor Outer segment 
damage / cell loss 
Smaller 
Smaller 
Moderate delay 
Normal 
Outer plexiform 
layer 
Altered synaptic 
transmission 
Normal or larger Large delay 
On-bipolar cells Cell loss Smaller Moderate delay 
Off-bipolar cell Cell loss Larger Slightly faster? 
Inner plexiform 
layer 
Altered synaptic 
transmission 
Approximately normal 
(waveform changes) 
Small delay 
(<3ms) 
Ganglion cell  Cell loss Approximately normal Approximately normal 
 
 
4.6 Experimental protocols 
 
Multifocal Electroretinography  
The VERIS science 6.1 (Electrodiagnostic imaging, San Mateo, California, USA) was used to 
record the mfERG. The multifocal stimulus, consisting of 61 scaled hexagons was displayed on 
a high-resolution, black-and-white cathode ray tube monitor 30cm wide and 30 cm high with a 
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frame rate of 75 Hz. The hexagon stimulus radius subtended approximately 20° of visual field. 
Each hexagon was independently alternated between white (200 cd/m²) and black (1cd/m²) 
according to a pseudorandom binary m-sequence [213]. Total recording time was four minutes. 
Recording time was divided into eight, 30 second segments allowing for participant rests. 
Fixation target perception was confirmed before testing commenced. The fixation target size 
was 1.5% of the area of the central hexagon. Each subject’s vision was optimally corrected with 
the VERIS system’s refractor/camera system. Participants were positioned 44cm from the 
stimulus, giving a stimulus viewing field of approximately 39 degrees. To allow equal 
magnification of the stimulus array on the retina, the distance between the participant’s eye and 
refractor/camera was adjusted by obtaining a sharp image on the observation monitor as per the 
manufacturer’s recommendation. The participant’s eye was monitored throughout testing using 
this system (figure 4.2).  Pupils were maximally dilated with tropicamide 1% (Bausch and 
Lomb, Kingston-Upon-Thames, Surrey, UK). Gold cup electrodes filled with signa gel (Parker 
laboratories, Fairfield, New Jersey, USA) were applied to the forehead (ground electrode) and 
approximately one centimetre posterior to the temporal canthus (reference electrode) of the 
tested eye after these areas were abraded and cleaned using nuprep (Weaver and company, 
Aurora, USA). A DTL fibre electrode (Diagnosys Ltd, Impington, Cambridge, UK) was used as 
the active electrode and was placed along the sclera adjacent to the lower eyelid. The participant 
was asked to blink to ensure that the electrode found the same natural position for each visit. 
These electrodes were used for the trial for participant comfort [325] and test-retest reliability 
[277, 278] while not obscuring vision. Proxymetacaine hydrochloride 0.5% (Bausch and Lomb, 
Kingston-Upon-Thames, Surrey, UK) was instilled to minimise blinking throughout the 
recording. Any recordings contaminated with artefact were discarded and repeated. The 
untested eye was obscured throughout the procedure. In order to remove signal artefacts and 
improve the signal to noise ratio but without attenuating mfERG waveforms, one iteration of 
artefact removal was performed for each mfERG recording. No spatial averaging was 
performed because this would reduce spatial resolution as each retinal area stimulated by a 
hexagon is averaged with 1/6
th
 of its neighbouring hexagons. Thus the waveform of each single 
retinal area stimulated by a single hexagon would lose some of its own identity as it was 
averaged with surrounding waveforms.  
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Figure 4.2: A picture of the refractor camera monitoring participant fixation. 
 
 
 
Contrast sensitivity 
The Pelli-Robson CS test (Clement Clarke International Ltd, Harlow, Essex, UK.) was 
measured at a 1 meter distance as per the manufacturer guidelines, with distance correction 
when required, as a quick and reliable method for testing contrast sensitivity [326]. Contrast 
sensitivity provides another tool for testing visual performance. Studies have shown it to be 
repeatable to within 3 letters or +/- 0.15 log units [327] and suggest that a significant change in 
CS score would be +/- 0.30 log units (1 line, or 6 letters) in healthy eyes [327, 328] and eyes 
with ARM [329]. Therefore this value was used as the effect size to calculate sample size in the 
power calculations for this trial. For consistency CS was undertaken in the same room for each 
visit with a background luminance of (142 lux) throughout the trial. The Pelli-Robson chart is a 
good measure of medium to low spatial frequencies [330]. 
 
Macular pigment optical density  
In order to obtain values for retinal accumulation of L and Z throughout the trial MPOD was 
obtained using the MPS 9000. The MPS 9000 uses the principle of heterochromatic flicker 
photometry (HFP). Participants were required to make flicker matches between two 
wavelengths of light, a blue light (~465nm), and green light (~530nm). Flicker matches were 
initially obtained centrally (1°). Flicker rate was gradually reduced from above the critical 
fusion frequency (60 Hz) by 6 Hz per second until the participant observed the flicker and 
pressed a response buzzer accordingly. This procedure continued for a series of pre-set blue-
green ratios. Once flicker was detected the luminance of the blue and green light was changed 
by 0.2dB increasing the blue light and decreasing the green light while the overall mean 
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luminance was kept constant. Then the temporal frequency was reset to 60 Hz and the 
frequency reduced by 6 Hz per second again. The sequence continued for a series of blue-green 
ratios until a V-shaped curve was obtained. The minimum value of this curve was where the 
blue and green lights were of equal luminance. This whole process was repeated peripherally 
(8°) and again a V-shaped curve was obtained, providing a minimum value where blue a green 
lights were equiluminant. Because MP selectively absorbs blue light and is found centrally but 
not peripherally, the central minimum value differed from the peripheral minimum value. 
MPOD was determined by dividing central minimum blue light intensity by peripheral 
minimum blue light intensity and log10 of this value using MPS 9000 computer software. 
Greater detail of this technique is described by Van Der Veen et al. [331]. Both the background 
and target luminance was set to 250 cd/m². Participants wore distance glasses for the test if 
required, and were instructed to fixate on the central target for obtaining central values. For 
peripheral testing participants were asked to blink frequently and adopt a more relaxed fixation 
at 8° around a 1.75° red fixation target to reduce Troxler’s effect. Troxler’s effect is named after 
the person who discovered this phenomenon, Ignaz Paul Vital Troxler in 1804 as cited by 
Martinez-Conde et al. [332]. When fixating at a single point for longer than 20 seconds, any 
stimulus away from that point will fade and disappear. This is due to neural adaptation. Small 
eye movements around the peripheral fixation target improve peripheral stimulus visibility, 
reducing Troxler’s effect when obtaining peripheral MPOD values [332]. Instructions were 
given to the participant prior to the test and a practice run was undertaken for each visit before 
undertaking the main test. A study assessing the repeatability of the MPS 9000 within the 
laboratory at Aston University demonstrated a coefficient of repeatability of 0.33, suggesting 
that a clinically significant change in MPOD would be 0.33 units or greater [333]. Therefore 
this value was chosen as the effect size to calculate sample size in the power calculations for 
this trial.   
 
Visual acuity 
LogMAR distance VA testing using a 3 meter ETDRS 750 lux retro-illuminated chart was 
undertaken for each participant (Sussex Vision, Rustington, West Sussex, UK). The eye with 
the best corrected VA was determined at the participant’s first visit and this eye was assessed 
for the subsequent 3 visits. In the case of the ARM participants, the eye with ARM was studied. 
If both eyes had ARM, the eye with the best corrected visual acuity was included in the study to 
ensure good mfERG fixation. Only one eye was chosen per participant because of intraclass 
correlation - environmental and genetic risk factors for ARMD such as smoking, age and 
genetic disposition, act on the individual and thus have an impact on the probability of the 
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disease occurring in both eyes, even if not clinically visible in both eyes [334]. Significance 
testing where total sample size (eyes) exceeds the number of participants is invalid and prone to 
false positive findings [335]. Confidence intervals and SDs would also be misleading due to a 
mixture of between-subject and within-subject variation [335].The advantage of using logMAR 
charts are that they have five letters per line with 0.1 logMAR progression per line, whereas 
Snellen charts do not provide this linear scale and have an increasing number of letters per line 
as the letter size decreases. LogMAR charts are reported to be an accurate tool for assessing VA 
[336]. Repeatability of logMAR VA tests has already been reported in the literature, with test-
retest variability ranging between 0.07-0.19 [336-340].  
 
Intraocular pressure 
Non-contact intraocular pressure readings (Topcon CT-80 non-contact tonometer, Topcon, 
Newbury, Berkshire, UK) were taken prior to instillation of tropicamide 1%. If readings of 
21mmHg or above were recorded, the participant was advised to see an optometrist for further 
measurements and advice, and was excluded from the study. This happened for one participant. 
If under 21mmHg, tropicamide 1% was instilled for the mfERG. Intraocular pressure was 
rechecked at the end of each participant visit.  
 
Fundus photography 
A central 45 degree fundal photograph was taken with the Topcon TRC-NW8, (Topcon, 
Newbury, Berkshire, UK) for each visit to determine any change in fundus or media opacity. 
Participants were instructed to fixate on a central fixation target for each visit to ensure identical 
fundus positioning. None of the healthy eyes progressed to ARM throughout the trial. None of 
the ARM participants progressed to AMD throughout the trial.  
 
Food Diaries 
In order to assess whether any changes in outcome measures were due to the lutein-based 
nutritional supplement rather than changes in dietary intake of nutrients, each participant was 
provided with a food diary (see appendix 9). The diary was filled in over two week days and 
one weekend day. Participants were given food diaries at visits one, three and four to complete. 
The data from the food diaries was inputted into the Weighted Intake Software Package (WISP, 
Tinuviel, Llanfechell, Anglesey, UK). Lutein values for foods were taken from the United 
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States department of agriculture (USDA) nutrient databank, release 23 
(http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Data/SR23/nutrlist/sr23a338.pdf). 
 
4.7 Chapter four summary 
This chapter described the primary and secondary outcome measures that were used to assess 
the effects of a L-based nutritional supplement on objective and subjective measures of visual 
and retinal function. The many factors that can affect mfERG waveforms were explained. The 
methods employed to reduce or eliminate these factors, while providing a comfortable mfERG 
recording experience for each participant were discussed. Experimental protocols were 
described for transparency and in order for the experiments to be replicated by other research 
groups.  
 
Because it is necessary for all laboratories to obtain normative mfERG data, the next chapter 
reports the normative data for HY and HO eyes. This is compared with mfERG values for ARM 
eyes to ascertain differences in mfERG values due to age and age-related eye disease. 
Coefficient of variability and repeatability for mfERG values are also determined for N1P1 
amplitude, and N1, P1 and N2 latency. Sample size calculations for the primary and secondary 
outcome measures are also reported in chapter five. Because there are conflicting findings as to 
whether dietary and retinal levels of L are reduced in individuals with ARMD, baseline dietary 
and MPOD analysis between HY, HO and ARM groups are also reported. 
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Chapter 5: Baseline data analysis 
 
5.1 Sample size 
Sample sizes were calculated as per Lehr [341]. Two previous studies assessing the effects of 
nutritional supplementation on retinal function using focal electroretinograms (fERG) [134] and 
mfERG [103] demonstrated significant results between groups treated with a nutritional 
supplement compared with non-treated groups. The fERG study suggested a sample size of 8 
healthy eyes for their healthy older (HO) group and 30 eyes for the age-related maculopathy 
(ARM) group [134], providing a 90% power, at α = 0.05, for detecting a between group 
difference of 25 – 30% in amplitude or phase. The mfERG study by the CARMIS investigators, 
suggested 27 ARM eyes, 15 in the supplemented group and 12 in the non-supplemented group 
[103], providing a power of 90%, at α = 0.05, for detecting a between-group difference of ≥ 
55% in mfERG amplitude. As such the 55% difference was used as the effect size in sample 
size calculations for this trial [103] (table 5.1 and 5.2).  
 
Because there is paucity in the literature about mfERG latency changes with nutritional 
supplementation, effect sizes for mfERG latency were based on a study for vitamin A 
supplementation by Dolan et al., who noted a change in central and peripheral P1 latency of 6 
ms with vitamin A supplementation in a single participant case study [342]. Thus, the sample 
sizes were adequate for the primary outcome measure in this thesis in providing an 80% power 
at the 5% significance level. 
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Table 5.1: Group sizes required to have 80% power at the 5% significance level for VA, CS, 
mfERG amplitude and MPOD for healthy eyes. The mean and standard deviation (SD) data 
were calculated from 52 healthy eyes at visit 1. 
 VA 
(logMAR) 
CS 
(log units) 
MPOD 
 
Central mfERG  
N1P1 amplitude 
(nV/deg
2
) 
Central mfERG P1 
latency (ms) 
Mean -0.11 1.89 0.39 173.17 29.09 
Standard 
deviation (SD) 
0.11 0.12 0.16 50.12 1.43 
Effect size (E) 0.10^^ 0.30^ 0.33* 95.24** 6.00*** 
E/S 0.91 2.50 2.06 1.90 4.20 
(E/SD)
2
 0.83 6.25 4.25 3.61 17.60 
Sample size = 
16/(E/SD)
2 
(two sided) 
19 3 4 4 1 
 
^^ Based on VA repeatability studies [336-340].  
^ Based on Elliott et al’s paper [327]. 
* Repeatability value from Bartlett et al’s of HFP repeatability paper [333] 
** Based on Parisi et al’s paper of a 55% change in mfERG amplitude [103] 
*** Based on Dolan et al’s paper [342]. 
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Table 5.2: Group sizes required to have 80% power at the 5% significance level for VA, CS, 
mfERG amplitude and MPOD for ARM eyes. The mean and SD data were calculated from 16 
ARM eyes at visit 1. 
 VA 
(logMAR) 
CS 
(log units) 
MPOD 
 
Central mfERG 
N1P1 amplitude 
(nV/deg
2
) 
Central mfERG 
P1 latency (ms) 
Mean 0.03 1.77 0.36 120.14 30.83  
Standard deviation 
(SD) 
0.06 0.15 0.24 38.82 1.72 
Effect size (E) 0.10^^ 0.30^ 0.33* 66.08** 6*** 
E/SD 1.67 2.00 1.38 1.70 3.48 
(E/SD)
2
 2.79 4.00 1.89 2.90 12.16 
Sample size = 
16/(E/SD)
2 
(two sided) 
6 4 9 6 2 
 
^^ Based on VA repeatability studies [336-340].  
^ Based on Elliott et al’s paper [327]. 
* Repeatability value from Bartlett et al’s of HFP repeatability paper [333]. 
** Based on Parisi et al’s paper of a 55% change in mfERG amplitude [103]. 
*** Based on Dolan et al’s paper [342]. 
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5.2 Investigating the effect of age and ARM, on mfERG measures - baseline values 
 
5.21 Purpose 
The mfERG response is affected by many variables as previously described in chapter 4. As an 
outcome measure for assessing the effects of a nutritional supplement versus non-
supplementation in ARM eyes and healthy eyes, it was important to establish normative mfERG 
data for comparison with diseased eyes. 
 
5.22 Methods 
Eighty one eyes from 81 participants aged between 18-83 (mean ± sd; 50.3 ± 18.1) were 
recruited over a nine month period from Aston University (Birmingham, UK) optometry 
department patients, and from staff and students from within the University. They were divided 
into three groups: a healthy younger (HY) group of 37 participants aged between 18-48, (mean 
age ± sd; 32.9 ± 9.0 years), a healthy older group (HO) of 28 participants aged between 50-77, 
(mean age ± sd; 63.4 ± 8.1 years) and an ARM group of 16 participants aged between 52-83 
(mean age 67.2 ± 8.5 years). Age-related maculopathy was defined as per the international 
classification system described in chapter 1 [34]. Multifocal ERG outcome measures were; 
N1P1 amplitude, measured from the N1 trough to the P1 peak; N1 latency, measured from the 
start of the trace to the N1 trough; P1 latency, measured from the start of the trace to the P1 
peak; and N2 latency, measured from the start of the trace to the N2 trough (see figure 4.1 in 
chapter 4). Multifocal ERG testing was carried out as per the experimental protocols set out in 
chapter 4.  
 
Kruskal-Wallis and one-way between groups analysis of variance (ANOVA) using statistical 
packages for social sciences - SPSS 16.0 (SPSS UK Ltd, West Street, Woking, Surrey) were 
conducted to explore the impact of age and ARM on retinal function of five retinal areas (see 
figures 5.1 and 5.2) using the mfERG. Each data set was checked for normality using the 
Shapiro-Wilk statistic which assesses the normality of distribution of the data. A non-significant 
result indicates normality and therefore ANOVA was used for analysis with Tukey’s post-hoc 
range test. When parametric assumptions were not met according to Shapiro-Wilk tests for 
normality (i.e. there was a statistical significance for the Shapiro-Wilk test), Kruskal-Wallis 
one-way analysis of variance for independent groups was performed with Mann-Whitney U 
tests demonstrating post-hoc differences between groups (tables 5.3, 5.4, 5.5 and 5.6).  
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Figure 5.1: Grouping of the mfERG areas analysed. Ring 1 - central hexagon (approximately 
0.0-2.5º), ring 2 (approximately 2.5-5.0º) surrounds the central hexagon, ring 3 (approximately 
5.0-10.0º) surrounds ring 2, ring 4 (approximately 10.0-15.0º) surrounds ring 3 and ring 5 
(approximately 15.0-20.0º) surrounds ring 4. 
  
                                        
Figure 5.2: mfERG waveforms. Each trace corresponds to the average of each ring of hexagons 
analysed. N1 is denoted by the first cursor, P1 by the second, and N2 by third cursor. The 
difference between the first two cursors denotes N1P1 amplitude. The x-axis is in milliseconds.  
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5.23 Results 
An independent-samples t-test demonstrated no significant difference in age between the ARM 
(mean ± sd: 67.2 ± 8.5 years) and HO (63.4 ± 8.1 years) groups; t = 1.45, p = 0.16. There was a 
significant difference using ANOVA in spherical equivalent refraction (F = 3.43, p = 0.04), 
between the HY (mean ± sd: -0.23 ± 1.90), HO (0.78 ± 2.39) and the ARM (1.29 ± 2.17) groups 
with post-hoc analysis demonstrating a difference between ARM and HY groups; p=0.02 but no 
difference between HY and HO eyes, or between HO and ARM eyes. A Chi-squared test for 
independence using SPSS 16.0 software indicated a significant difference between ethnicity and 
groups, with HO and ARM groups exclusively containing 28 and 16 caucasians respectively 
and the HY group containing 8 asians and 29 caucasians (χ² = 10.56, p = 0.01, p = 0.01). There 
was no significant difference between gender and groups (χ² = 0.14, p= 0.93) with 13 males and 
24 females in the HY group, 9 males and 19 females in the HO group and 6 males and 10 
females in the ARM groups. 
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Table 5.3: Baseline comparison data for multifocal electroretinogram rings 1-5 N1P1 amplitudes, between HY, HO and ARM cohorts using one way between-
groups ANOVA and Kruskal-Wallis one-way analysis of variance for independent groups when parametric assumptions were not met. 
 Ring 1 Ring 2 Ring 3  Ring 4  Ring 5 
N1P1 
Amplitudes  
χ² = 18.626 
(p = <0.001*) 
χ²  = 15.360 
(p = <0.001*) 
χ² = 9.258 
(p = <0.010*) 
χ² = 8.166 
(p = 0.017*) 
χ²  = 7.223 
(p = 0.027*) 
Post-hoc analysis 
HY / HO p = 0.107 
Mann-Whitney U 
p = 0.059 
Mann-Whitney 
U 
p = 0.251 
Mann-Whitney U 
p = 0.234 
Mann-Whitney U 
p = 0.366 
Mann-Whitney 
U 
HO / ARM p = 0.004* 
Mann-Whitney U 
p = 0.021* 
Mann-Whitney 
U 
p = 0.062 
Mann-Whitney U 
p = 0.078 
Mann-Whitney U 
p = 0.080 
Mann-Whitney 
U 
HY / ARM p = <0.001* 
Mann-Whitney U 
p = <0.001* 
Mann-Whitney 
U 
p = 0.002*  
Mann-Whitney U 
p = 0.005* 
Mann-Whitney U 
p = 0.007* 
Mann-Whitney 
U 
* Statistically significant where p=<0.05 
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Table 5.4: Baseline comparison data for multifocal electroretinogram rings 1-5 N1 Latencies between HY, HO and ARM eyes using one way between-groups 
ANOVA and Kruskal-Wallis one-way analysis of variance for independent groups when parametric assumptions were not met. 
 Ring 1 Ring 2 Ring 3  Ring 4  Ring 5 
N1 latency  χ² = 12.630 
(p = 0.002*) 
 χ² = 11.917 
(p = 0.003*) 
 χ² = 15.348 
(p = <0.001*) 
χ²  = 8.059 
(p = 0.018*) 
 χ² = 13.444 
(p = 0.001*) 
                       Post-hoc analysis   
HY / HO p = 0.024* 
Mann-Whitney U 
p = 0.033* 
Mann-Whitney U 
p = 0.070 
Mann-Whitney U 
p = 0.152 
Mann-Whitney U 
p = 0.115 
Mann-Whitney U 
HO / ARM p = 0.071 
Mann-Whitney U 
p = 0.104 
Mann-Whitney U 
p = 0.006* 
Mann-Whitney U 
p = 0.093 
Mann-Whitney U 
p = 0.018* 
Mann-Whitney U 
HY / ARM p = 0.001* 
Mann-Whitney U 
p = 0.001* 
Mann-Whitney U 
p = <0.001* 
Mann-Whitney U 
p = 0.007* 
Mann-Whitney U 
p = <0.001* 
Mann-Whitney U 
* Statistically significant where p=<0.05 
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Table 5.5: Baseline comparison data for multifocal electroretinogram rings 1-5 P1 Latencies between HY, HO and ARM eyes using one way between-groups 
ANOVA and Kruskal-Wallis one-way analysis of variance for independent groups when parametric assumptions were not met. 
 Ring 1 Ring 2 Ring 3  Ring 4  Ring 5 
P1 latency χ² = 16.184 
(p = 0.001*) 
χ² = 21.806 
 (p = <0.001*) 
χ²  = 19.090 
(p = <0.001*) 
χ² = 15.759 
(p = <0.001*) 
χ² = 28.491 
(p = <0.001*) 
                                    Post-hoc analysis   
HY / HO  p = <0.001*  
Mann-Whitney U 
p = <0.001*  
Mann-Whitney U 
p = <0.001*  
Mann-Whitney U 
p = <0.001* 
Mann-Whitney U 
p = <0.001* Mann-
Whitney U 
HO / ARM p = 0.807 
Mann-Whitney U 
p = 0.864  
Mann-Whitney U 
p = 0.740 
Mann-Whitney U 
p = 0.892 
Mann-Whitney U 
p = 0.186 
Mann-Whitney U 
HY / ARM p = 0.003*  
Mann-Whitney U 
p = 0.002*  
Mann-Whitney U 
p = 0.003* 
Mann-Whitney U 
p = 0.005* 
Mann-Whitney U 
p = <0.001*  
Mann-Whitney U 
*Statistically significant where p=<0.05 
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Table 5.6: Baseline comparison data for multifocal electroretinogram rings 1-5 N2 Latencies between HY, HO and ARM eyes using one way between-groups 
ANOVA and Kruskal-Wallis one-way analysis of variance for independent groups when parametric assumptions were not met. 
 Ring 1 Ring 2 Ring 3  Ring 4  Ring 5 
N2 latency χ² = 7.634 
(p = 0.022*) 
F = 10.247 
 (p = <0.001*) 
χ²  = 20.985 
(p = <0.001*) 
χ² = 18.457 
(p = <0.001*) 
χ² = 14.794 
(p = 0.001*) 
                                    Post-hoc analysis   
HY / HO  p = 0.014*  
Mann-Whitney U 
p = 0.002*  
 
p = <0.001*  
Mann-Whitney U 
p = <0.001* 
Mann-Whitney U 
p = <0.002* Mann-Whitney 
U 
HO / ARM p = 0.706 
Mann-Whitney U 
p = 0.756 
 
p = 0.652 
Mann-Whitney U 
p = 0.777 
Mann-Whitney U 
p = 0.263  
Mann-Whitney U 
HY / ARM p = 0.041*  
Mann-Whitney U 
p = 0.001*  p = <0.001* 
Mann-Whitney U 
p = 0.004* 
Mann-Whitney U 
p = 0.002* 
Mann-Whitney U 
*Statistically significant where p=<0.05 
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Table 5.7: Mean values for mfERG N1P1 amplitude, N1 latency, P1 latency and N2 latency between HY, HO and ARM eyes for 5 rings of eccentricity. 
 Ring 1 Ring 2 Ring 3  Ring 4  Ring 5 
 Mean amplitudes ± SD (nV/deg
2
)          
HY  178.65 ± 54.02 72.11 ± 19.84 41.88 ± 12.46 28.09 ± 8.51 17.12 ± 5.48 
HO  155.77 ± 38.82 61.83 ± 15.12 37.43 ± 10.15 24.70 ± 7.19 15.82 ± 5.69 
ARM  120.14 ± 38.82 52.00 ± 15.30 32.10 ± 9.31 21.96 ± 6.39 13.21 ± 4.43 
 Mean N1 latencies ± SD (ms)         
HY 15.16 ± 2.45 14.08 ± 1.53 14.80 ± 1.13 14.95 ± 0.96 14.62 ± 1.42 
HO 15.58 ± 1.91 15.18 ± 1.97 15.39 ± 0.95 15.17 ± 1.13 14.95 ± 1.52 
ARM 15.60 ± 3.06 15.21 ± 1.54 15.78 ± 1.38 15.36 ± 1.22 15.00 ± 1.69 
Mean P1 latencies ± SD (ms)        
HY 28.45 ± 1.47 27.12 ± 1.50 27.64 ± 1.52 28.24 ± 1.37 28.83 ± 1.07 
HO 30.71 ± 2.88 29.17 ± 1.59 29.28 ± 1.18 29.38 ± 1.13 30.21 ± 1.00 
ARM 30.14 ± 3.09 28.85 ± 2.58 29.06 ± 2.27 29.69 ± 1.52 30.83 ± 1.72 
Mean N2 latencies ± SD (ms)         
HY 42.95 ± 1.45 42.31 ± 1.68 41.50 ± 1.06 41.66 ± 1.69 42.11 ± 1.45 
HO 44.28 ± 2.11 43.26 ± 2.09 42.65 ± 0.95 42.88 ± 1.28 43.16 ± 1.39 
ARM 43.93 ± 1.80 43.57 ± 1.86 42.86 ± 0.91 43.04 ± 1.55 43.69 ± 1.62 
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N1P1 amplitudes were significantly reduced in the ARM group compared with the HO group 
for rings 1 and 2. Amplitudes were reduced for all 5 rings in the ARM group compared to the 
HY group (table 5.3 and 5.7).  
 
N1 latencies were significantly longer in HO group compared to the HY group in rings 1 and 2. 
The ARM group showed longer N1 latencies in rings 3 and 5 than in the HO group and for all 5 
rings when compared to the HY group (table 5.4 and 5.7). 
 
P1 latencies were significantly longer in HO and in ARM eyes when compared to HY eyes for 
all 5 rings (table 5.5 and 5.7).  
 
N2 latencies were also significantly longer for all 5 rings in HO and ARM eyes compared to HY 
eyes for all 5 rings (table 5.6 and 5.7).  
 
5.24 Discussion  
Because mfERG was going to be used to assess the longitudinal effects of a nutritional 
supplement on retinal function in healthy and diseased eyes, the aim of this study was to 
compare the effects of age and ARM on mfERG N1P1 amplitudes and N1, P1 and N2 latencies 
at baseline, and to establish a normative database for our laboratory as recommended by ISCEV 
guidelines [243]. 
 
The effect of age on retinal function as assessed by the mfERG  
Mean amplitudes were reduced for all 5 rings in HO eyes when compared to HY eyes but this 
did not reach statistical significance in this study. There were statistically significantly 
prolonged N1 latencies in rings 1 and 2 in HO eyes compared to HY eyes. There were 
prolonged P1 latencies in rings 1-5 of HO eyes when compared to HY eyes. N2 latencies for all 
5 rings were also delayed in HO eyes compared to HY eyes. Nabeshima et al., found reduced 
mfERG N1P1 amplitudes in all 5 rings in subjects over 50 years compared to younger subjects, 
but not prolonged P1 latencies. Their study included 52 eyes and assessed rings of retinal 
eccentricity with 61 hexagonal stimuli as used in this study [240]. Our study compared a larger 
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number of 65 healthy eyes. However, in a further study by Nabeshima et al., reduced N1P1 
amplitudes and delayed P1 latencies in 93 normal eyes of 56 participants were seen, although it 
was not stated whether ring analysis was used or which areas were affected [343]. Jackson et 
al., also found lower mean amplitudes and prolonged N1 and P1 latencies in older adults 
compared to younger adults, with mfERG ageing changes being greatest at the fovea and 
decreasing with eccentricity in a seven ring 103 hexagon analysis [344] and this was echoed in 
other studies [345, 346]. Anzai et al., found a significant inverse correlation between amplitude 
and age in the central retina up to 8 degrees but not at other locations [347],  although there was 
no statistically significant change in latency with age in this study. Seiple et al., found that the 
rate of amplitude reduction was greatest in the central 3º [348] but found that age had less 
influence on latency. Conversely a small number of studies have found no difference in mfERG 
amplitude with age [241, 349].  
 
It is thought that ageing-related mfERG changes are due to preretinal optical and neural 
contributions [350-353]. We used the conventional mfERG for this study, which is cone-driven. 
It has been shown that cone and rod photoreceptor density decline with age, with rods declining 
at a greater rate than cones [354]. There are significant interactions between rods and cones, 
with evidence to suggest that rods are required for cone survival [355] and secrete factors that 
enhance cone survival [356]. Thus, rod and cone photoreceptor decline with age may explain 
age-related changes within the mfERG.  
 
The effect of ARM on retinal function as assessed by the mfERG  
This study demonstrated significantly reduced amplitudes in rings 1 and 2, and prolonged N1 
latencies in rings 3 and 5 in eyes with ARM when compared to age, gender and ethnicity-
matched HO eyes. Foveal (ring 1) amplitude reductions and delayed N1 latency was found in 15 
eyes with ARM in a study by Li et al., using a 6 ring analysis of 103 hexagonal stimuli [227]. A 
similar result was seen in another study with ring 1 and 2 amplitudes being reduced in 15 ARM 
eyes, although N1, P1 and N2 latency results were not reported here [357]. Gerth et al., were 
able to demonstrate reduced amplitudes and prolonged N1, P1 and N2 latencies in 31 ARM 
eyes extending out to 25 degrees in radius in some eyes [221] when using 103 hexagonal 
stimuli. However they did not use ring analysis for their study but rather individual retinal area 
per hexagon analysis.  No N1P1 amplitude reduction or prolonged N1 or P1 latency was found 
in a 61 hexagonal stimuli study of 24 ARM eyes when using 5 ring analysis, although the 
summed responses of all 5 rings showed reduced N1 amplitude which is a different measure 
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than the N1P1 amplitude used in our analysis [228].  N2 latency was not reported in their study. 
Another study using both 103 and 61 hexagonal stimuli and using a curve-fitting data analysis 
method also found no statistical significant mfERG changes in ARM eyes, although ring 
analysis was not carried out here but a central versus peripheral analysis [233]. 
 
As described in chapter 1, the RPE phagocytoses the outer segment discs of the photoreceptors 
and is a point of metabolite and waste exchange [21]. In ARM there are variations within and 
below the RPE, seen as alterations in the pigmentation of the RPE, with or without the 
occurrence of drusen [35]. Drusen may cause displacement of photoreceptor outer segments and 
disturb nutrient exchange between the choriocapillaris and photoreceptors [358]. Accumulation 
of lipofuscin within the RPE and lipids in Bruch’s membrane occurs with age [37], possibly 
caused by the reduced ability of the RPE’s phagocytic-lysosomal system to efficiently digest 
photoreceptor outer segment membranes [38]. This accumulated material may interrupt the 
supply of nutrients from the choroid to the retina ultimately leading to photoreceptor atrophy 
[39]. Oxidative stress causes injury and inflammation to the RPE and choriocapillaris which 
may lead to an altered extracellular matrix, also affecting nutrient supply to the RPE and retina, 
further damaging the RPE and retina, leading to the retinal atrophy seen in the later stages of 
ARMD [40].  
 
There is some evidence to suggest that rods are the first photoreceptors to degenerate in ARMD 
[358, 359]. As mentioned previously, cone photoreceptor function is dependent on the support 
of rod photoreceptors. Rods are more prolific within the peripheral retina than the central retina 
and support cone photoreceptor function. Cone photoreceptors drive the conventional cone-
mediated mfERG. It may be that the prolonged N1 latencies found for rings 3 and 5 in ARM 
eyes in this study may be due to attenuation of rod function, on which cone function relies.  
 
Results showed prolonged N1 (rings 1 and 2), P1 (rings 1-5) and N2 latencies (rings 1-5) with 
ageing. However, with ARM, prolonged ring 3 and 5 N1 latencies were seen and were 
accompanied by a reduction in central mfERG amplitudes when compared to age-matched 
healthy eyes. According to Gerth et al., [221] and Hood et al., [216] (see table 4.1) altered 
synaptic transmission results in delayed mfERG latency whereas cell loss reduces mfERG N1P1 
amplitude. This may suggest that photoreceptor synaptic transmission slows with age, whereas 
photoreceptor damage and dysfunction as seen in ARMD causes the central amplitude 
reductions seen here in ARM eyes [221].  
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It may appear obvious that due to the effects of age and disease there were prolonged N1, P1 
and N2 latencies, and reduced N1P1 amplitudes for all 5 rings in the ARM group compared 
with the HY group in post-hoc tests for our study. However for transparency of research 
reporting the data was included. A mean difference in refractive error was found between the 
HY and ARM group of 1.52 dioptres. A large variation in refractive error (greater than +3.00 
dioptres) does have a significant impact on mfERG N1P1 amplitude. However, small variations 
such as ours have minimal responses on mfERG measures [360]. Furthermore, any refractive 
error was corrected for with the refractor camera when measuring the mfERG in our study. 
There is no evidence in the literature to suggest that the mfERG varies between differing ethnic 
groups. Therefore the difference between group ethnicity in our study should not have affected 
the results. 
 
5.25 Conclusion 
The aim of this study was to establish a normative database for our laboratory as recommended 
by ISCEV guidelines and to compare the effects of age and ARM on mfERG N1P1 amplitudes 
and N1, P1 and N2 latencies at baseline prior to undertaking a study to assess the effects of a 
nutritional supplement on retinal function in healthy eyes and eyes with ARM.  
 
This baseline study demonstrated age-related changes in the mfERG which emphasised the 
importance of having age-matched groups for comparing the effects of intervention when using 
the mfERG to assess retinal function. It also revealed changes in retinal function in ARM, 
highlighting the sensitivity of the mfERG as a tool for detecting central outer retinal dysfunction 
in ARM. 
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5.3 Investigating the coefficient of variation and coefficient of repeatability of mfERG 
measures for different rings of retinal eccentricity between younger, older and diseased 
eyes 
 
5.31 Purpose 
The previous section demonstrated that mfERG responses were age-dependent. Further to 
ageing, ARM caused N1P1 amplitude reductions in rings 1 and 2, and N1 latency delays in 
rings 3 and 5 when compared to age-matched HO eyes.  
 
As described in chapter 4, mfERG amplitudes can show a high degree of variability depending 
on technical and participant factors. Thus the purpose of this study was to assess the reliability 
of recordings within the laboratory by comparing the coefficient of variation (CV) for the HY, 
HO and ARM groups for N1P1 amplitudes and N1, P1 and N2 latencies for five rings of 
eccentricity. Coefficient of repeatability (CR) was also assessed in healthy eyes.  
 
Short and medium term CR were assessed to compare repeatability of mfERG over time for 
healthy eyes. Medium term CR was also assessed in ARM eyes to compare repeatability of 
mfERG between healthy and ARM eyes. 
 
The CV is a ratio of the SD to the mean (μ) (SD / μ) and is useful for measuring mfERG 
amplitude and latency variability between the differing rings of eccentricity and for examining 
variation between groups of data for a single visit. The CR can be used to analyse the 
repeatability of a single measurement method over two visits [361]. It is calculated as 1.96 
multiplied by the SD of the mean differences between two sets of data from the mfERG (one set 
per visit in this case) and this provides 95% confidence limits for the difference between two 
sets of data. In this study the CR values demonstrated the amount of change in mfERG 
measures between visits which could be put down to measurement noise.  
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5.32 Methods 
Coefficient of variation (CV): 81 eyes from 81 participants as per the characteristics described 
in section 4.22 were recruited over a nine month period from Aston University (Birmingham, 
UK) optometry department patients, and from staff and students from within the university. 
They were divided into three groups: a HY group of 37 participants, a HO group of 28 
participants and an ARM group of 16 participants.  
 
Coefficient of repeatability (CR): Repeatability of the mfERG was assessed over the short (CRS 
and medium term (CRM) in healthy eyes. Medium term mfERG repeatability (CRM) was also 
assessed for ARM eyes. 
 
Short term CR (CRS) for healthy eyes: Eight healthy eyes, aged between 19 and 57 (mean ± sd; 
35.8 ± 11.7 years) were available to evaluate the CRS. Multifocal ERG was performed at two 
visits, the second visit being within seven days of the first (mean ± sd; 2.63 ± 2.72 days).  
 
Medium term CR (CRM) for healthy eyes: Twenty six healthy eyes, aged between 21 and 69 
(mean ± sd; 43.7 ± 16.4 years) were available to evaluate the CRM. Multifocal ERG was 
performed at two visits, the second visit being approximately 5 months after the first (mean ± 
sd; 4.92 ± 0.63 months). 
 
Medium term CR (CRM) for ARM eyes: Four eyes with ARM, aged between 61 and 70 (mean 
± sd; 65.0 ±3.9 years) were available to evaluate CRM for this group. Multifocal ERG was 
performed at two visits, the second visit being approximately 5 months after the first (mean ± 
sd; 5.00 ± 0.82 months). Multifocal ERG was carried out as per the mfERG methods in chapter 
4.  
 
5.33 Results 
All repeatability measures were calculated using Microsoft Excel software (Microsoft 
Corporation, Microsoft Way, Redmond, WA, USA).  
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The CV for all parameters for all five rings of eccentricity can be seen in tables 5.8, 5.9, 5.10 
and 5.11. The mean overall variability for mfERG N1P1 amplitude was 30% for the HY group, 
29% for the HO group and 31% for the ARM group. The mean overall variability for N1 
latency was 10% for the HY group, 10% for the HO group and 12% for the ARM group. The 
mean overall variability for P1 latency was 5% for the HY group, 5% for the HO group, and 8% 
for the ARM group. The mean overall variability for N2 latency was 3% for the HY and HO 
groups and 4 % for the ARM group.  
 
The CRS for all mfERG measures for five rings of eccentricity can be seen in table 5.12. The 
overall mean area CRS was 1.30 ms for N1 latency, 1.90 ms for P1 latency, 1.72 ms for N2 
latency and 40.45 nV/deg
2 
for N1P1 amplitude. The CRM for all mfERG measures for five 
rings of retinal eccentricity can be seen in table 5.13. The total mean area CRM was 2.12 ms for 
N1 latency, 2.54 ms for P1 latency, 2.74 ms for N2 latency and 43.36 nV/deg
2 
for N1P1 
amplitude.  
 
The CRM for ARM eyes for all mfERG measures for five rings of retinal eccentricity is shown 
in table 5.14. The total mean area CRM for ARM eyes was 2.83 ms for N1 latency, 2.82 ms for 
P1 latency, 2.89 ms for N2 latency and 15.58nV/deg
2
 for N1P1 amplitude. 
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Table 5.8: Coefficient of variability (CV) for N1P1 amplitude for each of the five areas of retinal eccentricity and mean CV for all rings 
 
 
 
Table 5.9: Coefficient of variability (CV) for N1 latency for each of the five areas of retinal eccentricity and mean CV for all rings 
 
 
 
CV for N1P1 amplitude (%) Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 total area mean CV 
HY (n=37) 29.58 27.24 29.52 30.27 30.68 29.46 
HO (n=28) 25.10 24.63 27.25 27.67 37.36 28.40 
ARM (n=16) 29.46 28.64 28.16 28.59 32.34 29.40 
CV for N1 latency (%) Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 total area mean CV 
HY (n=37) 7.04 7.80 5.39 5.31 5.62 6.23 
HO (n=28) 6.16 5.83 3.94 4.23 4.98 5.03 
ARM (n=16) 9.45 6.84 6.18 5.89 5.82 6.84 
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Table 5.10: Coefficient of variability (CV) for P1 latency for each of the five areas of retinal eccentricity and mean CV for all rings. 
 
 
 
Table 5.11: Coefficient of variability (CV) for N2 latency for five areas of retinal eccentricity and mean CV for all rings.
CV for P1 latency (%) Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 total area mean CV 
HY (n=37) 4.62 5.48 5.75 4.28 3.53 4.73 
HO (n=28) 4.88 4.32 4.11 3.83 2.67 3.96 
ARM (n=16) 7.71 7.93 6.62 4.80 5.26 6.46 
CV for N2 latency (%) Ring 1 Ring 2 Ring 3 Ring 4 Ring 5 total area mean CV 
HY (n=37) 3.64 3.47 3.18 2.38 3.45 3.22 
HO (n=28) 4.06 3.66 2.77 2.37 2.47  3.07 
ARM (n=16) 3.95 3.94 2.28 3.66 3.79  3.52 
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Table 5.12: Short term coefficient of repeatability (CRS) for N1, P1 and N2 latency and N1P1 amplitude for all rings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRS healthy eyes (n=8) N1 latency (ms) P1 latency (ms)  N2 Latency (ms)  N1P1 amplitude (nV/deg
2
) 
Ring 1 2.31 2.22 1.74 96.83 
Ring 2 1.24 2.54 1.50 44.49 
Ring 3 0.00 1.74 2.04 28.73 
Ring 4 1.74 1.37 1.36 17.40 
Ring 5 1.23 1.62 1.95 14.78 
Total area mean CRS 1.30 1.90 1.72 40.45 
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Table 5.13: Medium term coefficient of repeatability (CRM) for N1, P1, and N2 latency and N1P1 amplitude for all rings 
CRM healthy eyes (n=26) N1 latency (ms) P1 latency (ms) N2 Latency (ms) N1P1 amplitude 
(nV/deg
2
) 
Ring 1 1.90 3.20 4.48 125.56 
Ring 2 3.18 2.26 2.40 40.97 
Ring 3 1.86 2.08 1.87 20.52 
Ring 4 1.89 2.68 2.66 16.48 
Ring 5 1.76 2.48 2.27 13.27 
Total mean area CRM 2.12 2.54 2.74 43.36 
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Table 5.14: Medium term coefficient of repeatability (CRM) for N1, P1, N2 and N1P1 amplitude for all rings for ARM eye
CRM ARM eyes (n=4) N1 latency (ms) P1 latency (ms) N2 Latency (ms) N1P1 amplitude (nV/deg
2
) 
Ring 1 4.50 2.05 4.08 13.97 
Ring 2 1.56 4.29 3.62 18.31 
Ring 3 2.06 3.63 0.94 19.31 
Ring 4 4.00 2.05 4.23 14.37 
Ring 5 2.05 2.06 1.56 11.96 
total mean area 2.83 2.82 2.89 15.58 
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5.34 Discussion 
The aim of this study was to determine the variability and repeatability of all first-order mfERG 
measures in HY, HO and ARM eyes.  
 
The mean overall CV for N1P1 amplitude was 29% in HY eyes and 28% in HO eyes which 
correlates well with a another study showing an overall N1P1 amplitude CV of 28% in a group 
of 70 eyes aged 9-80, and a P1 latency CV of 7% [346], although CV for N1 or N2 latency was 
not reported in that study. Comparatively, P1 latency for this study was less variable at 5% for 
HY and 4% for HO eyes. Other mfERG variability studies have shown differing figures for 
N1P1 amplitude CV in healthy eyes, ranging from 10% to 47% [283, 286, 362-364], suggesting 
quite a wide-ranging degree of variability. Some of these studies did not report CV for mfERG 
latency. However Harrison et al. found CV for mfERG latencies varied from 2.2% to 4.3% with 
average whole area latencies of 3.0%, although it was not stated whether these were N1, P1 or 
N2 latencies [364]. Another study found a CV for N1 and P1 latency of 12% and 8% 
respectively [363], higher than this study’s findings. Different electrode types and methods of 
mfERG analysis may account for variability between studies, along with attenuation in stimulus 
retinal position, signal to noise ratio and electrode placement.   
 
Interestingly, Gundogan et al. demonstrated a reduction in CV with increasing eccentricity 
[363]. No such reduction in CV for any mfERG measures was found in this study. This may 
suggest consistency throughout the retinal field being stimulated and good central fixation as 
central CV was largely consistent with peripheral CV. 
 
There is scant reporting about the CV of mfERG responses and macular disease. A study by 
Tosha et al. [365] looked at the variability of mfERG responses in Stargardt’s disease (a form of 
juvenile macular degeneration). They found a larger CV in mfERG P1 amplitude in this group 
when compared to a normal group, with variation being larger in the central region in eyes with 
Stargardt’s disease whereas the variation in normal eyes was greatest in the periphery. In eyes 
with Stargardt’s disease the central amplitude and latency variation was twice that of normal 
eyes (22.8% vs 10.9% for amplitude and 2.11% vs 0.85% for latency), which the authors 
attributed to unsteady fixation. The average VA of the Stargardt’s diseased eyes was 6/18 in that 
study, whereas the VA of the ARM eyes in this study was 6/9.5 or better and therefore able to 
see the fixation cross for recording the mfERG.  
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As already described in chapter 4, although contact lens electrodes give the highest recorded 
amplitudes when undertaking mfERG, for this study DTL plus electrodes were used as the 
active corneal electrode for participant comfort [325] and test-retest reliability [277], while not 
obscuring vision. A study by Mohidin et al. [276] showed that the CV of mfERG amplitudes 
was 23% with DTL electrodes and not significantly different to the CV of contact lens or gold 
foil electrodes, although N1, P1 and N2 latency CV was not reported here. Another study has 
demonstrated a greater inter-session reliability using DTL electrodes when compared to Burian-
Allen bipolar contact lens electrode [366]. 
 
The CRS and CRM for N1P1 amplitude in our study did reduce with retinal eccentricity which 
is in accordance with another study [367]. There is paucity in the literature about mfERG CR 
data, with a greater reporting of CV data. This may be because of the high variation in mfERG 
recordings over time which are affected by changes in signal to noise ratios, electrode position 
and retinal stimulus position, whereas the CV is a normalised index (SD / mean) of a single 
visit.  
 
5.35 Conclusion 
This study demonstrated comparable mfERG CVs between HY, HO and ARM-affected eyes, 
and with increasing eccentricity. It would appear that latencies are more stable than amplitudes 
over recording sessions with regards to CV and CR in healthy and ARM-affected eyes. 
Maintaining constant calibration of the equipment as per the ISCEV guidelines [281], using the 
same person to undertake mfERG measurements on each participant for each visit, the same 
mfERG technique, electrode type and electrode placement for each participant and carefully 
monitoring participant fixation for each visit minimises mfERG variability between visits and 
groups. This is essential when trying to determine differences between groups over time and 
when trying to assess the effectiveness of an intervention on mfERG measures such as 
nutritional supplementation. 
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5.4 Baseline measures of dietary, supplemented and retinal lutein and zeaxanthin 
Because MP is a modifiable factor potentially linked with reduced risk for ARMD, and ageing 
and smoking are predominant risk factors for developing ARMD, a study was undertaken to 
determine whether there were any baseline differences in dietary, supplemented L and Z, and 
retinal L and Z (MPOD) between HY, HO and ARM eyes.  Baseline smoking pack years were 
also assessed between groups. This work has been published (see appendix 10) [368]. No 
statistical significance was found in dietary L and Z between HO, HY or ARM eyes in this 
baseline study. There was a significant difference in supplementary L and Z in ARM eyes 
compared to HY and HO eyes but no statistical significance for MPOD between all three groups 
even when the 3 L and Z supplemented eyes in the ARM groups were removed from the 
analysis. Based on participant’s current intake of dietary and supplemental L and Z, the results 
did not support the theory that ARM develops as a result of L and Z deficiency because the 
ARM group consumed similar levels of L and Z as the other groups in this study. It could be 
that historically ARM participants consumed low levels of L and Z and this may have 
predisposed them to ARM, although it seems likely that higher pack years smoked by this group 
could be a factor in the development of the disease.  
 
5.5 Analysis of the remainder of the supplement components, and non-supplement 
nutrients  
The nutritional supplement also contained vitamin C and E, copper, zinc and omega 3, which 
have been associated with reduced risk of developing ARMD (as described in chapter 1). 
Dietary levels of these nutrients were analysed at baseline to ascertain any differences between 
HY, HO and ARM groups. Although not contained within the nutritional supplement, dietary 
levels of carotene (plant forms of vitamin A) and retinol (animal forms of vitamin A) were also 
analysed because of the potential protective effect of vitamin A against ARMD described in 
chapter 1. Methods of data collection and analysis were as for published work in section 5.4 
(full details in appendix 10) [368]. No significant difference was demonstrated between groups 
for any of the nutrients at baseline (table 5.15). 
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Table 5.15: Dietary nutrient levels between HO, HY and ARM groups 
  Mean nutrient Values ± SD 
  HY HO ARM 
Copper (mg) F=2.124 
p=0.333 
0.93 ± 0.27 1.36 ± 0.83 1.13 ± 0.37 
Zinc (mg) F=2.097 
p=0.147 
6.37 ± 1.94 7.69 ± 1.85 8.40 ± 3.39 
Vitamin C (mg) F=3.043 
p=0.059 
68.00 ± 45.53 116.94 ± 65.81 103.55 ± 50.55 
Vitamin E (mg) F=1.873 
p=0.167 
4.38 ± 1.91 5.92 ± 2.63 5.84 ± 2.55 
Lutein and zeaxanthin 
(μg) 
Χ2=4.983 
p=0.083 
1316.81 ± 
1623.62 
1916.03 ± 
1505.83 
1924.36 ± 
1054.13 
omega 3 (g) F=0.314 
p=0.732 
0.18 ± 0.12 0.14 ± 0.15 0.15 ± 0.13 
Carotene (μg) F=1.582 
p=0.218 
1608.07 ± 
1715.61 
2707.18 ± 
1917.65 
2184.27 ± 
1314.31 
Retinol (mg) F=0.960 
p=0.392 
178.14 ± 114.16 641.47 ± 
1435.84 
377.82 ± 
283.70 
 
 
5.6 Chapter five summary 
Sample sizes were calculated for healthy and ARM eyes to provide 80% power at the 5% 
significance level for primary and secondary outcome measures.  
 
The results of baseline data analysis of mfERG measures between HY, HO and ARM eyes 
emphasised the importance of having age-matched groups when comparing healthy eyes to 
diseased eyes, or when comparing intervention to non-intervention groups using the mfERG to 
assess retinal function. The data also revealed changes to retinal function in ARM, highlighting 
the sensitivity of the mfERG as a tool for detecting central retinal dysfunction in ARM. 
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As the primary outcome measure, reliability and repeatability of mfERG measures were 
assessed and were found to be comparable to other studies. Equipment calibration, electrode 
position, fixation monitoring and mfERG recordings were carried out by the same personnel 
which gave the results seen in this study, highlighting the need for consistency when 
undertaking mfERG. 
 
Because the nutrients in the nutritional supplement are thought to reduce the risk of developing 
ARMD, dietary levels of these were determined for each group. Baseline levels of dietary and 
retinal levels of L and Z between HY, HO and ARM eyes found no statistically significant 
difference for any group. Also no significant difference was found between groups for copper, 
zinc, omega 3 and vitamins C or E. Although not contained within the nutritional supplement, 
dietary vitamin A levels were also analysed between groups because of its potentially protective 
effect against risk of developing ARMD.  
 
Chapter six reports the results from a prospective longitudinal randomised controlled trial, 
assessing the effects of a nutritional supplement on retinal and visual function in HY, HO and 
ARM eyes. Dietary levels of these nutrients are also assessed over the trial to clearly delineate 
whether any changes in retinal and/ or visual function are due to dietary levels of nutrients, or 
the nutritional supplement. 
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Chapter 6: Randomised controlled trial supplementation results 
 
A mixed between-within subjects analysis of variance (ANOVA) using SPSS 16.0 software was 
conducted to explore  the effects of nutritional supplementation compared with no treatment on 
retinal function over three time periods using mfERG amplitudes and latencies for different 
areas of retinal eccentricity as the main outcome measures. This provided analysis of the 
between-subjects variable (treated and non-treated group), and within-subject variable (time) on 
the outcome measures (dependent variable). There is no non-parametric alternative to the mixed 
between-within ANOVA. 
 
6.1 Healthy older group result post-unmasking 
There were 22 participants in the healthy older (HO) group that completed all three visits before 
unmasking occurred; 11 in the treated (T) group and 11 in the non-treated (NT) group. The 
treated group age range was 52-77 years and the non-treated group age range was 51-69 years. 
There were six females (55%) and five males (45%) in the treated group. There were nine 
females (82%) and two males (18%) in the non-treated group. A chi-squared test for 
independence demonstrated no significant difference between treated and non-treated groups for 
gender (Χ2 = 1.886, p = 0.170). Due to a three month fault with the VERIS mfERG equipment 
only 14 participants (seven in the treated group and seven in the non-treated group) undertook 
this test for all three visits. However the visual acuity (VA), contrast sensitivity (CS) and 
macular pigment optical density (MPOD) were undertaken on all 22 participants. All 
participants in the HO cohort were Caucasian. A summary of differences in baseline 
characteristics between treated and non-treated HO participants are detailed in table 6.1 below 
and were analysed using independent-samples t-tests using SPSS 16.0. Of the treated group 
seven participants (64% of the 11 treated participants) returned their baseline dietary 
questionnaire. Of the non-treated group 10 returned their baseline dietary questionnaire (91% of 
the 11 non-treated participants).  
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Table 6.1: A summary of baseline characteristics for the HO group using independent-samples 
t-tests. 
Variable Treated group (T) 
(n=11) 
Non-treated group (NT) 
(n=11) 
 
 mean ±SD mean ±SD t p 
Age (years)  65.00 9.76  60.45 6.74  1.27 0.22 
Smoking (pack-years)*  2.69  4.14  4.82  8.08  -0.78 0.45 
Spherical equivalent 
(D) 
0.40 2.90 0.65 2.23 -0.23 0.82 
Axial length (mm) 23.49 1.48 23.64 1.17 -0.28 0.79 
Baseline dietary 
questionnaires 
Treated group 
(n=7) 
Non-treated group 
(n=10) 
 
 mean ±SD mean ±SD t p 
Dietary copper (mg) 1.76 1.11 1.08 0.43 1.78 0.96 
Dietary zinc (mg) 8.23 1.56 7.31 2.01 1.01 0.33 
Dietary retinol (µg) 1181.86 2212.99 263.20 118.95 1.10 0.31 
Dietary carotene (µg) 2455.00 1303.92 2883.70 2305.52 -0.44 0.67 
Dietary Vitamin E (mg) 5.84 1.85 5.98 3.17 -0.10 0.92 
Dietary Vitamin C (mg) 120.57 73.27 114.40 64.06 0.18 0.86 
Dietary lutein and 
zeaxanthin (µg) 
1393.05 542.31 2297.25  1926.20 -1.41 0.19 
Dietary Omega 3 (g) 0.17 0.15 0.13 0.15 0.56 0.59 
*pack-years= (cigarettes smoked per day x years smoked) / 20  
 
The HO cohort ANOVA results for mfERG are displayed in table 6.2 (in appendix 11). For all 
mfERG outcome measures for the HO group there was no significant interaction between 
treated and non-treated groups over three time periods or for group (treated versus non-treated) 
for any mfERG parameters. There was no significant effect for time for any mfERG parameter 
except for ring 1 P1 latency with longer latencies for both groups at visit two (tables 6.2 and 6.3 
in appendix 11).  
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All participants (11 in the treated group and 11 in the non-treated groups) undertook VA, CS 
and MPOD measurements at all three visits (table 6.4 in appendix 11).  
 
For VA and CS for the HO cohort there was no significant interaction between treated and non-
treated groups over three time periods. There was no significant effect for time or group. For 
MPOD there was no significant effect for time or group but a significant interaction between 
time and group. There was an increase in MPOD of 0.1 over the three visits in the treated group 
compared to a reduction in MPOD 0.02 in the non-treated group (figure 6.1 below and table 6.5 
in appendix 11).  
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Figure 6.1: Differences between mean MPOD values over three visits between treated and non-
treated groups for HO eyes. 
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Of the 7 people in the HO treated group who completed the baseline dietary questionnaire, four 
completed a further questionnaire at visit three. Of the 10 people in the HO non-treated group 
who completed the baseline dietary questionnaire, seven completed a further questionnaire at 
visit three. A paired-samples t-test using SPSS 16.0 demonstrated no significant difference for 
any of the dietary components between visits one and three in the HO treated group or for the 
HO non-treated group (tables 6.6 and 6.7 in appendix 11).  
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6.2 Healthy younger group result post-unmasking 
There were 30 participants in the healthy younger (HY) cohort that completed all three visits 
before unmasking occurred; 14 in the treated group aged 18-46 years and 16 in the non-treated 
group aged 21-48 years. All participants in the treated group were Caucasian, consisting of nine 
females (64.3%) and five males (35.7%). In the non-treated group there were 11 females 
(68.8%) and 5 males 32.1%) of five South Asians (31.2%) and 11 Caucasians (68.8%). A chi-
squared test for independence demonstrated a significant difference between treated and non-
treated groups for ethnicity (Χ2 = 5.250, p = 0.022) but not for gender (Χ2 = 0.067, p = 0.796). 
Due to a three month fault with the VERIS mfERG equipment 11 participants (eight in the 
treated group and three in the non-treated group) underwent this test for all three visits. 
However the VA, CS and MPOD were undertaken on all 30 participants. A summary of 
differences in baseline characteristics are detailed in table 6.8 below and were analysed using 
independent-samples t-tests using SPSS 16.0. Of the treated group seven participants returned 
their baseline dietary questionnaire (50% of the 14 treated participants). Of the non-treated 
group seven returned their baseline dietary questionnaire (44% of the 16 non-treated 
participants). 
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Table 6.8: A summary of baseline characteristics for the HY group using independent-samples 
t-tests. 
Variable Treated group 
(n=14) 
Non-treated group 
(n=16) 
 
 mean ±SD mean ±SD t p 
Age (years)  35.86 8.93 32.56 9.14 1.00 0.33 
Smoking (pack-years)*  1.49 2.53  1.29 3.88 0.17 0.87 
Spherical equivalent 
(D) 
 0.83 1.56 -0.07 2.26 1.25 0.22 
Axial length (mm)  23.17 0.78 23.71 1.03 -1.59 0.12 
Baseline dietary 
questionnaires 
Treated group 
(n=7) 
Non-treated group 
(n=7) 
 
 mean ±SD mean ±SD t p 
Dietary copper (mg) 0.98 0.27 0.88 0.28 0.74 0.48 
Dietary zinc (mg) 6.57 2.30 6.17  1.66 0.37 0.72 
Dietary retinol (µg) 229.29 126.15 127.00 78.87 1.82 0.09 
Dietary carotene (µg) 1124.43 686.43  2091.71 2315.22 -1.06 0.31 
Dietary Vitamin E (mg) 3.67 1.25 5.09 2.26 -1.45 0.17 
Dietary Vitamin C (mg) 50.29 28.77 85.71 54.15 -1.53 0.16 
Dietary lutein and 
zeaxanthin (µg) 
1197.62 1238.45 1614.90 2293.37 -0.42 0.68 
Dietary Omega 3 (g)  0.17 0.09 0.19 0.15 -0.35 0.74 
 
The HY cohort ANOVA results for mfERG are displayed in table 6.9 in appendix 11. All 
participants (14 in the treated group and 16 in the non-treated groups) undertook VA and CS 
measurements at all three visits (table 6.11 in appendix 11). One participant in the treated group 
was unable to perform the MPOD at one of their visits (therefore, n=13 for the treated group 
and n=16 in the non-treated group for this outcome measure). 
 
For the HY group there was no statistically significant difference between treated and non-
treated eyes for any mfERG measures or for CS (tables 6.9 – 6.12 in appendix 11). There was a 
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significant difference over time in VA for both treated and non-treated groups, VA reducing by 
approximately two letters from baseline to visit two and then improving by two letters from visit 
two to visit three (table 6.12 in appendix 11). As the test was undertaken in the same room for 
each visit it could be that the background illumination of the logMAR chart fluctuated. This 
change of two letters is well within the repeatability of ETDRS visual acuity testing for adults 
[369]. There was a significant interaction effect between time and group for MPOD, with 
MPOD increasing over the three visits by 0.1 in the treated group compared with a 0.03 
reduction in MPOD in the non-treated group between visits one and three (table 6.11 and 6.12 
in appendix 11 and figure 6.2 below).  
 
Figure 6.2: Differences between mean MPOD values over three visits between treated and non-
treated groups for HY eyes. 
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Of the seven people in the HY treated group who completed the baseline dietary questionnaire, 
four completed a further questionnaire at visit three. Of the seven people in the HY non-treated 
group who completed the baseline dietary questionnaire, three completed a further questionnaire 
at visit three. An independent samples t-test using SPSS 16.0 demonstrated no significant 
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difference for any of the dietary components between visits one and three in the HY treated 
group except for carotene, or for the HY non-treated group except for retinol (tables 6.13 and 
6.14 respectively in appendix 11). Dietary carotene levels for the HY treated group were lower 
at visit one (mean ± SD: 1138.25 ± 561.10) compared to visit three (mean ± SD: 2097.75 ± 
466.31). Dietary retinol levels for the HY non-treated group were lower at visit 1 (mean ± SD: 
69.33 ± 34.36) compared to visit three (mean ± SD: 316.67 ± 117.69). 
 
6.3 Healthy younger and healthy older group combined result post-unmasking 
To fully exploit the data and provide greater statistical power for VA and mfERG measures the 
HY and HO groups were also combined. There were 52 participants in the combined HO and 
HY groups that completed all three visits before unmasking occurred; 25 in the treated group 
aged 18-77 years and 27 in the non-treated group aged 21-69 years. All participants in the 
treated group were Caucasian, consisting of 15 females (60.0%) and 10 males (40.0%). In the 
non-treated group there were 20 females (74.1%) and seven males (25.9%) of five Asians 
(18.5%) and 22 Caucasians (81.5%). A chi-squared test for independence demonstrated a 
significant difference between treated and non-treated groups for ethnicity (Χ2 = 5.122, p = 
0.024) but not for gender (Χ2 = 1.169, p = 0.280). Due to a three month fault with the VERIS 
mfERG equipment only 25 participants (15 in the treated group and 10 in the non-treated group) 
underwent this test for all three visits. However the VA, CS and MPOD were undertaken on all 
52 participants. A summary of differences in baseline characteristics are detailed in table 6.15 
below and were analysed using independent-samples t-tests. Of the treated group 14 participants 
returned their baseline dietary questionnaire (56.0%). Of the non-treated group 17 returned their 
baseline dietary questionnaire (63.0%). 
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Table 6.15: A summary of baseline characteristics for combined HY and HO groups using 
independent-samples t-tests. 
Variable Treated group 
(n=25) 
Non-treated group 
(n=27) 
 
 mean ±SD mean ±SD t p 
Age (years) 48.68 17.35 43.93 16.15 1.02 0.31 
Smoking (pack-years)* 2.02 3.32 2.73 6.08 -0.52 0.61 
Spherical equivalent 
(D) 
0.64  2.21 0.22 2.24 0.68 0.50 
Axial length (mm) 23.31 1.12 23.68 1.07 -1.23 0.23 
Baseline dietary 
questionnaires 
Treated group 
(n=14) 
Non-treated group 
(n=17) 
 
 mean ±SD mean ±SD t p 
Dietary copper (mg)  1.37 0.87 1.00 0.38 1.60 0.12 
Dietary zinc (mg) 7.40 2.08 6.84 1.91 0.78 0.44 
Dietary retinol (µg) 705.57  1584.91 207.12 122.74 1.17 0.26 
Dietary carotene (µg) 1789.71  1216.07 2557.59 2272.45 -1.20  0.24 
Dietary Vitamin E (mg) 3.67 1.25 5.09 2.26 -1.45 0.17 
Dietary Vitamin C (mg) 85.43  64.73 102.59 60.16 -0.76 0.45 
Dietary lutein and 
zeaxanthin (µg) 
1295.33 924.07 2016.29 2044.30 -1.30  0.21 
Dietary Omega 3 (g) 0.17  0.12 0.15 0.15 0.30 0.76 
 
The combined HO and HY cohort ANOVA results for mfERG are displayed in table 6.16 in 
appendix 11. For all mfERG outcome measures for the combined HY and HO group there was 
no significant interaction between treated and non-treated groups over three time periods or for 
group (treated versus non-treated) for any mfERG parameters. There was no significant effect 
for time for any mfERG parameter except for ring 2 P1 and ring 2 N2 latency (table 6.17 in 
appendix 11). Ring 2 N2 latency became longer over the three visits for both groups. Ring 2 P1 
latency became shorter over three visits in the treated group.  
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All participants (25 in the treated group and 27 in the non-treated groups) undertook VA and CS 
measurements at all three visits (table 6.18 in appendix 11). One participant in the treated group 
was unable to perform the MPOD at one of their visits (therefore n=24 for the treated group and 
n=27 in the non-treated group for this outcome measure). 
 
For the combined HO and HY group there was no statistically significant difference between 
treated and non-treated eyes for VA or CS (table 6.18 and 6.19 in appendix 11). There was a 
significant interaction effect between time and group for MPOD, with MPOD increasing over 
the three visits by 0.1 in the treated group compared with a 0.03 reduction in MPOD in the non-
treated group between visits one and three (figure 6.3 below and tables 6.18 and 6.19 in 
appendix 11).  
 
Figure 6.3: Differences between mean MPOD values over three visits between treated and non-
treated groups for HY and HO eyes. 
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Of the 14 people in the combined HY and HO treated group who completed the baseline dietary 
questionnaire, eight completed a further questionnaire at visit three. Of the 17 people in the 
combined HY and HO non-treated group who completed the baseline dietary questionnaire, 10 
completed a further questionnaire at visit three. A paired-samples t-test using SPSS 16.0 
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demonstrated no significant difference for any of the dietary components between visits one and 
three in the combined HY and HO treated group or for the combined HY and HO non-treated 
group (tables 6.20 and 6.21 respectively in appendix 11). 
 
6.4 Age-Related Maculopathy group result post-unmasking 
There were 14 participants in the ARM cohort that completed all three visits before unmasking 
occurred; eight in the treated group and six in the non-treated group. The treated group age 
range was 56-81 years and the non-treated group age range was 61-83 years. There were five 
females (62.5%) and three males (27.5%) in the treated group. There were five females (83%) 
and one male (17%) in the non-treated group. A chi-squared test for independence demonstrated 
no significant difference between treated and non-treated groups for gender (Χ2 =0.729, p = 
0.393). Due to a three month fault with the VERIS mfERG equipment, seven participants (four 
in the treated group and three in the non-treated group) undertook this test for all three visits. 
However the VA, CS and MPOD were undertaken on all 14 participants. All participants in the 
ARM group were Caucasian. A summary of differences in baseline characteristics are detailed 
in table 6.22 below and were analysed using independent-samples t-tests. Of the treated group 
seven participants (88% of the eight treated participants) returned their baseline dietary 
questionnaire. Of the non-treated group four returned their baseline dietary questionnaire (67% 
of the six non-treated participants). None of the ARM eyes tested developed into AMD 
throughout the study or they would have been excluded. None of the ARM eyes clinically 
changed over the study period as recorded by 45º fundus photographs.  
 
 
 
 
 
 
 
 
124 
 
Table 6.22: A summary of baseline characteristics for the ARM group using independent-
samples t-tests. 
Variable Treated group 
(n=8) 
Non-treated group 
(n=6) 
 
 mean ±SD mean ±SD t p 
Age (years) 65.50 9.27 69.67 7.52 -0.87 0.40 
Smoking (pack-years)* 7.04 9.42 13.5 15.86 -0.96 0.36 
Spherical equivalent 
(D) 
0.72 2.27 0.96 2.30 -0.20 0.85 
Axial length (mm) 23.11 0.86 23.48 1.25 -0.65 0.53 
Baseline dietary 
questionnaires 
Treated group 
(n=7) 
Non-treated group 
(n=4) 
 
 mean ±SD mean ±SD t p 
Dietary copper (mg) 1.08 0.30 1.22 0.51 -0.60 0.57 
Dietary zinc (mg) 8.07 2.43 8.98 5.06 -0.41 0.69 
Dietary retinol (µg) 492.00 347.89 288.25 97.02 0.78 0.46 
Dietary carotene (µg) 2399.71 1530.05 1807.25 882.10 0.70 0.50 
Dietary Vitamin E (mg) 5.06 1.60 7.21 3.55 -1.41 0.19 
Dietary Vitamin C (mg) 98.71 49.42 112.00 59.02 -0.40 0.70 
Dietary lutein and 
zeaxanthin (µg) 
1606.50 686.20 2550.02 1557.50 -1.42 0.19 
Dietary Omega 3 (g) 0.14 0.10 0.17 0.18 -0.35 0.73 
*pack-years=(cigarettes smoked per day x years smoked) / 20  
 
The ARM cohort ANOVA results for mfERG are displayed in table 6.23 in appendix 11. For all 
mfERG outcome measures for the ARM group there was no significant interaction between 
treated and non-treated groups between visits one and three. There were no significant effects 
for time or group (treated versus non-treated), except for ring 3 and ring 4 N1P1 amplitude for 
time (tables 6.23 and 6.24 in appendix 11) with the amplitudes of both rings for both groups 
reducing between visits one and two, and increasing between visits two and three.  
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All eight treated participants underwent mfERG at visit one and visit three. Therefore to exploit 
this greater sample size, paired-samples t-tests were carried out using SPSS 16.0. This analysis 
also showed statistical significance for ring 3 N1P1 amplitude, with amplitude increasing by 
6.67 nV/deg
2
 (table 6.25 in appendix 11).  
 
Five eyes in the non-treated group had mfERG at visit one and three so an independent-samples 
t-test between treated and non-treated groups was undertaken to assess the differences between 
visit one and three for the eight treated and five non-treated ARM eyes for mfERG measures 
(table 6.26 in appendix 11). No statistically significant differences were seen in differences 
between treated and non-treated groups between visits one and three for any mfERG measures 
except for ring 3 N1 latency with the non-tested group ring 3 N1 latency  having a greater 
difference between visit one and three (2.17 ms) than the treated group (0.31 ms). This is a 
spurious result as N1 latency improved in the non-treated group between visits 1 and 3 when 
compared to the treated group. 
 
All participants (eight in the treated group and six in the non-treated group) undertook VA, CS 
and MPOD measurements at all three visits (table 6.27 in appendix 11). There was no 
significant interaction between treated and non-treated groups for VA, CS and MPOD in the 
ARM group (figure 6.4) between visits one and three. Furthermore, there was no significant 
effect for time or group (tables 6.27 and 6.28 in appendix 11).  
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Figure 6.4: Differences between mean MPOD values over three visits between treated and non-
treated groups for ARM eyes. 
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Of the seven people in the ARM treated group who completed the baseline dietary 
questionnaire, five completed a further questionnaire at visit three. Of the four people in the 
ARM non-treated group who completed the baseline dietary questionnaire, four completed a 
further questionnaire at visit three. An independent samples t-test using SPSS 16.0 
demonstrated no significant difference for any of the dietary components between visits one and 
three in the ARM treated group or for the ARM non-treated group (tables 6.29 and 6.30 
respectively in appendix 11). 
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Although our sample size was small, a study by Koh et al.,  [186] found a statistically 
significant increase in MPOD of 0.07 in seven patients with ARM  supplemented with 10mg of 
lutein daily over 18-20 weeks. Our L supplement contained 12mg of lutein and 0.6mg of 
zeaxanthin. All participants from HO, HY and ARM groups were asked to provide details of 
any additional nutritional supplementation at baseline. Not all participants were able to specify 
the amounts of nutrients within their supplements. Therefore chi-squared tests for independence 
were carried out to investigate differences between treated and non treated groups. There were 
no statistically significant differences at baseline between treated and non-treated groups for 
participants own supplements (table 6.31). There were no changes to participants own 
supplement use throughout the study when questioned at visits two and three.    
 
6.5 Study nutritional supplement compliance 
Compliance was assessed by asking participants to return any boxes of the supplement that were 
not taken and remaining tablets were counted. Those who forgot to bring back the tablets were 
asked to contact the principle investigator after counting tablets at home (table 6.32). Patient 
compliance was elicited using supportive language to minimise the number of participants 
concealing supplement non-adherence [262], and reporting lower levels of remaining tablets 
than was actually the case. The sole reason for non-adherence was forgetfulness.  A one way 
ANOVA using SPSS 16.0 found no statistically significant difference between groups for 
supplement compliance during the study (see table 6.32) (F = 0.396, p = 0.676). 
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Table 6.31: Summary of the baseline differences between treated (T) and non-treated (NT) participants own supplement use using chi-squared tests for 
independence. 
Supplement HO T HO NT Χ2 p HY T HY NT Χ2 P ARM T ARM 
NT 
Χ2  p 
Multivitamin 0 3 1.544 0.214 1 1 <0.001 1.000 2 0 0.304 0.581 
Vitamin C 1 1 <0.001 1.000 0 0   1 0 <0.001 1.000 
Vitamin E 0 0   0 0   0 0    
Vitamin D 0 0   0 0   0 0    
Vitamin B12 1 0 <0.001 1.000 0 1 <0.001 1.000 0 0    
Zinc 1 0 <0.001 1.000 0 0   0 0    
Selenium 0 0   0 0   0 0   
Calcium 0 0   0 0   1 1 <0.001 1.000 
Cod liver  oil 1 2 <0.001 1.000 0 2 0.404 0.525 1 1 <0.001 1.000 
GLA 0 0   0 0   0 0   
Ginkgo biloba 1 1 <0.001 1.000 0 1 <0.001 1.000 0 1 0.022 0.881 
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Table 6.31 continued. 
Supplement HO T HO NT Χ2 p HY T HY NT Χ2 P ARM T ARM 
NT 
Χ2  p 
Omega 3 1 0 <0.001 1.000 0 0   2 1 <0.001 1.000 
Glucosamine 2 2 0.550 0.458 0 1 <0.001 1.000 4 3 <0.001 1.000 
Folic acid 0 0   0 0   1 0 <0.001 1.000 
Starflower oil 0 0   0 0   0 0   
Garlic  1 1 <0.001 1.000 0 0   0 0   
Evening primrose 0 0   0 1 <0.001 1.000 0 0   
Royal jelly 0 0   0 0   0 0   
Ginseng 0 0   0 0   0 0   
Flaxseed 0 0   0 0   0 0   
I-caps 0 0   0 0   1 0 <0.001 1.000 
Visionace 0 0   0 0   0 0   
Saw palmetto 0 1 <0.001 1.000 0 0   0 0   
Rosehip 0 1 <0.001 1.000 0 0   0 0   
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Table 6.31 continued. 
Supplement HO T HO NT Χ2 p HY T HY NT Χ2 P ARM T ARM 
NT 
Χ2  p 
Iron 0 1 <0.001 1.000 0 0   1 0 <0.001 1.000 
Lutein 0 0   0 0   1 1 <0.001 1.000 
Aloe 0 1 <0.001 1.000 0 0   0 0   
Chondroitin 0 1 <0.001 1.000 0 1 <0.001 1.000 0 1 0.022 0.881 
Magnesium 0 0   0 0   1 0 <0.001 1.000 
MSM 0 0   0 0   2 0 0.304 0.581 
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Table 6.32: Summary of trial duration with independent t tests (mean ± SD) and participant compliance (% ± SD). 
Mean trial duration 
(months) 
HY T HY NT t test  
(p value) 
HO T HO NT t test  
(p value) 
ARM T ARM NT t test  
(p value) 
VISIT 1-2 5.1 ± 0.9 5.1 ± 0.6 0.304 (0.764) 4.9 ± 0.8 4.7 ± 0.7 0.573 (0.573) 5.6 ± 0.9 5.3 ± 0.8 0.617 (0.549) 
VISIT 1-3 10.7 ± 1.5 10.7 ± 1.2 0.055 (0.957) 10.5 ± 0.9 10.5 ± 1.7 0.000 (1.000) 10.4 ± 1.1 10.5 ± 1.4 -0.192 (0.851) 
Mean compliance (% 
tablets taken) 
 76.9 ± 14.8 -   82.1 ± 17.0 -  81.1 ± 13.0 -  
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6.6 Chapter six summary 
For all mfERG outcome measures for the HO group there was no significant interaction 
between treated and non-treated groups over three time periods or for group (treated versus non-
treated). There was no significant effect for time for any mfERG parameter except for ring 1 P1 
latency with longer latencies for both groups at visit two. This was not clinically significant 
based on the CR studies undertaken in chapter five. For VA and CS for the HO cohort there was 
no significant interaction between treated and non-treated groups over three time periods. There 
was also no significant effect for time or group. For MPOD there was no significant effect for 
time or group but a significant interaction between time and group. There was an increase in 
MPOD of 0.1 over the three visits in the treated group compared to a reduction in MPOD 0.02 
in the non-treated group.  
 
For the HY group there was no statistically significant difference between treated and non-
treated eyes for any mfERG measures or for CS. There was a significant difference over time in 
VA for both treated and non-treated groups, with VA reduced by approximately two letters from 
baseline to visit two and then improved by two letters from visit two to visit three. As the test 
was undertaken in the same room for each visit it could be that the background illumination of 
the logMAR chart fluctuated. This is not clinically significant as a change of 2 letters is well 
within the repeatability of ETDRS visual acuity testing [369]. There was a significant 
interaction effect between time and group for MPOD, with MPOD increasing over the 3 visits 
by 0.1 in the treated group compared with a 0.03 reduction in MPOD in the non-treated group 
between visits 1 and 3.  
 
In order to exploit the larger sample size, data from HY and HO eyes were also combined for 
analysis. There was no significant interaction between treated and non-treated groups over three 
time periods or for group (treated versus non-treated) for any mfERG parameters. There was no 
significant effect for time for any mfERG parameter except for ring 2 P1 and ring 2 N2 latency. 
Ring 2 N2 latency became longer over the three visits for both groups. Ring 2 P1 latency 
became shorter over three visits for treated eyes and became longer and then shorter for non-
treated groups. There was no statistically significant difference between treated and non-treated 
eyes for VA or CS. There was a significant interaction effect between time and group for 
MPOD, with MPOD increasing over the three visits by 0.1 in the treated group compared with a 
0.03 reduction in MPOD in the non-treated group between visits 1 and 3.  
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For all mfERG outcome measures for the ARM cohort there was no significant interaction 
between treated and non-treated groups over three time periods for mfERG measures. There 
were no significant effects for time or group, except for ring 3 and ring 4 N1P1 amplitude for 
time with the amplitudes of both rings for both groups reducing between visits one and two, and 
increasing between visits two and three. For VA, CS and MPOD there was no significant 
interaction between treated and non-treated groups over three time periods. Furthermore there 
was no significant effect for time or group. 
  
No effect of antioxidant supplementation was demonstrated for any outcome measures over 40 
weeks in HO, HY, combined HY and HO or ARM groups except for an increase in MPOD over 
the study period in HY and HO eyes, and in combined HO/HY eyes.  
 
The next chapter describes the results of 20 weeks of withdrawal of the lutein-based supplement 
on the primary and secondary outcome measures. 
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Chapter 7: Supplementation withdrawal results 
 
Once unmasking occurred at visit 3 a further study was undertaken to assess the effects of 
supplement withdrawal on visual function. This was done for all participants in the HO, HY and 
ARM groups who took the supplement. These participants attended for a fourth visit at 60 
weeks where mfERG, MPOD, VA and CS were repeated.  
The data were analysed with SPSS 16.0. using paired-samples t-tests when parametric 
assumptions were met according to normality as shown by non-significance for the Shapiro-
Wilk test. The Wilcoxon Signed Rank test was carried out when parametric assumptions were 
not met. 
 
7.1 Healthy older group 
Although there were 11 treated participants at visit three, there were 10 participants in the HO 
group that completed both visit three and four, with one participant dropping out due to illness. 
The age range was 54-77 years (mean ± SD; 64.0 ± 9.02 years). There were six females (60%) 
and four males (40%). Due to a three month fault with the mfERG equipment, eight undertook 
this test for both visits. However the VA, CS and MPOD were undertaken on all 10 participants. 
All participants were Caucasian. Four of the 10 participants completed a dietary questionnaire at 
visit three, of which three completed a further questionnaire at visit four. Spherical equivalent 
did change from a mean ± SD of 0.14 ± 3.15 at visit three to 0.43 ± 3.16 dioptres of sphere at 
visit four (t = -3.183, p = 0.011). This 0.29 change is not clinically significant and well within 
the repeatability values of the NVision K5001 autorefractor based on Davies et al’s work [370]. 
 
A summary of the changes in objective and subjective outcome measures of visual function and 
changes in dietary differences of participant characteristics between visits three and four are 
detailed in table 7.1, 7.2 and 7.3 respectively in appendix 12.  
 
After withdrawal of the nutritional supplement for 20 weeks, there was no statistically 
significant change for any outcome measure except for mfERG ring 1 N1P1 amplitude which 
reduced on supplementation withdrawal. There was also no change in dietary intake of nutrients 
during the withdrawal period. 
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7.2 Healthy younger group 
Although there were 14 treated participants at visit three, there were 12 participants in the HY 
group that completed both visit three and four, with one participant unable to return and another 
developing ocular hypertension. The age range was 18-46 years (mean ± SD = 36.0 ± 8.96 
years). There were seven females (58%) and five males (42%). Due to a three month fault with 
the mfERG equipment, nine undertook this test for both visits. However the VA, CS and MPOD 
were undertaken on all 12 participants. All participants were Caucasian. Three of the 12 
participants completed a dietary questionnaire at visit three, of which two completed a further 
questionnaire at visit four. The spherical equivalent did not change between visit three (mean ± 
SD; 0.42 ± 0.99 dioptres of sphere) and visit four (mean ± SD; 0.49 ±0.92 dioptres of sphere). 
 
A summary of the changes in objective and subjective outcome measures of visual function and 
changes in dietary differences of participant characteristics between visits three and four are 
detailed in table 7.4, 7.5 and 7.6 respectively in appendix 12. The data were analysed with SPSS 
16.0 using paired-samples t-tests when parametric assumptions were met according to normality 
as shown by non-significance for the Shapiro-Wilk test. The Wilcoxon Signed Rank test was 
carried out when parametric assumptions were not met.  
 
After withdrawal of the nutritional supplement for 20 weeks, there was no statistically 
significant change for any outcome measure except for mfERG ring 3 P1 latency which reduced 
with supplementation withdrawal. There was also no change in dietary levels of nutrients during 
the withdrawal period. 
 
7.3 Healthy younger and healthy older groups combined 
In order to provide an adequate sample size for VA, HY and HO groups were combined for all 
outcome measures. Although there were 25 treated participants at visit three, there were 22 
participants in the combined HY and HO groups that completed both visit three and four. The 
age range was 18-77 years (mean ± SD = 51.0 ± 17.31 years). There were 13 females (59%) and 
nine males (41%). Due to a three month fault with the mfERG equipment, 17 undertook this test 
for both visits. However the VA, CS and MPOD were undertaken on all 22 participants. All 
participants were Caucasian. Seven of the 22 participants completed a dietary questionnaire at 
visit three, of which five completed a further questionnaire at visit four. The spherical 
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equivalent did not change between visit 3 (mean ± SD; 0.50 ± 2.23 dioptres of sphere) and visit 
four (mean ± SD; 0.46 ± 2.17 dioptres of sphere), t = -0.094 p = 0.926.  
A summary of the changes in objective and subjective outcome measures of visual function and 
changes in dietary differences of participant characteristics between visits three and four are 
detailed in table 7.7, 7.8 and 7.9 respectively in appendix 12.  
After withdrawal of the nutritional supplement for 20 weeks, there was no statistically 
significant change for any outcome measure except for mfERG ring 1 and ring 2 N1P1 
amplitudes which reduced on supplement withdrawal. There was also no change in dietary 
levels of nutrients during the withdrawal period except for increased omega-3 levels.  
 
7.4 Age-related maculopathy group 
There were eight treated ARM participants at visit three, and they were all able to complete visit 
four. The age range was 56-81 years (mean ± SD = 65.50 ± 9.27 years). There were five females 
(62.5%) and three males (27.5%). All eight undertook all tests for both visits. All participants 
were Caucasian. Four of the eight participants completed a dietary questionnaire at visit three, 
of which three completed a further questionnaire at visit four. The spherical equivalent did not 
change between visit three (mean ± SD; 1.02 ± 2.15 dioptres) and visit four (mean ± SD; 0.85 ± 
2.15 dioptres), Z = -0.980 p = 0.327. 
 
A summary of the changes in objective and subjective outcome measures of visual function and 
changes in dietary differences of participant characteristics between visits three and four are 
detailed in table 7.10, 7.11 and 7.12 respectively in appendix 12.  
 
After withdrawal of the nutritional supplement for 20 weeks, there was no statistically 
significant change for any outcome measure except for mfERG ring 3 N2 latency and ring 4 P1 
latency which increased on supplementation withdrawal. There was no change in dietary levels 
of nutrients during the withdrawal period. 
 
There appears to be a trend in HY, HO and combined HY/HO eyes for all N1P1 amplitudes to 
be reduced for all five rings after supplementation withdrawal. This is also true for ARM eyes 
for rings 1, 3 and 4.  
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7.5 Chapter seven summary 
After 20 weeks of supplement withdrawal there were no changes in any outcome measures for 
any groups except for; a reduction in ring 1 N1P1 amplitude in HO eyes; a reduction in ring 3 
P1 latency in HY eyes; a reduction in ring 1 and ring 2 N1P1 amplitude when HY and HO eyes 
were combined; and an increase in mfERG ring 3 N2 latency and ring 4 P1 latency in ARM 
eyes. There was a trend for reduced N1P1 amplitudes for all rings in HY and HO eyes and in 
rings 1, 3 and 4 in ARM eyes. 
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Chapter 8 Discussion 
 
8.1 Main outcomes 
This randomised controlled trial was designed to assess the effect of a nutritional supplement 
containing 12 mg L, 0.6 mg Z, 150 mg vitamin C, 15 mg of vitamin E, 400 µg copper, 20 mg 
zinc and 1080 mg omega-3 fatty acids on objective and subjective clinical measures of visual 
and retinal function. It was further designed to assess the effects of supplement withdrawal on 
these measures.  
Participants were divided into HY, HO and ARM groups. The primary outcome measure was 
mfERG N1P1 amplitude. The secondary outcome measures were mfERG N1, P1, and N2 
latency, VA, CS and MPOD.  
 
Supplementation effects in healthy eyes 
Lutein and Z within the supplement was found to accumulate in the retinae of both HO and HY 
eyes over a 40 week period, in the form of a statistically significant increase in MPOD.  
When HO and HY groups were combined, the increase in MPOD over three visits remained in 
the treated eyes, and mfERG ring 2 P1 latency became statistically significantly shorter over the 
three visits.  
Many studies have demonstrated an increase in MPOD with L-based supplementation in healthy 
eyes [132, 133, 186, 371-377]. However not all studies have assessed whether this increased 
retinal accumulation of MP is associated with changes to other measures of visual and retinal 
function such as CS, VA or mfERG [186, 371-376]. Some studies also fail to report dietary 
levels of L and Z during supplementation [371, 372, 374-377].  
There have been conflicting results within the literature with regards to the effects of L-based 
nutritional supplementation on visual function in healthy eyes. A recent prospective 
interventional study by Sasamoto et al., assessing the effects of a L-based nutritional 
supplement on MPOD and visual function in 43 eyes of 43 subjects, showed that MPOD did not 
significantly increase over 12 months, although improvements in CS were seen [378]. It is 
difficult to compare Sasamoto’s work with this (the Aston) study as different methods of 
assessing MPOD (autofluorescence spectrometry) and CS (area under the log contrast 
sensitivity function) were used, and supplement formulation (6mg L), ethnicity (Japanese) and 
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study design were not the same. Also some of the participants in Sasamoto et al’s study 
consisted of healthy fellow eyes of those with AMD or central serous chorioretinopathy which 
may have been subject to subtle retinal changes not clinically visible.  
The Collaborative Optical Macular Pigment Assessment Study (COMPASS) investigators 
concluded that supplementing with 12 mg of L, 1 mg of Z and antioxidants in healthy eyes 
significantly increased MPOD over 12 months, but this did not correspond with an 
improvement in VA or photopic CS [379] in this prospective interventional study. This is in 
agreement with the Aston study but a different method of CS assessment was used (contrast 
sensitivity function), the sample size was larger at 121 subjects and the supplement formulation 
differed.  
A 12 week randomised, double blind, placebo-controlled intervention study of 37 healthy eyes 
found no statistically significant improvement in VA or central CS when supplementing with 6 
or 12 mg of L [380]. Improvements were noted at wider fields of CS analysis. This study differs 
from the Aston study in supplement formulation, ethnicity (Chinese) and methods of CS 
(automated contrast glare tester) assessment.  
A double-masked, randomised controlled trial of 46 eyes by Bartlett and Eperjesi concluded that 
supplementing with 6 mg of L combined with vitamins and minerals did not improve CS or VA 
over 9 or 18 months [381]. This is in concordance with the Aston study. The same methods of 
VA and CS assessment were used, and a similar study design, but supplement formulation 
differed.  
As previously discussed, the mfERG principally measures cone photoreceptor and bipolar cell 
function. Tubulin is found in the cone photoreceptor axon layer of the fovea where it may 
selectively bind to L and Z [126], leading to the MPOD increases seen on supplementation. The 
rationale was that an increase of L and Z binding to tubulin around the cone photoreceptor 
axons may have affected cone function which could be objectively assessed by the mfERG.  
To the author’s knowledge, the literature provides no information with regards to the effects of 
L-based supplementation on mfERG measures in healthy eyes. Ring 2 P1 latency of the mfERG 
became statistically significantly shorter over time in those taking the supplement. However this 
was not clinically significant.  
 
Supplementation effects in ARM eyes 
The nutritional supplement had no effect on any outcome measure for ARM eyes for this study.  
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Three studies have demonstrated an increase in MPOD with L-based supplementation in eyes 
with ARMD [102, 186, 375]. However not all studies have assessed whether this increased 
retinal accumulation of MP causes changes to other measures of visual and retinal function such 
as CS, VA or mfERG [186, 375]. Some studies also failed to report dietary levels of L and Z 
during supplementation [375].  
The Lutein Nutrition Effects Measured by Autofluorescence (LUNA) prospective interventional 
study found that although a 12 mg L-based supplement increased MPOD in 100 eyes with ARM 
and atrophic AMD over 6 months overall, some participants did not show augmentation of 
MPOD even though serum levels of L and Z increased [375]. The larger sample size, mixed 
ARMD categories, differing supplement formula and dissimilar assessment of MPOD make it 
difficult for the LUNA study to be compared to the Aston study.  
A study prospective interventional by Richer [104] concluded that L supplementation in 14 
males with atrophic AMD improved CS and VA, although CS (CS function) and VA (Snellen) 
assessment, ARMD type and gender composition differed from the Aston study. Supplement 
formulation was incompatible, with spinach used for 11 subjects, and the remainder receiving a 
L-based antioxidant.  
The Lutein Antioxidant Supplementation Trial (LAST) investigators concluded that a 12 month 
prospective randomised, double masked, placebo-controlled, supplementation trial with 10 mg 
L, or 10 mg L with other carotenoids, antioxidants and minerals, improved MPOD and CS (CS 
function) [102]. A larger sample size of 90 participants was enrolled in the LAST, and was 
predominantly male with atrophic AMD, thus incompatible with the Aston study.  
A randomised controlled trial by Bartlett and Eperjesi found that supplementation with 6 mg of 
L combined with vitamins and minerals was not beneficial for improving CS in 15 eyes with 
ARM or atrophic AMD over 9 months [382]. Although the method of assessing CS was 
comparable to the Aston study, supplementation formulation differed.  
The Taurine, Omega-3 fatty acids, Zinc, Antioxidant, Lutein (TOZAL) prospective, double-
blind study concluded that 76.7% of 37 eyes with atrophic AMD had stable or improved VA at 
6 months when taking an 8 mg L-based supplement. Although VA assessment was the same as 
the Aston study the type and ARMD and supplement composition differed [101].  
The CARMIS randomised controlled trial found that a 10 mg L-based supplement over 12 
months increased N1P1 amplitudes in rings 1 and 2 of the mfERG in 15 eyes with ARM or non-
central geographic atrophy [103]. As the supplement composition and ARMD categories were 
not the same as for the Aston study, it is difficult to compare the CARMIS study with the Aston 
study. Unlike the Aston study, the CARMIS study did not report dietary levels of L and Z 
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throughout the study period, thus it is difficult to determine if the mfERG changes seen were 
due supplementary or dietary changes in L and Z. Retinal accumulation of L and Z (MPOD) 
were not measured in the CARMIS study, thus it is impossible to ascertain if increased retinal 
levels of L and Z were related to the increased central mfERG amplitudes reported in the study. 
 
Withdrawal effects  
Of those who were assigned to taking the supplement for the supplementation trial, a further 
study was undertaken to assess the effects of withdrawal of the supplement 20 weeks after 
supplementation had ceased.  
On withdrawal of the supplement ring 1 N1P1 amplitudes were reduced in HO eyes and ring 3 
P1 latency became shorter in HY eyes. When HY and HO eyes were combined, increasing 
sample size, ring 1 and ring 2 N1P1 amplitudes were reduced. In ARM eyes ring 3 N2 latency 
and ring 4 P1 latency became longer. There were no changes to any other outcome measures or 
for any other groups.  
There is paucity in the literature with regard to the effects of L supplement withdrawal on 
measures of visual function. A further LUNA study concluded that 9 months after 
discontinuation of a L-based supplement, MPOD levels were still elevated in 108 participants, 
of which 100 had ARMD and 8 were healthy [383]. This is in concordance with the Aston 
study, with no statistically significant reduction in MPOD seen for HO, HY, combined HO and 
HY, and ARM eyes after supplement withdrawal. However, it is difficult to analogise the Aston 
and LUNA studies due to the larger sample size, combining of healthy and ARMD eyes, and 
differing supplement withdrawal time period assessed in the LUNA study. 
Cystic fibrosis (CF) is associated with decreased carotenoid absorption and hence reduced 
retinal levels of L and Z [384]. Although this is not the same as supplement withdrawal, it may 
provide some information about the effects of reduced levels of retinal carotenoids on retinal 
and visual function. A study of 10 participants with CF demonstrated that although MPOD was 
significantly reduced in these eyes when compared to healthy controls, CS and mfERG 
measures were no different in CF eyes compared to healthy eyes [384]. This was echoed in 
another study of rhesus monkeys whose mfERG was normal even when L and Z were excluded 
from their diets from birth to 10-18 years [385].  
A trend became apparent for reduced mfERG N1P1 amplitudes for all 5 rings for the HO group, 
HY group and combined HO and HY groups on withdrawal of the supplement. This was also 
true for rings 1, 3 and 4 in ARM eyes. A possible reason for this is that changes to retinal 
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function may occur more rapidly than depletion of retinal levels of L and Z. It may also be that 
the variability of the MPOD equipment masked any subtle reductions in L and Z levels. The 
other components of the supplement rather than L and Z may deplete faster in the retina on 
supplement withdrawal which may cause the reduction in mfERG amplitudes. However, if this 
was the case amplitudes may have increased during supplementation. 
 A possible mechanism for the trend for reduced N1P1 amplitudes is that although L and Z may 
deplete from around the tubulin binding sites in cone axons on supplement withdrawal, 
variability in MPOD equipment may mask any subtle reductions in L and Z levels. Therefore no 
reduction in retinal levels of L and Z (MPOD) are seen but subtle changes in retinal function are 
found in the form of reduced mfERG amplitudes. The trend for selective reduction in N1P1 
amplitudes in ARM (rings 1, 3 and 4) may be due to inconsistent accumulation and depletion of 
L and Z in the diseased retina due to the disruption of nutrient and waste exchange as discussed 
in chapter 1.   
 
8.2 Limitations 
Technical difficulties affected sample sizes for mfERG measures. However this was 
compensated for by combining HY and HO eyes which increased the sample size. This also 
provided an adequate sample size for VA analysis. Paired t-tests for treated ARM eyes between 
visits one and three also provided an adequate sample size for mfERG analysis. All other 
outcome measures had sufficient sample sizes for data analysis with the exception of MPOD in 
the ARM group. However, a study by Koh et al. found a statistically significant mean rise of 
0.07 in MPOD with supplementation of 10mg of free lutein in 7 ARM eyes over 18-20 weeks 
[186], a smaller sample size than for the Aston study.  
The initial aim was to recruit 120 participants to obtain 40 HO, 40 HY and 40 ARM eyes. The 
recruitment process was extensive as described in section 2.2 and more difficult than predicted. 
On reflection, older participants and those with ARMD had more mobility problems than 
younger participants. Financial recompense for time and travel expenses may have encouraged 
older participants and those with ARMD to participate, especially as many visits were required.  
Food diaries were prospective and were completed over several days in order to provide 
detailed dietary information. Return rates were lower than anticipated. Increased return rates 
may have occurred if a small fee was attached to each returned diary. A recall food diary would 
have provided a greater number of returned questionnaires as participants could have completed 
these during their visit to Aston. However, this may not have been as accurate due to 
participants having to remember their food intake over a 3 day period. 
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It may be argued that using a combination of supplement components does not allow for the 
assessment of individual effects of each active ingredient on measures of visual function. 
However many eye supplements available are combination supplements due to the synergistic 
nature of ingredients. Appropriate examples of these synergistic relationships include copper 
and zinc combinations required for copper-zinc superoxide dismutase, a part of the antioxidant 
system within RPE and retina [164], and increased bioavailability of L with the addition of 
certain fats, including olive and peanut oils [386, 387]. Because the causes of ARMD are multi-
faceted it may be that multi-ingredient supplement is of more benefit than a single nutrient. 
Indeed, the AREDS investigators found that zinc and antioxidants reduced the relative risk of 
developing advanced AMD by 21% and 17% respectively. When zinc and antioxidants were 
combined, the risk reduced further to 25% [100].  
A further limitation may be that the study population characteristics did not precisely replicate 
those of the general population. It may be that study participants who choose to partake in 
research do so because they have a greater interest in their own health than those within the 
general population. They may be more proactive in taking care of their health. 
Serum L and Z levels could have been monitored throughout the trial. However, this would not 
necessarily reflect the levels accumulated within the retina [371] and the invasive nature of the 
procedure may have hindered recruitment further.  
The lack of placebo in the non-treated group may be considered a limitation. The time 
constraints of the trial, and the costly and time consuming nature of placebo manufacture meant 
that placebo allocation was not feasible. It may be argued that participants not receiving a 
treatment may bias the results by not engaging in the study as enthusiastically as those given a 
treatment or placebo. However the results of the trial did not reflect this.  
Supplement compliance was the same for treated ARM eyes, older eyes and younger eyes, 
averaging around 80%. However, better compliance for all groups may have provided different 
results. Forgetfulness was the sole reason for this level of compliance. Participants were 
required to take a tablet and a capsule in the morning and repeat this of an evening. Compliance 
may have improved if a supplement of single dosage was provided.  
 
8.3 Confounding variables 
Randomised controlled trials are the gold standard for assessing whether a cause-effect 
relationship exists between interventions and outcomes [189]. This is because random allocation 
of participants to intervention groups limits the influence of confounding variables. The trial 
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was single-masked, eliminating the possibility that observed effects were due to investigator 
bias.  
For the supplementation trial, there were no differences between treated and non-treated groups 
for gender, age, smoking, spherical equivalent, axial length, dietary copper, zinc, L and Z, 
retinol, carotene, vitamin C, vitamin E or omega 3. This was true for HO, HY, combined HY 
and HO and ARM groups. There was a difference between treated and non-treated groups for 
ethnicity in the HY and combined HY and HO groups, but not for the HO or ARM group. There 
is no reason to believe that the results would have been different if the treated group had 
contained similar numbers of Asians as the non-treated group. 
Although not contained within the nutritional supplement, dietary levels of carotene (plant 
forms of vitamin A) and retinol (animal forms of vitamin A) were also analysed throughout 
supplementation and withdrawal trials because of the potential protective effect of vitamin A 
against ARMD described in chapter 1. It could be argued that the increased dietary retinol levels 
(table 6.14 in appendix 11) in the non-treated group, and increased dietary carotene levels (table 
6.13 in appendix 11) in the treated group of HY eyes during the supplementation trial (chapter 
six) confounded the results of the study. This is not likely to be the case as no clinically 
significant changes were seen for any measure between treated and non-treated HY eyes. 
Statistically significant changes were seen for MPOD measures. However MPOD measures 
accumulation of L and Z within the retina and not carotene or retinol.  
 
It may also be argued that the increase in dietary omega-3 in the combined HY and HO eyes 
during the supplement withdrawal trial confounds the results. Omega 3 has a potentially 
protective effect on the retina as discussed in chapter one. Therefore any dietary increase may 
have masked any changes caused by supplement withdrawal. However there was a statistically 
significant reduction in ring 1 and ring 2 mfERG N1P1 amplitudes for this group. Nevertheless 
this reduction was not clinically significant.  
 
8.4 Improvements and future work 
A recent study found that nine months after the withdrawal of a L-based supplement MPOD 
was still elevated [383]. However the study participants were a mix of ARM and healthy eyes, 
and other measures of visual function were not assessed. Therefore extended supplement 
withdrawal trial duration may have identified further changes in outcome measures. 
145 
 
The method of MPOD collection was HFP. This is a subjective measure. Objective measures of 
retinal accumulation of MP such as fundus autofluorescence or fundus reflectometry may be 
more appropriate to compare with objective measures of retinal function such as the mfERG.  
 
8.5 Conclusions 
The study found statistically significant improvements in MPOD in HY and HO groups treated 
with a L-based supplement. When HY and HO groups were combined MPOD improvements 
were maintained, and mfERG ring 2 P1 latency became shorter.  
On withdrawal of the supplement mfERG ring 1 N1P1 amplitude reduced in HO eyes. When 
HO and HY eyes were combined, mfERG ring 1 and ring 2 N1P1 amplitudes were reduced.  In 
ARM eyes, ring 3 N2 latency and ring 4 P1 latency became longer.  
While there were some statistically significant changes in outcome measures during 
supplementation and withdrawal, none of these changes were clinically significant. The trial 
was sufficiently powered to assess the effect of the supplement on all outcome measures for all 
groups with the exception of MPOD in ARM-affected eyes.  
The results suggest that there is no clinically significantly beneficial effect of supplementation 
with 12 mg L, 0.6 mg Z, 150 mg vitamin C, 15 mg of vitamin E, 400 µg copper, 20 mg zinc and 
1080 mg omega-3 fatty acids on visual or retinal function in healthy eyes or eyes with ARM. 
There is also no clinically significantly detrimental effect of supplement withdrawal on visual or 
retinal function in healthy eyes or eyes with ARM in this study. However, the statistically 
significant trend for increase in MPOD is encouraging and suggests that macular pigment does 
accumulate within the retina on L-based supplementation. It may be that any beneficial effect of 
accumulated macular pigment on retinal and visual function is not seen for many years. Longer-
term studies may yield greater information. 
 
The Aston study adds to literature in several ways. The CARMIS investigators concluded that 
central mfERG amplitudes were augmented after 12 months with a 10 mg L-based supplement 
in ARMD-affected eyes [103]. The Aston study extended on the CARMIS study by assessing 
the effects of a L-based supplement on mfERG latency, subjective measures of visual function 
in ARM and healthy eyes, by assessing accumulation of L and Z within the retina, by assessing 
dietary levels of supplement nutrients and by assessing the effects of supplement withdrawal on 
visual and retinal function.  
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Unlike the CARMIS study, the Aston study contributes to the debate about the use of nutritional 
supplementation in healthy younger and healthy older eyes, before the commencement of 
ARMD. Any positive effects of the nutritional supplement in the HY or HO cohort may have 
implied that there is a function for nutritional supplementation in delaying or possibly 
preventing the onset of ARMD. Any negative effects from supplement withdrawal may have 
also supported this hypothesis. However, while the trend for an increase in MPOD with 
supplementation is encouraging, it did not reach clinical significance to support this hypothesis. 
Any negative effects from withdrawal of the supplement in ARM eyes may have supported the 
use of nutritional supplementation in delaying progression of the disease. However, there were 
no clinically significant findings to support this theory.   
The pathogenesis of ARMD although currently unclear, is purported to be a combination of 
genetic predisposition and environmental factors, leading to eventual photoreceptor death with 
accompanying visual loss. Sensitive, objective methods for early diagnosis of ARMD, and 
strategies for disease prevention need to be developed.  
Randomised controlled trials remain the gold standard for investigating cause-effect 
relationships. Large-scale, long-term RCTs such as the AREDS 2 (www.areds2.org) will 
provide clinicians with more information about the effects of L and omega 3 on visual function 
and on the risk of developing ARMD.  
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Risk factors for ARMD development 
The odds ratio is the ratio of the odds of ARMD occurring in those exposed to a risk factor to 
the odds of it occurring in those not exposed to a risk factor. The relative risk is a ratio of the 
probability of the ARMD occurring in a risk factor exposed group versus a non-exposed group. 
 
Modifiable risk factors 
Smoking 
Smoking is the one modifiable risk factor that has been largely consistently associated with an 
increased risk of developing ARMD [1-9]. The Rotterdam study found that the higher the pack-
years smoked, the higher the risk of developing neovascular AMD, with a 6.6 fold increase  in 
risk for developing neovascular AMD when compared to non-smokers [10]. The Pathologies 
Oculaires Liees a l'Age (POLA) study found an increased risk of neovascular AMD and 
geographic atrophy in those who smoked for more than 20 years (odds ratio 3.0 for 20-39 pack 
years and 5.2 for 40 pack years). The risk remained elevated until 20 years after smoking 
cessation [11]. Smoking was not associated with risk for ARM development in this study. 
Increase of ARMD development risk with increase in smoking was also demonstrated in a study 
by Seddon et al., [12] in a 12 year prospective study of 31843 females and in a 12 year 
prospective study of 21157 males by Christen et al., [13].   The Rotterdam study results are 
echoed in a study on Japanese males [14]. All of these studies show that even previous smokers 
who had ceased smoking still had an elevated risk of ARMD development when compared with 
non-smokers, but not as elevated as current smokers. A study undertaking pooled and separate 
analysis of 14,752 participants from the Beaver Dam eye study, Rotterdam study and Blue 
Mountains eye study showed that apart from age, smoking was the only consistent risk factor 
associated with any form of ARMD [15]. This pooled study was taken from three different 
continents (North America, Europe and Australia). Another study based on 3271 Australians 
also highlighted this consistent association for ARM and AMD [16]. A review of the literature 
in conjunction with New Zealand morbidity and smoking prevalence data found an associated 
risk of AMD with smokers in New Zealand [17]. In the United Kingdom a two-fold risk of 
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ARMD has been associated with smoking when compared with non-smoker in 28000 
individuals [18]. Cigar smoking in India has also been linked with a higher risk for developing 
AMD [19]. A study of Latino subjects also demonstrated an association between smoking and 
advanced AMD in the Hispanic population [20]. The effects of passive smoking on AMD risk 
have been examined in a United Kingdom study, comparing 435 end-stage AMD subjects with 
280 healthy controls. The results showed an odds ratio of 1.87 in passive smoking exposure in 
non-smokers [21]. This prolific evidence across continents and differing ethnicities suggests 
that smoking is highly toxic to the retina, although the pathogenic mechanisms between 
smoking and retinal toxicity still remains unclear.  
 
There are approximately 4000 toxic components in cigarette smoke one of which is nicotine. A 
study assessing the effects of nicotine on the vascular smooth muscle cells confirmed that 
nicotine increases CNV size and severity in laser induced CNV in the mouse eye model [22]. 
Nicotine attaches to nicotinic acetyl choline receptors on photoreceptors, bipolar, horizontal and 
ganglion cells [23]. Tar within cigarette smoke, contains hydroquinone – an oxidant, which in 
the mouse eye has been shown to encourage sub-RPE deposits and thickening of Bruch’s 
membrane [24]. Cadmium is another toxic oxidant found in cigarette smoke, of which higher 
urinary levels in smokers is linked with an increased risk of AMD [25]. It accumulates 2.5 times 
higher in the choroid-RPE complex of smokers compared with non-smokers [26] and increases 
reactive oxygen species, alters RPE cell morphology and decreases cell survival [27]. Studies on 
mice eyes have demonstrated that chronic exposure to smoke causes changes to the RPE similar 
to those observed in AMD, with RPE apoptosis, increased oxidative damage [28], DNA damage 
to the RPE and increased inflammatory activity [29]. 
 
The effects of the combination of smoking and genetics of ARMD have been studied with many 
studies showing an additive effect of smoking for increased risk of developing ARMD when 
there is a genetic disposition for the disease [30-34] .  
 
Alcohol intake 
Studies assessing the association between ARMD risk and alcohol intake have shown 
inconsistent findings [8, 35, 36]. A relationship between beer consumption and risk for CNV 
has been identified in the Beaver Dam eye study, although no such relationship was seen with 
wine or spirit consumption [37]. This was echoed in subjects taken from the Latino community 
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with beer consumption and high alcohol intake being linked with a greater risk of developing 
the disease [20]. Conversely, no association between any type of alcohol and ARMD risk has 
also been shown in other studies [20, 38-40]. Interestingly, moderate wine consumption has 
been associated with a decreased risk of developing AMD [41] and in the Reykjavik eye study 
alcohol consumption decreased the risk for drusen formation [42] suggesting a protective effect 
of alcohol against ARMD. Chronic, heavy alcohol consumption is linked with an increased 
accumulation of ethyl esters and an increase in laser induced CNV of 28% within the rat 
choroid models [43]. Ethanol is the key component of alcohol, and when exposed to ethanol 
photoreceptor outer segment growth in the Zebrafish retina is inhibited, leading to poor 
photoreceptor function as demonstrated by reduced a- and b- wave amplitudes of the ERG [44]. 
Red wine has a high level of phenolic compounds that increase antioxidant activity which may 
reduce oxidative stress and abnormal proliferation of the RPE [45]. 
 
Socioeconomic factors 
Socioeconomic factors have been inconsistently associated with an increased risk of developing 
ARMD.  A Canadian study looking at socioeconomic status and CNV found that the severity of 
CNV was associated with lower socioeconomic status [46]. However in another Brazilian study 
assessing AMD in two differing socioeconomic populations no association between AMD and 
socioeconomic background was seen [47]. No association was demonstrated between ARMD 
and socioeconomic factor in a case-control study by Hyman et al., [48] or in the Framingham 
eye study [49], the Beaver Dam eye study [50] and the third NHANES Study [51]. 
 
Education 
The Age-Related Eye Disease Study (AREDS) report number three found that education was 
inversely linked with drusen, GA and CNV [52]. The Eye Disease Case-Control Study Group 
(EDCCS) found a similar trend for education and neovascular AMD risk, although no statistical 
significance was demonstrated in their final multiple regression model [1]. The first NHANES 
study also demonstrated this association but statistical significance was lost on logistic 
regression modelling [53].  
 
Nutrition 
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Nutrition as an associated risk factor for developing ARMD has also been subject to conflicting 
findings within the literature. The first NHANES study found dietary vitamin A provides a 
protective effect against AMD with no beneficial effect shown with vitamin C [53]. The Beaver 
Dam eye study found no association between vitamins A, C and E and reduced risk of 
developing ARM [54]. Another study of serum lycopene in the Beaver Dam eye study showed 
an increased risk of ARMD with reduced lycopene levels [55]. However, lower levels of lutein, 
zeaxanthin and vitamin E were not related to an increased risk for ARMD development in this 
study. Conversely higher serum alpha tocopherol and an antioxidant index including ascorbic 
acid, alpha tocopherol and beta carotene, were found to be conducive to lower ARMD risk in 
the Baltimore longitudinal study [56]. The Physicians Health study and the Blue Mountains eye 
study did not find a protective effect for vitamin C, E and multivitamins [57], and vitamin E and 
beta carotene [58] against ARMD respectively. The EDCCS found a reduced risk of 
neovascular AMD with higher serum and dietary carotenoid levels [59]. An antioxidant index 
combining selenium, vitamin C, vitamin E and carotenoids also showed reductions in risk in 
this study. A further study from the EDCCS reported that spinach and collards, high in the 
carotenoids lutein and zeaxanthin, were most strongly associated with a reduced risk for AMD 
(p<0.001) [60]. Collard greens are various loose-leafed vegetables of Brassica oleracea, the 
same species that produces cabbage and broccoli. They are genetically similar to kale and spring 
greens. High-dose vitamins C, E beta carotene and zinc were found to be effective in lowering  
the odds ratio of developing advanced AMD in eyes with intermediate drusen, large drusen and 
non-central GA in a large trial undertaken by the AREDS group [61]. Improvements in visual 
function in eyes with ARM or non-exudative AMD were reported in several studies involving 
carotenoids [62-65]. 
 
High levels of omega-3 fatty acid consumption (>75 percentile) have been shown to provide a 
protective effect against progression to AMD [66]. Lowering the dietary glycaemic index with 
higher omega-3 intake also showed a reduction in AMD progression in this study. The benefits 
of a low glycaemic diet in reducing ARM risk have been identified in other studies [66-68]. The 
Blue Mountains eye study found a lower risk of developing ARM when consuming omega-3 
fatty acids in the form of one serving of fish per week [69]. Consumption of linoleic acid in the 
form of 1 to 2 servings of nuts per week was also associated with reduced ARM risk in this 
study. The AREDS study found a reduction in risk of progression from drusen to geographic 
atrophy in those with the highest dietary intake of omega-3 fatty acid [70] and reduced risk of 
developing neovascular AMD [71, 72]. It is thought that omega-3 provides a protective role 
within the retina by inhibiting oxidative stress and reducing inflammation within the retina [73].  
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Association between higher trans-unsaturated fat intake and increased prevalence of AMD was 
reported in a large study of 6734 participants [74]. Omega-3 fatty acids and olive oil were 
associated with a reduced prevalence of ARM and AMD in this study. However, the third 
NHANES results showed no association between dietary fat intake and ARM risk in 7883 
participants [75] and this was echoed in 3654 participants from the Blue Mountains eye study 
[76]. Studies of mouse retinae have shown an increase in the accumulation of basal laminar 
deposits when consuming a high fat and cholesterol diet [77]. Some studies have shown that 
diets higher in fats have a propensity to be lower in essential nutrients and antioxidants [54, 78]  
Body mass index (BMI) 
A high BMI has been inconsistently linked with risk for developing ARMD. The Blue 
Mountains eye study found an odds ratio of 1.78 for risk of early ARM in obese subjects 
compared to those with a normal BMI [79]. The Age-related Eye AREDS group reported that a 
higher BMI was associated with a risk for developing neovascular AMD [80] and GA (odds 
ratio of 1.93) [81]. A 2.29-fold risk of AMD and a 1.54-fold risk of pigmentary abnormalities 
were demonstrated in the Pathologies Oculaires Liees a l'Age (POLA) study in obese subjects 
[82]. The relative risk was 2.35 for a BMI of 30 or more and 2.32 in a BMI of 25 to 29 for 
developing AMD in this study. Larger waist circumference and a larger waist-hip ratio have 
also been associated with an increasing relative risk for AMD development [83]. An inverse 
relationship between BMI and retinal levels of L and Z (macular pigment optical density, or 
MPOD) was reported [84]. The authors also assessed dietary L and Z intake and found that 
individuals with the highest BMI consumed lower amounts of L and Z. They concluded that 
lower dietary intake of L and Z, and/or competition between adipose tissue and retina for L and 
Z uptake were likely to affect retinal levels of L and Z [84]. Conversely, associations between 
lean males and dry AMD have been found [85]. A pooled study of 14,752 participants from the 
Beaver Dam eye study, Rotterdam study, and Blue Mountains eye study did not report any 
consistent association between BMI and risk for any forms of ARMD [15] and this was echoed 
in other studies [9, 86]. 
 
Cardiovascular disease 
Cardiovascular disease (CVD) has been associated with risk for developing ARMD in several 
studies and discounted in others. The Beaver Dam eye study showed no association between 
CVD and neovascular AMD or geographic atrophy [87]. Arterial stiffness - an indicator for 
CVD, has been shown to be associated with the presence of AMD [88]. The Blue Mountains 
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eye study did show associations between CVD (relative risk 1.57) for early incident ARM. 
Higher HDL cholesterol levels were protective for late AMD, and high total/HDL cholesterol 
ratio was linked to increased risk of late AMD and GA [89]. C-reactive protein (CRP) is an 
inflammatory marker for CVD. Some studies have shown increased levels of CRP in ARMD 
[90-92] suggesting an inflammatory role in the development of ARMD. Conversely better 
cardiovascular health was associated with reduced risk of ARMD in the Cardiovascular Health 
and Age-Related Maculopathy (CHARM) study [93]. The POLA study showed a reduced risk 
(odds ratio of 0.72) for developing drusen and no association between AMD and a history of 
cardiovascular disease [82]. No association between CVD and ARMD risk was reported in the 
AREDS studies [52, 81], EDCCS study [1] or Smith et al’s., pooled analysis from the 
Rotterdam, Blue Mountains and Beaver Dam eye studies [15]. Hyman et al., found a link 
between ARMD and CVD [48] in an earlier study but not in a later study [94]. 
Hyman et al., also found an association between moderate to severe hypertension (diastolic >95 
mmHg) and risk for developing neovascular AMD, especially in those receiving 
antihypertensive medication. The same association was not found for GA and hypertension, 
leading the authors to suggest that comparable disease processes may occur in neovascular 
AMD and hypertension [94].  Reduced choroidal blood flow in hypertensive individuals with 
neovascular AMD may account for this relationship [95]. The Framingham eye study [49] and 
the first NHANES study [53], reported links between ARMD development risk and 
hypertension. The AREDS group found increased risk for developing neovascular AMD and 
large drusen in those with hypertension and those taking hypertensive treatment [52], although 
no association with incident neovascular AMD was seen in their further study [81]. 
Hypertensive disease severity has been linked with neovascular AMD, with doubled odds in the 
severest of hypertension [96]. The Beaver Dam eye study [97, 98], Blue Mountains eye study 
[89], EDCCS [1] and others [99, 100] found no evidence to suggest that ARMD development 
risk and hypertension was linked. 
 
Cholesterol levels and treatment 
Links between cholesterol levels, cholesterol-lowering treatments and risk of ARMD 
development have been conflicting. A possible protective effect of statins and lipid-lowering 
treatments against ARMD has been found in a number of studies [101-105]. Some studies have 
suggested statins protect the vascular endothelium from oxidative damage [106] and reduce 
basal linear deposit accumulation in Bruch’s membrane by reducing cholesterol [107]. 
Conversely, a review, assessing pooled data of the use of statins and lipid-lowering treatments 
did not show a reduced risk of developing ARMD when using statins [108]. Pooled data 
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analysis of the Beaver Dam, Rotterdam and Blue Mountains eye studies did not report effects of 
statins on ARMD risk [15]. Other studies have found no association between statin use and 
reduced risk for developing ARMD [82, 109-111]. Furthermore, some have reported an 
increased risk of ARMD development in those taking statins [112]. In the EDCCS higher levels 
of cholesterol were associated with an increased risk of neovascular AMD (≥6.7 mm/L = odds 
ratio of 4.1) [1], but no information about statins was presented in this study. The AREDS study 
also did not provide data about statin use or cholesterol levels in their study [52]. Because the 
benefits of statins for reducing heart disease and lowering cholesterol were not largely reported 
and routinely used until 1994 [113] this is the likely reason for lack of data before this period. 
The first NHANES study found no association between cholesterol levels and risk for ARMD 
development, but again statins were not assessed here as the study results were published in 
1988 [53]. High-density lipoprotein (HDL) cholesterol levels were inversely related to AMD 
and a raised total/HDL ratio predicted AMD in the Blue Mountains Eye Study [89]. Statins and 
aspirin were found to be associated with reduced rates of CNV in a retrospective study of 326 
patients with ARMD [102]. Aspirin was not found to be related to an increased risk of ARM or 
AMD development in the AREDS study [52] but was positively correlated in a later AREDS 
study [81]. It was not linked in other studies [114-116] or its effects were not reported [1, 48, 
53].  
 
Medication 
Conflicting associations between the use of other medication and risk for developing ARMD 
have been reported. Those with GA were more likely to take antacids, and those with large 
drusen or extensive intermediate drusen were more likely to take hydrochlorothiazide diuretics 
in one AREDS report [52]. Antacid use and increased incidence of GA was also seen in another 
AREDS group study [81]. This report also highlighted an association between anti-
inflammatory medication and increased incidence of GA. In a further study assessing the use of 
antacids and thiazide diuretics in ARMD no relationship was found for increased risk of the 
disease and either medication [117]. Van Leeuwen et al., found an increase in risk for ARM 
development in those taking antihypertensive treatment and a decreased risk in women taking 
tricyclic antidepressants [118].   
 
Hormones 
The use of differing hormones has been associated with risk for developing ARMD. Thyroid 
hormones were associated with an increased risk of GA in the AREDS study, although the use 
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of oestrogen and progesterone in women was not associated with any form of ARMD in this 
study [81]. Thyroid and antithyroid hormones were not associated with ARMD in another study 
[117]. There was also no association between the use of hormone replacement therapy (HRT), 
hysterectomy or oopherectomy in women and ARMD risk in the POLA study [119]. However, 
a protective effect of HRT was found in another study with a 48% lower risk of developing 
CNV compared to those who had never used HRT, although no protective effect was found for 
ARM [120]. Reduced risk of developing ARM was seen in another study in women taking HRT 
[118]. Lack of oestrogen was shown to be associated with an increase basal laminar deposits 
and  thickened bruch’s membranes in mice retinae [121].The authors postulated that oestrogen 
down-regulated matrix metalloproteinase-2 – which is responsible for breaking down bruch’s 
membrane and RPE basement membranes. Another study demonstrated that lack of oestrogen 
up-regulates a glycoprotein called YKL-40, leading to CNV. The function of YKL-40 in the 
retina is unknown [122]. 
 
Type II diabetes 
Inconsistent links between type II diabetes and ARMD risk have been described. The Blue 
Mountains eye study also found a relationship between type II diabetes and development of GA 
after ten years with a relative risk of 3.89, but no relationship for neovascular AMD [89].  Type 
II diabetes was associated with an increased risk for developing ARMD compared to type I 
diabetics and controls [123]. The European Eye study (EUREYE) and AREDS group 
demonstrated a relationship between type II diabetes and risk of neovascular AMD development 
but not for GA and type II diabetes [81, 124]. Conversely, a study assessing the ten year follow-
up of 133 newly diagnosed type II diabetic participants and 144 controls found no significant 
difference between groups in risk for ARMD development over the ten years [125]. No 
relationship between type II diabetes and ARMD was seen in the POLA study [82] a further 
Blue Mountains eye study [79], or reported by others [1, 15]. The mechanisms for any 
association between diabetes and ARMD are unknown. Hyperglycaemia in diabetes has been 
associated with reduced choroidal circulation within the foveal area [126, 127]. This may reduce 
the exchange of oxygen, nutrients and waste products within the outer retina which may 
increase susceptibility to ARMD. 
 
Sunlight exposure 
There are contradictory findings in the literature about the relationship between exposure to 
sunlight and risk for ARMD development. No statistically significant associations were reported 
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in a Brazilian study [47], Italian study [128] or studies from other global locations [1, 52, 129, 
130]. Intriguingly, two studies have demonstrated a protective effect of light against ARMD 
[131, 132]. However, other studies have shown a detrimental effect of sunlight with increased 
risk of ARMD development. Blue light exposure was associated with a risk of developing GA 
in a study of 838 watermen [133]. The Beaver Dam eye study found a relationship between high 
sunlight exposure and a higher 10-year incidence and progression of ARM [134], with 
sunglasses and headwear providing protection against drusen development and RPE 
depigmentation. The Blue Mountains eye study found that abnormal skin sensitivity to sunlight 
was associated with AMD but not ARM [135]. Retinal photochemical injury occurs 
cumulatively over a long period to tolerable light levels. Sunlight damages the RPE-
photoreceptor complex causing the formation of free radicals which peroxidise the fatty acids 
within the photoreceptor outer segments, leading to RPE and photoreceptor dysfunction and 
death [136]. Free radicals also increase the production of lipofuscin in RPE cells. A2E, a major 
fluorophore of lipofuscin, generates free radicals in response to light which leads to RPE 
apoptosis [137].  
 
Miscellaneous 
Other, less reported modifiable risk factors inconsistently associated with ARMD include parity 
greater than zero. Increased risk of neovascular AMD has been seen with parity greater than 
zero in the EDCCS study [1, 138] but this relationship is not apparent in another study [139]. 
Conversely parous women were found to have a 26% lower risk of developing ARM [120] in a 
more recent study. Although not clear, hormonal mechanisms such as the effects of oestrogen 
mentioned earlier may play a role. 
 
Non-modifiable risk factors 
Increasing age is strongly linked with a higher risk of developing ARMD [15, 19, 52, 128, 140-
146], but there are other non-modifiable risk factors for developing the disease which are 
inconsistent within the literature.  
 
Cataracts and intraocular lenses 
Cataracts are known to protect the retina by reducing the amount of ultraviolet and blue light 
entering the eye. Thus after cataract extraction the retina is subjected to increased light levels 
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and increased photochemical damage. The Blue Mountains eye study and the Beaver Dam eye 
study found an increased risk for developing ARMD in eyes that had undergone cataract 
surgery [147-149].  This was evident in other work, showing an increased risk of AMD in eyes 
post-cataract extraction [150, 151]. Intraoperative photic damage and surgical inflammation 
have also been discussed as possible mechanisms for increasing AMD risk post-cataract 
extraction [152]. Other studies such as the AREDS group report 25 found no risk of ARMD 
progression after cataract surgery [153, 154]. It has been postulated that the cataract itself 
increases the risk of developing ARMD. In pooled findings from three studies severe cataract 
was associated with higher prevalence of ARMD [155]. Studies assessing the risk of ARMD 
development associated with the use of newer intraocular lenses with short-wavelength blue 
light filtering properties may provide more information in the coming years.  
 
Cognitive impairment 
Evidence from the AREDS group showed a link between reduced cognitive impairment and 
increased risk of AMD development [156]. This was resonated in ARM subjects in the 
Cardiovascular Health Study [157], a weak association in another study [158], and in AMD 
subjects in an Australian population [159]. The Rotterdam study demonstrated that tobacco and 
atherosclerosis may play a role in the pathogenesis of both ARMD and Alzheimer’s disease 
[160]. Amyloid beta peptide is found in the neuritic plaques in Alzheimer’s disease and also in 
drusen. It contributes to inflammatory processes in both of these diseases [161] and in many 
neurodegenerative diseases of ageing such as Parkinson’s disease, arthritis, atherosclerosis and 
myocardial infarction [162]. Many people with ARMD reduce their physical and mental activity 
levels which is associated with cognitive decline [163]. Conversely, no significant relationship 
was established between Alzheimer’s disease and ARMD [164] in 33 Alzheimer’s cases when 
compared to 24 controls. The authors believe that small sample size and age-differences 
between the groups may have accounted for the lack of any relationship.  They did not specify 
between ARM or AMD for their study. 
 
Genetics 
Although knowledge about the role of genetic variants in ARMD is currently rudimentary, 
many genes have been identified as providing either deleterious or protective effects against the 
disease [165]. A review of the many genes identified [166] found that genes within the 
complement cascade (CFH, C2, BF and C3), ARMS2 and HTRA1 are most strongly associated 
with ARMD development. Many studies have assessed familial predisposition to ARMD by 
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looking at monozygotic and dizygotic twins [167-172] with monozygotic twins showing a 
stronger concordance than dizygotic twins.  The higher prevalence of ARMD in first-degree 
relatives of those with the disease than those without the disease further strengthens the case 
that genetic factors may play a part in ARMD pathogenesis [173-175].  More may be learnt over 
time as genetic marker testing becomes increasingly sophisticated, identifying greater numbers 
of genes associated with ARMD.  
 
Gender 
Female gender has been associated with increased risk for development of ARMD, although no 
consensus seems to prevail. A Croatian study of 6617 patients found that ARMD incidence was 
slightly increased in females compared to males [176]. This was echoed by the AREDS group 
with ARM being more apparent in females [52] and other work [141]. However this was not 
replicated in pooled analysis from the Beaver Dam, Rotterdam and Blue Mountains Eye studies 
[15, 177]. Males were more likely to undergo photodynamic therapy than females for 
neovascular AMD in an Israeli study [178], and were more likely to have AMD than women in 
two Japanese studies [179, 180] although the authors suggest that this may be due to the 
significantly higher proportion of Japanese men who smoke. A recent study of the Beaver Dam 
offspring study also showed that being male was associated with ARM [9].  
 
Arthritis 
An association between arthritis and increased likelihood of ARM was reported in one AREDS 
study [52], whereas another AREDS study suggested a weak association between anti-
inflammatory medications and progression to AMD [81]. One study found subjects with 
rheumatoid arthritis (RA) had less prevalence of AMD and suggested anti-inflammatory agents, 
commonly used to manage the symptoms of RA, provide a protective effect against 
development of ARMD [181] since there is some  evidence that inflammation may play a role 
in the development of ARMD [182]. However environmental and genetic factors may also be 
relevant as RA is commonly a disease of the young and ARMD more apparent over 50 years of 
age [183]. 
 
Ethnicity 
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Higher prevalence of ARMD has been shown in white people when compared with blacks 
although genetics, culture and diet may play a role in these differences. Darker iris pigmentation 
may also confer some protective effect in the black population [184]. The AREDS group found 
a higher risk of developing large drusen and CNV in whites [52]. A further AREDS study 
echoed these results for incident CNV [81]. However no such association was found in a 
Brazilian study of 107 participants with ARMD [47]. In the Salisbury Eye Evaluation (SEE) 
project the risk of developing large drusen and RPE pigmentation was higher in whites than 
blacks but the risk of developing GA or CNV was no different than for blacks [185].  A south 
Indian study found a prevalence of AMD in its population similar to other developed countries 
[19]. A Japanese population study reported similar prevalence of ARM to the white population 
of the Blue Mountains eye study. This similarity also held true for AMD in Japanese males, but 
AMD prevalence was lower in Japanese women when compared to the Blue Mountains Eye 
Study population. This disparity was assumed to occur due to a high proportion of Japanese 
male smokers according to the authors [179]. Another Japanese study suggested that the 9 year 
incidence of AMD was lower among the Japanese than among white people, but higher than 
among black people [180]. The prevalence of ARM in South Koreans was also found to be 
similar to other studies but the prevalence of AMD was lower [146]. Exudative AMD was 
found to be higher in Chinese compared to whites in a study assessing four different ethnic 
groups, even when smoking age, gender, pupil size, BMI, alcohol intake, diabetes and 
hypertension were adjusted for [186]. A putative mechanism for reduced risk of ARMD in 
blacks compared to whites is the protective effect of the darker pigmentation of the iris [184] 
and higher concentrations of melanin within the choroid of blacks compared to whites [187]. 
Melanin acts as an antioxidant, scavenging free radicals and reducing oxidative stress [188].  
 
Iris Pigmentation 
Iris pigmentation has been inconsistently associated with an increased risk for ARMD with the 
EDCCS demonstrating no association between iris colour and neovascular AMD [1, 151], 
incident ARMD [81] or GA [151]. Conversely light irises were associated with increased risk 
for ARMD in other studies [143, 189, 190]. Blue iris colour was linked with increased risk of 
both ARM and AMD in the Blue Mountains eye study [191]. However, five years later 
longitudinal data did not support this association. A study of 1000 Danes also showed no 
difference between light iris and dark iris colour for AMD [192].   
 
Hypermetropia 
179 
 
Hypermetropia and its associated shorter axial length have been linked with increased ARMD 
development risk [48, 193-197]. An association between ARM risk and hypermetropia was 
found in the Blue Mountains Eye Study [198] and the Rotterdam study [199]. In a further Blue 
Mountains eye study no association was found between hypermetropia and the 5-year incidence 
of ARM [200]. Large drusen, extensive intermediate drusen and CNV were associated with 
hypermetropia in the AREDS study [52].  Other studies have reported no effect of 
hypermetropia on risk for developing ARMD [47, 201]. A biological mechanism for increased 
risk of ARMD with hypermetropia has not yet been elucidated. One study suggests shorter, 
thicker eyes with increased scleral rigidity decreases choroidal blood flow and thus retinal 
nutrient and waste exchange leading to increased oxidative stress [199]. 
 
Miscellaneous 
Other, less reported non-modifiable risk factors inconsistently associated with ARMD include 
hand-grip strength, optic disc appearance and birth weight. A couple of studies have linked 
decreased hand grip strength to increased risk for AMD [48, 49]. Unusual optic disc appearance 
has been associated with ARMD risk [202] but repealed in other studies [203, 204]. Babies with 
increased birth weight were found to have a higher possibility of developing AMD than those 
with lower birth weight in one study [205] and this was echoed in another study but only in 
white participants for ARM although AMD risk was not assessed in this study [206]. 
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Appendix 2 – Current treatment of ARMD 
 
Currents treatment of ARMD 
Treatment for ARMD has changed significantly in the last decade. Current recommendation for 
the first line treatment of CNV according to the Royal College of Ophthalmologists (RCO) is 
intravitreal anti-vascular endothelial growth factor (anti-VEGF) such as ranibizumab (Lucentis, 
Novartis) and pegaptanib (Macugen, Pfizer) which binds to and inhibits the action of VEGF-A, 
thus inhibiting neovascularisation [1].  
 
Evidence from the ANCHOR and MARINA randomised controlled trials (RCTs) showed a 
mean improvement in visual acuity after treatment with ranibizumab. The ANCHOR study 
compared intravitreal injection of ranibizumab with sham photodynamic therapy (PDT) to PDT 
treatment with sham injection in classic CNV. At a dose of 0.5 mg of ranibizumab with sham 
PDT treatment, mean visual acuity improved by 11.3 letters compared to a drop of 9.5 letters in 
the PDT group with sham injection at 12 months [2]. In the MARINA study intravitreal 
ranibizumab was compared with a sham injection.  At a dose of 0.5mg of ranibizumab mean 
visual acuity improved by 7.2 letters but in the sham injection group visual acuity dropped by 
10.4 letters. [3]. The primary outcome measure for both studies was the loss of fewer than 15 
letters of visual acuity. Both the MARINA and ANCHOR studies found that significantly more 
patients lost less than 15 letters of visual acuity when receiving 0.5mg of ranibizumab when 
compared with sham injection [3] or PDT [2]. This was echoed in the PIER [4] and FOCUS 
RCTs [5]. The RCO recommend the use of intravitreal anti-VEGF to treat all CNV lesion types 
(classic, predominantly classic, minimally classic, occult and retinal angiomatous lesions). 
Extrafoveal CNV (lesions 200µm or greater from the centre of the foveal avascular zone) may 
be treated with focal argon laser photocoagulation, or anti-VEGF therapy if it is decided that 
laser induced scotoma may disrupt normal visual function [1].  
 
The national institute of health and clinical excellence (NICE) current recommendations for the 
treatment of CNV is a 0.5mg dose of ranibizumab via intravitreal injection at 1 per month for 3 
consecutive months followed by further monthly injections if a further visual acuity loss of 
greater than 5 letters occurs [6]. Treatment can only be administered if:  
- best corrected visual acuity is between 6/12 and 6/96 
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- there is no permanent structural damage to the fovea 
- the lesion is ≤ 12 disc areas in size 
- there is evidence of disease progression 
 
Although no long-term comparative studies have been executed it appears that ranibizumab has 
greater efficacy than pegaptanib according to RCO and NICE comparisons of studies between 
these 2 treatments [1]. On balance NICE noted statistically significant mean gains of letters for 
ranibizumab treatment while pegaptanib largely only reduced mean loss of letters [6]. Some 
studies have looked at combination treatments for CNV but currently there is insufficient 
evidence to suggest they are superior to monotherapy with ranibizumab and may increase safety 
concerns [7].  
 
Other anti-angiogenic therapy includes anecorvate acetate (Alcon), an angiostatic steroid and 
bevacizumab (Avastin, Genentech) derived from the same antibody as ranibizumab. Both of 
these treatments have not been licensed for use in the UK. Although ranibizumab is the gold 
standard for treating CNV, injections cost the NHS approximately £10,700 per patient for a 
course of 14 with the drug manufacturer paying additional costs if further injections are required 
[6]. 
 
Treatments for non-neovascular AMD are limited but include antioxidant supplementation [8], 
counselling and rehabilitation. Surgical options include the IOL-Vip system where a -64.0 
dioptre intraocular lens (IOL) is implanted in the capsular bag and a +53.0 IOL is implanted into 
the anterior chamber, reproducing a Galilean telescope and providing a distance magnification 
of 1.3. The lenses divert the image away from the diseased macular to a non-diseased area. 
Studies have shown improved visual acuity in patients with low vision due to end-stage macular 
degeneration although those with hyperopia were left with a high residual refraction [9, 10]. 
Another implantation system called the implantable miniature telescope (IMT) showed 
improved visual acuity of 2 lines or more after one year after in 77% of patients [11]. 
Improvements were also seen in another study [12], although it has been demonstrated that strict 
criteria need to be met for eye selection when undertaking telescopic implantation for patient 
satisfaction [13]. Surgical telescope treatments have very select inclusion criteria and require a 
specific post-operative visual rehabilitation programme with possible periodic endothelial cell 
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count due to the position of the anterior chamber IOL [14]. Miniature intraocular telescope 
surgery is not available on the NHS currently and is costly at around £6000 per eye. 
 
Although the last decade has shown promising changes in the treatment of CNV, these limited 
and costly therapies are not appropriate for ARM or non-neovascular AMD. This has prompted 
interest in developing preventative measures and exploring supplementary methods to recognise 
ARM earlier and monitor treatment efficacy on disease outcomes.  
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Appendix 4 – Patient leaflet 
 
 
 
Assessment of nutritional intervention on the 
electrophysiology of the retina 
 
Within the Ophthalmic Research Group we are investigating the 
effect of taking an ocular nutritional supplement on eye health. It is 
thought that this supplement might be useful for people with age-
related macular disease, as well as for those with a family history of 
this condition. We are looking for volunteers of all ages to take part. 
The project will involve visiting the Optometry department every five 
months for a period of twenty months. Each visit will last for about 
one hour. 
 
If you are interested in hearing more about the project, please 
contact Mrs Emma Berrow on 0121 204 4208, or 
berrowej@aston.ac.uk 
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Appendix 5 – Patient poster 
TEMPLATE DESIGN © 2008
www.PosterPresentations.com
What is age-related macular degeneration?
Emma Berrow
Telephone 0121 204 4208
What is the macula?
The macula is found near the centre of the retina at 
the back of your eye. It is very important because it 
is responsible for what we see right in front of us. It 
gives us vision for fine detail that helps with 
reading, sewing and recognising faces.
Symptoms Include
Blurred vision
Distorted vision –wavy lines
Areas of missing vision
If you notice any of these symptoms you should 
make an appointment to see an optometrist or GP 
who will refer you to an eye specialist.
What is age-related macular degeneration?
http://www.lighthouse.org/medical/how-the-eye-works/
Age-related macular degeneration (AMD) is a 
disease associated with aging that affects the 
central vision. 
Broadly speaking, there are 2 forms of AMD, “wet” 
and “dry”.
It is not yet fully understood as to what causes 
AMD
Risk factors for AMD
Aging
Family history
Genetics
Drusen (yellow deposits in the retina)
High fat intake
High blood pressure
High cholesterol
Obesity
Smoking
Exposure to sunlight
Nutrition
Studies at Aston University
Treatment
Dry AMD does not tend to affect vision as much as 
wet AMD.
There is currently no treatment for the dry form of 
AMD but it is thought that nutritional supplements 
may help slow progression of the condition.
There is treatment available within the NHS that is 
suitable for some people with wet AMD. The 
treatment involves a course of injections. There is 
also a form of laser light therapy available.
At Aston University the Ophthalmic Research 
Group are very interested at looking into the 
effects of nutritional supplementation on the 
early stages of AMD. 
We require volunteers of all ages who have no 
signs of the disease and those who have early 
signs of AMD to see whether lutein, omega-3 
and antioxidants may be beneficial to your eyes.
The tests take around an hour and a half and 
can be arranged at a time convenient to you.
If you are interested in taking part in this study 
please do not hesitate to contact Emma Berrow 
on 0121 204 4208 or berrowej@aston.ac.uk
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Appendix 6 - Participant consent form 
 
ASTON UNIVERSITY  REG/06/288(1) 
 
HUMAN SCIENCE ETHICAL COMMITTEE 
 
 
CONSENT FORM FOR VOLUNTEERS 
 
 
PROJECT TITLE 
 
Clinical trial of Ocuvite Duo ocular nutritional supplements for retinal 
health 
RESEARCH WORKERS, SCHOOL AND SUBJECT AREA 
RESPONSIBLE 
 
Mrs Emma Berrow, Life & Health Sciences, Vision Sciences 
Dr Hannah Bartlett, Life & Health Sciences, Vision Sciences  
 
EXPLANATION OF ANY POSSIBLE HAZARDS AND THE 
PROCEDURES TO BE USED 
 
We are assessing the effect of taking nutritional supplements on the 
health of the eye. We are doing this to try and determine whether 
taking these supplements is useful for people with and without age-
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related macular degeneration, as well as people with a family history 
of this condition.  
 
You will be randomly allocated to either take the supplement or not. 
The name of the supplement is Ocuvite Duo, and it is commonly 
available worldwide. You will also be asked to provide information 
about your diet, lifestyle, health, medications, and whether or not 
you currently take nutritional supplements. All of this information will 
be treated confidentially. 
 
You will be asked to attend the Aston University Optometry Clinic 
once every 20 weeks for a period of 80 weeks. This visit will take 
around 1 hour in total and during the visit various measurements will 
be taken. Most of the measurements are similar to those that you 
would undergo in a routine eye test with your optician. We will 
undertake measurements of your visual acuity, contrast sensitivity, 
eye pressure and take a photograph of the back of your eye. You 
will be able to take regular breaks between tests. 
 
Two of the tests are slightly different to what you might have 
experienced during an eye examination. One simply involves looking 
at a screen with your chin in a chin rest and pressing a button when 
you see blue lights flickering. This measurement will take around 
three minutes. 
 
The other test that differs from a standard eye examination, is one 
called the multi-focal electroretinogram. This test tells us about how 
well the tissues at the back of your eyes are functioning. This is test 
takes around 15 minutes. The whole visit will last about 1hour in 
total.  
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It will be necessary to put drops into your eyes to dilate the pupils 
(i.e. make your pupils larger; the drops are called tropicamide). It will 
also be necessary to put in drops to numb the front of your eye to 
help you stop blinking (i.e. a mild surface anaesthetic; the drops are 
called proxymetacaine).  
 
A small electrode is taped on the skin of the temple and another 
electrode is taped onto the forehead after both areas have been 
cleansed. A very fine fibre is then placed just inside your lower lid in 
order to take the measurements. You will then be asked to look into 
a bowl and look steadily at a central target while different patterns 
hexagon shapes alternate quickly from black to white.  We take our 
measurements while you are looking at these patterns for intervals 
of around 15 seconds – we will ask you not to blink during this time. 
We will repeat the sequence of measurements 12 times with short 
breaks at appropriate intervals. The whole procedure normally does 
not last longer than 15 minutes. If you suffer from dry eyes during 
the procedure we can use artificial tears to make you more 
comfortable. 
 
The tests are not diagnostic and do not constitute a full eye 
examination. However, we will inform you if we find any obvious 
abnormality, and will advise you about what type of healthcare 
professional you should consult to have any abnormality checked. 
You are perfectly free to ask any questions about any aspect of the 
study before deciding whether or not to take part. You are also free 
to withdraw from the study at any time, without giving a reason. 
 
Explanation of potential hazards 
Some individuals are sensitive to the type of flickering patterns that 
are presented in the study. It is important that you tell us whether 
you are sensitive in this way and very important that you tell us 
before the tests if you are epileptic or have had tests for epilepsy. 
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The drops that we are using are the same drops they use in 
hospitals and by optometrists to make your pupil larger. After 
receiving the drops there is a very slight risk of them causing 
pressure to build up in your eye. We will check that this does not 
happen by measuring the pressure before and after the 
measurements. However if the pressure does increase significantly 
we will ensure that you receive treatment at an eye department 
immediately.  
 
Due to the dilating drops instilled in your eyes you will find that your 
vision may be blurred for a period of up to 6 hours (especially for 
reading) and that you are more sensitive to bright light such as 
sunlight. Because of this it is necessary that you do not drive or 
operate heavy or moving machinery during this period. General care 
with your environment and bright sunlight especially (i.e. it may be 
necessary to wear sunglasses) is also advised. If after the 
examination you find that you are experiencing any pain or 
discomfort with your eyes please contact your local eye department 
or any of the individuals listed below. 
The eye drops used to numb your eyes can also produce in some 
individuals a reaction in the cornea that causes blurry vision. The 
reaction is very rare but if it is going to occur it will occur within 15 to 
30 minutes so we will be able to detect it. In this case we will not 
continue with the measurements and the condition of the cornea will 
be monitored until it has recovered – which usually takes around two 
hours. It is important not to rub your eyes for an hour after having 
the numbing drops as you may scratch you eye without feeling it. 
 
There is also a very slight risk of scratching the front of your eye 
when placing the cotton fibre in the lower lid. This risk however is 
minimal as the procedure is carried out carefully. Nevertheless the 
eyes of all individuals will be checked with an instrument following 
an eye drop that will show up any damage (called fluorescein). This 
is a standard procedure in everyday optometric practice.  
 
 
CONFIDENTIALITY OF INFORMATION 
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The confidentiality of personal information and the anonymity of all 
volunteers involved in this investigation will be preserved by storage 
of the data in a locked filing cabinet, and will be accessible only to the 
investigators. 
 
 
VOLUNTEER STATEMENT 
 
I have read and understand the above explanation. I have had the 
opportunity to discuss it with the investigators and to ask any 
questions. I agree to take part in the above project and I have been 
informed that I am free to withdraw at any time. I understand that I 
will not benefit financially from taking part in the research or from its 
outcomes. I agree that any invention or other intellectual property 
that arises from the research will belong to Aston University. I agree 
to the information being used for research purposes, some of which 
may be included in scientific materials for publication.  
 
 
Signed: ................................................................................. 
 
 
Name (block capitals): .......................................................... 
 
 
Date: .................................................................................... 
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Appendix 7 
 
 
Health questionnaire 
 
 
Please answer the following questions in             
block capitals 
 
 
1. Name_________________ 
 
    
2. Male/Female ___________ 
 
 
3. Date of Birth ___________ 
 
 
4. Please list any general health problems you 
have (e.g. blood pressure or diabetes) 
______________________________________
______________________________________
______________________________________
______________________________________
_________________________________ 
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5. Do you take any tablets or medicines?  If so, 
please list the names below 
______________________________________
______________________________________
______________________________________
______________________________________
_________________________________ 
 
 
6. Do you take any nutritional supplements (e.g. 
vitamins)?  If so, please list the name or brand 
below 
______________________________________
______________________________________
___________________________________ 
 
 
7. Do you smoke? ________________________ 
 
 
8. If so, how many cigarettes per day__________ 
 
 
9. If you don’t smoke at the moment but you have 
done previously, please give details 
below__________________________________
______________________________________
___________________________________ 
216 
 
10. Please give information about any previous 
visits to an eye clinic or eye specialist 
______________________________________
______________________________________
______________________________________
__________________________________ 
 
 
11. If you know the name of your eye condition, 
please give details below 
______________________________________
____________________________________ 
 
 
12. How does your eye condition affect your 
vision? 
___________________________________________________________________________
_________________________________________________________________________ 
 
 
 
13. Have you always lived in the UK? ______     
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14. If you have lived abroad for more than a year 
please give details of where, when and for how 
long 
________________________________________
________________________________________
________________________________________
____________________________________ 
 
 
Contact address: 
________________________________________
________________________________________
________________________________________
________________________________________
___________________________________ 
 
 
   Telephone number: 
   _______________________________________ 
 
 
Thank you for your time. 
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Appendix 8 – Ethics approval letter 
Response from the LHS School Ethics Committee 
11
th
 July 2008 
 
Project title: Assessment of nutritional intervention on the electrophysiology of the retina 
Reference Number: 300608/PF1 
Researchers: Dr Bartlett, Dr Eperjesi and Dr Wolffsohn 
 
 
I am pleased to inform you that the School LHS Ethics Committee has approved the 
above named project.  
 
 
The details of the investigation will be placed on file.  You should notify The Committee of any 
difficulties experienced by the volunteer subjects, and any significant changes which may be 
planned for this project in the future.  
 
 
Yours sincerely 
 
 
 
School LHS Ethics Committee  
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Appendix 9 – Food diary 
OCULAR HEALTH AND LIFESTYLE 
As part of our research portfolio here at Aston, we are interested in 
investigating the effect of diet and lifestyle on ocular factors. Please 
take the time to complete the following food diary and ocular comfort 
questionnaire to help us with our studies. We are particularly 
interested in macular pigment, which is made up of carotenoids that 
are only available in the food we eat. We believe that the macular 
pigment may protect against sight-threatening age-related eye 
disease, and are currently testing a new method of measurement. 
We would really appreciate your participation in this project, and will 
arrange a convenient time for you to attend. 
The food diary will help us to assess the relationships between 
macular pigment and dietary intake. Please fill out this sheet and 
bring it with you to your appointment. 
 
Thanks again for your time  
 
DATE_________________________ 
 
TIME_________________________ 
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Instructions on how to fill in your food diary 
 
Please fill out this food diary for three days. Every time you eat or drink 
something write it down in the diary provided under the correct day.  
 
Try and describe the food as accurately as possible: 
For example:  
One small or large bowl of cornflakes with skimmed milk 
Two slices of toast thinly or thickly spread with butter 
Wholemeal, white or brown bread 
Skimmed or semi-skimmed milk 
Large, medium or small banana 
 
Try to give rough estimates of the food and drink consumed: 
For example: 
One small cup of tea or one large cup of coffee 
Two or three chocolate biscuits 
Two or three tablespoons of baked beans 
Try to be as accurate as possible (it would be great if you could include 
weights!). 
 
Remember to include all foods and drinks consumed at home and at other 
places such as restaurants and friend’s houses etc. 
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Try to fill in the diary as you eat, instead of leaving it till the end of the day.  This 
ensures that you won’t forget what you have eaten. 
 
THANK YOU FOR YOUR TIME 
 
 
NAME____________________________________ 
 
 
Day 1 (weekday) 
Breakfast: Supper: 
Lunch: Snacks: 
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Day 2 (weekday) 
Breakfast: Supper: 
Lunch: Snacks: 
Day 3  (weekend day) 
Breakfast: Supper: 
Lunch: Snacks: 
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Appendix 11 - Supplementation results tables 
 
Table 6.2: Mixed between-within ANOVA for mfERG N1P1 amplitude, N1 latency, P1 latency 
and N2 latency over 3 visits for 5 areas of retinal eccentricity between treated and non-treated 
groups for HO eyes. The shaded area indicates statistical significance. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
Ring 1 N1-P1 amplitude 1.287 0.315 0.454 0.513 0.352 0.711 
Ring 2 N1-P1 amplitude 2.081 0.171 0.098 0.759 0.367 0.701 
Ring 3 N1-P1 amplitude 1.277 0.317 0.001 0.976 1.260 0.322 
Ring 4 N1-P1 amplitude 0.410 0.673 0.081 0.781 1.225 0.331 
Ring 5 N1-P1 amplitude 0.297 0.749 1.315 0.274 0.664 0.534 
Ring 1 N1 latency 0.864 0.448 0.904 0.361 0.345 0.716 
Ring 2 N1 latency 1.249 0.324 1.603 0.230 0.935 0.422 
Ring 3 N1 latency 1.384 0.291 2.565 0.135 0.571 0.581 
Ring 4 N1 latency 0.406 0.676 2.919 0.113 0.168 0.848 
Ring 5 N1 latency 0.873 0.445 2.251 0.159 0.546 0.594 
Ring 1 P1 latency 5.928 0.018 0.517 0.486 0.016 0.984 
Ring 2 P1 latency 3.077 0.087 0.709 0.416 3.060 0.088 
Ring 3 P1 latency 0.178 0.840 3.978 0.069 0.106 0.901 
Ring 4 P1 latency 0.079 0.924 1.389 0.261 0.242 0.789 
Ring 5 P1 latency 0.323 0.731 0.371 0.554 3.300 0.075 
Ring 1 N2 latency 1.030 0.389 0.509 0.489 0.416 0.670 
Ring 2 N2 latency 1.567 0.252 1.331 0.271 0.035 0.966 
Ring 3 N2 latency 0.831 0.461 2.790 0.121 1.437 0.279 
Ring 4 N2 latency 0.947 0.417 0.194 0.667 1.556 0.254 
Ring 5 N2latency 0.278 0.762 1.617 0.228 1.497 0.266 
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Table 6.3: Mean values ± SD for mfERG measures for 5 rings (R) of eccentricity for HO treated 
and non-treated groups over 3 visits. The shaded areas indicate statistical significance. 
  Visit 1 HO Visit 2 HO Visit 3 HO 
  Mean ± SD Mean ± SD Mean ± SD 
R1 N1 latency  Treated  15.36 ± 1.43 15.95 ± 1.12 15.83 ± 1.27 
(ms) Non-treated  15.28 ± 2.56 15.60 ± 1.15 14.88 ± 0.89 
R1 P1 latency Treated  29.29 ± 1.48 30.24 ± 1.15 30.12 ± 1.22 
(ms) Non-treated  29.64 ± 1.43 30.71 ± 0.89 30.48 ± 1.16 
R1 N2 latency Treated  44.88 ± 1.89 44.29 ± 1.89 45.36 ± 1.35 
(ms) Non-treated  44.40 ± 2.13 44.05 ± 2.43 44.28 ± 1.22 
R1 N1P1 amplitude Treated  154.25 ± 27.39 149.86 ± 46.47 144.86 ± 32.40 
(nV/deg
2
) Non-treated  153.64 ± 46.53 130.29 ± 39.32 132.71 ± 29.63 
R2 N1 latency Treated  15.95 ± 0.89 15.48 ± 1.06 15.24 ± 1.05 
(ms) Non-treated  15.00 ± 0.68 15.24 ± 1.24 14.88 ± 0.89 
R2 P1 latency Treated  29.29 ± 1.62 29.29 ± 1.63 29.29 ± 1.63 
(ms) Non-treated  28.45 ± 1.22 29.40 ± 0.79 28.33 ± 1.18 
R2 N2 latency  Treated  43.33 ± 1.86 44.17 ± 1.36 44.29 ± 1.55 
(ms) Non-treated  42.74 ± 1.78 43.45 ± 1.12 43.45 ± 1.31 
R2 N1P1 amplitude Treated  63.13 ± 16.10 59.43 ± 14.39 58.71 ± 12.66 
(nV/deg
2
) Non-treated  64.79 ± 16.42 55.29 ± 17.49 55.14 ± 13.12 
R3 N1 latency Treated  15.24 ± 0.79 15.71 ± 0.75 15.83 ± 0.68 
(ms) Non-treated  15.00 ± 0.48 15.12 ± 1.12 15.12 ± 0.57 
R3 P1 latency Treated  29.76 ± 0.93 29.65 ± 0.94 29.52 ± 1.58 
(ms) Non-treated  28.57 ± 1.15 28.69 ± 1.72 28.33 ± 1.28 
R3 N2 latency  Treated  43.10 ± 1.04 43.21 ± 1.22 43.69 ± 1.26 
(ms) Non-treated  42.14 ± 0.66 42.86 ± 1.79 42.38 ± 0.89 
R3 N1P1 amplitude Treated  34.60 ± 9.17  34.86 ± 9.15 33.57 ± 7.55 
(nV/deg
2
) Non-treated  37.96 ± 10.13 32.00 ± 9.76 33.43 ± 8.54 
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Table 6.3 continued: 
 
  Visit 1 HO Visit 2 HO Visit 3 HO 
  Mean ± SD Mean ± SD Mean ± SD 
R4 N1 latency  Treated  15.48 ± 0.81 15.71 ± 0.89 15.83 ± 0.68 
(ms) Non-treated  15.00 ± 0.48 15.24 ± 1.15 15.12 ± 0.89 
R4 P1 latency Treated  29.76 ± 0.79 29.64 ± 1.51 29.76 ± 0.93 
(ms) Non-treated  28.93 ± 1.50 29.40 ± 1.33 29.05 ± 1.01 
R4 N2 latency Treated  43.09 ± 1.34  41.31 ± 5.46 43.81 ± 1.06 
(ms) Non-treated  42.86 ± 1.06 43.57 ± 1.42 42.86 ± 0.66 
R4 N1P1 amplitude Treated  22.35 ± 6.83 23.29 ± 5.43 23.71 ± 6.13 
(nV/deg
2
) Non-treated  23.63 ± 6.01 20.71 ± 5.53 22.57 ± 7.76  
R5 N1 latency Treated  15.71 ± 0.75 15.83 ± 0.96 15.71 ± 0.75 
(ms) Non-treated  14.88 ± 0.57 15.60 ± 1.15 15.24 ± 0.93 
R5 P1 latency Treated  29.76 ± 0.79 29.64 ± 1.58 30.11 ± 0.89 
(ms) Non-treated  30.36 ± 0.81 30.48 ± 1.66 29.64 ± 1.06 
R5 N2 latency Treated  43.57 ± 1.15 43.33  ± 1.08 43.57 ± 0.93 
(ms) Non-treated  42.74 ± 1.05 43.45 ± 0.89 42.86 ± 0.44 
R5 N1P1 amplitude Treated  15.28 ± 6.36 17.00 ± 3.42 14.29 ± 4.96 
(nV/deg
2
) Non-treated  14.26 ± 3.90 13.00 ± 4.32 13.14 ± 5.01 
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Table 6.4: Mixed between-within ANOVA for VA, CS and MPOD over 3 visits between treated 
and non treated groups in HO eyes. The shaded area indicates statistical significance. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
VA  1.352 0.282  0.236  0.632 1.429 0.264 
 CS  1.877 0.180  0.367 0.551 0.192 0.827 
 MPOD  2.254 0.132  1.509 0.234 5.176 0.016 
 
 
Table 6.5: Mean values ± SD between treated and non-treated HO eyes for VA, CS and MPOD 
over 3 visits. The shaded areas indicate statistical significance. 
 Visit 1 HO Visit 2 HO Visit 3 HO 
 Mean ± SD Mean ± SD Mean ± SD 
                                                   VA (logMAR units) 
Treated   -0.05 ± 0.07 -0.05 ± 0.06 -0.05 ± 0.08 
Non-treated   -0.11 ± 0.17 -0.03 ± 0.06 -0.06 ± 0.09 
                                                   CS (log units) 
Treated   1.79 ± 0.16 1.81 ± 0.16 1.81 ± 0.16 
Non-treated   1.81 ± 0.16 1.84 ± 0.15 1.87 ± 0.14 
                                                MPOD (optical density units) 
Treated   0.32 ± 0.19 0.36 ± 0.15 0.42 ± 0.12 
Non-treated   0.46 ± 0.17 0.45 ± 0.18 0.44 ± 0.17 
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Table 6.6: HO treated group dietary questionnaire analysis showing no difference between visits 
1 and 3 using paired-samples t-tests. 
Dietary component t p 
Copper 1.070 0.363 
Zinc -0.867 0.450 
Vitamin E -0.494 0.655 
Vitamin C 1.154 0.332 
Retinol 1.017 0.384 
Carotene 1.771 0.175 
Lutein and zeaxanthin -0.316 0.773 
Omega 3  -1.189 0.320 
 
 
Table 6.7: HO non-treated group dietary questionnaire analysis showing no difference between 
visits 1 and 3 using paired samples t-tests. 
Dietary component t p 
Copper 0.297 0.776 
Zinc -0.320 0.760 
Vitamin E -0.159 0.879 
Vitamin C -0.217 0.835 
Retinol -0.683 0.520 
Carotene 0.163 0.876 
Lutein and zeaxanthin 0.854 0.426 
Omega 3  0.263 0.801 
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Table 6.9: Mixed between-within ANOVA for mfERG N1P1 amplitude, N1 latency, P1 latency 
and N2 latency over 3 visits for 5 areas of retinal eccentricity between treated and non-treated 
groups for HY eyes. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
Ring 1 N1-P1 amplitude 0.522  0.612  0.048  0.831  1.250  0.337 
Ring 2 N1-P1 amplitude  1.279  0.330  0.369  0.558  0.774  0.493 
Ring 3 N1-P1 amplitude  1.415  0.298  0.000  0.993  0.093  0.912 
Ring 4 N1-P1 amplitude  0.723  0.514  0.022  0.884  0.137  0.874 
Ring 5 N1-P1 amplitude  0.835  0.468  0.072  0.794  0.652  0.547 
Ring 1 N1 latency 1.533 0.273 3.268 0.104 2.401 0.153 
Ring 2 N1 latency 0.325 0.732 1.427 0.263 0.609 0.567 
Ring 3 N1 latency 0.190 0.830 0.591 0.462 0.316 0.737 
Ring 4 N1 latency 0.251 0.784 2.435 0.153 0.005 0.995 
Ring 5 N1latency 1.462 0.288 1.767 0.216 0.522 0.612 
Ring 1 P1 latency  0.229  0.800 0.347  0.570 1.498 0.280 
Ring 2 P1 latency  0.949 0.427 0.840 0.383 3.053 0.103 
Ring 3 P1 latency 1.643 0.253 0.019 0.894 0.145 0.868 
Ring 4 P1 latency 1.461 0.288 0.529 0.486 0.632 0.556 
Ring 5 P1 latency 1.265 0.333 0.056 0.819 1.635 0.254 
Ring 1 N2 latency 2.616 0.134  1.753 0.218 0.293 0.754 
Ring 2 N2 latency 1.673 0.247 1.300 0.284 0.115 0.893 
Ring 3 N2 latency 2.079 0.187 0.835  0.385 0.141 0.871 
Ring 4 N2 latency 2.508 0.143 1.404 0.266 1.998 0.198 
Ring 5 N2 latency 3.295 0.090 0.314 0.589 0.836 0.468 
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Table 6.10: Mean values ± SD for mfERG measures for 5 rings (R) of eccentricity for HY 
treated and non-treated groups over 3 visits. 
  Visit 1 HY Visit 2 HY Visit 3 HY 
  Mean ± SD Mean ± SD Mean ± SD 
R1 N1 latency Treated  15.00 ± 0.77 15.10 ± 0.53 15.10 ± 0.69 
(ms) Non-treated  15.28 ± 0.48 14.44 ± 0.96 13.87 ± 0.96 
R1 P1 latency Treated   28.85 ± 1.47 28.75 ± 1.72 28.33 ± 1.00 
(ms) Non-treated  28.61 ± 1.73  29.17 ± 3.00 29.72 ± 0.48 
R1 N2 latency Treated  42.50 ± 1.72 42.92 ± 1.72 44.17 ± 1.09 
(ms) Non-treated   43.06 ± 1.27 44.72 ± 3.76  45.00 ± 1.67 
R1N1P1 amplitude Treated   178.81 ± 40.62  168.75 ± 50.51 171.38 ± 31.14 
(nV/deg
2
) Non-treated  154.58 ± 55.70  187.00 ± 43.86 194.00 ± 60.80 
R2 N1 latency Treated  15.10 ± 1.13  14.79 ± 0.59 15.31 ± 0.99 
(ms) Non-treated  14.72 ± 0.48 14.17 ± 2.21  14.44 ± 1.27 
R2 P1 latency Treated   27.92 ± 1.00 27.81 ± 0.99 26.67 ± 0.89 
(ms) Non-treated   27.78 ± 1.92  28.33 ± 2.20 28.33 ± 1.67 
R2 N2 latency Treated  41.46 ± 1.39  42.08 ± 1.72 42.40 ± 1.22 
(ms) Non-treated  42.22 ± 1.92 43.33 ± 1.67 43.33 ± 1.67 
R2 N1P1 amplitude Treated  74.05 ± 20.37   64.13 ± 17.87 70.13 ± 10.09 
(nV/deg
2
) Non-treated  71.35 ± 21.55  75.67 ± 23.76 81.67 ± 30.27 
R3 N1 latency Treated  14.90 ± 1.13 14.90 ± 0.53 15.00 ± 0.77 
(ms) Non-treated  15.56 ± 0.96  15.00 ± 0.00 15.00 ± 0.00 
R3 P1 latency Treated   27.40 ± 1.57 28.23 ± 1.13 27.92 ± 1.41 
(ms) Non-treated  27.50 ± 2.50  28.61 ± 0.96 27.78 ± 2.10 
R3 N2 latency Treated  41.04 ± 0.86  41.67 ± 1.48 41.98 ± 1.17 
(ms) Non-treated  41.94 ± 1.73  42.22 ± 1.74 42.50 ± 1.67 
R3 N1P1 amplitude Treated  42.10 ± 14.33 35.75 ± 7.27 40.13 ± 5.79 
(nV/deg
2
) Non-treated   39.48 ± 12.36 37.33 ± 14.74 41.00 ± 16.37 
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Table 6.10 continued. 
 
  Visit 1 HY Visit 2 HY Visit 3 HY 
  Mean ± SD Mean ± SD Mean ± SD 
R4 N1 latency Treated   14.69 ± 0.76 14.90 ± 0.53 14.90 ± 0.82 
(ms) Non-treated   15.28 ± 0.96 15.56 ± 0.96 15.56 ± 1.27 
R4 P1 latency Treated   28.13 ± 0.86  28.75 ± 0.89 28.13 ± 1.07 
(ms) Non-treated   29.16 ± 1.44 28.89 ± 1.27 28.33 ± 2.20 
R4 N2 latency Treated   41.67 ± 0.77 41.98 ± 1.25 41.88 ± 0.86 
(ms) Non-treated   41.67 ± 0.84 42.50 ± 0.83  43.06 ± 0.96 
R4 N1P1 amplitude Treated  27.77 ± 9.42  23.63 ± 4.87 25.75 ± 3.49 
(nV/deg
2
) Non-treated  26.46 ± 7.40  24.67 ± 10.02 27.67 ± 11.59 
R5 N1 latency Treated  14.69 ± 0.99 14.48 ± 0.43 14.69 ± 0.88 
(ms) Non-treated  15.28 ± 0.96  14.72 ± 0.48 15.56 ± 1.27 
R5 P1 latency Treated  28.54 ± 0.97  29.27 ± 0.70 28.44 ± 1.04 
(ms) Non-treated  29.16 ± 1.44 28.89 ± 0.96 28.61 ± 2.09 
R5 N2 latency Treated  41.77 ± 1.13 42.19 ± 0.43 42.29 ± 1.07 
(ms) Non-treated   41.94 ± 1.27 42.22 ± 1.27 43.06 ± 0.96 
R5 N1P1 amplitude Treated  17.01 ± 5.79 15.38 ± 2.62 16.50 ± 3.34 
(nV/deg
2
) Non-treated  13.54 ± 3.44  16.00 ± 4.36 17.67 ± 6.51 
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Table 6.11: Mixed between-within ANOVA for VA, CS and MPOD over 3 visits between 
treated and non treated groups in HY eyes. The shaded areas indicate statistical significance. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
VA 8.037 0.002 0.050 0.825  0.006 0.994 
 CS 2.010 0.167 0.009 0.925 0.009 0.925 
 MPOD 2.726 0.84 0.990 0.329 11.476 <0.001 
 
 
Table 6.12: Mean values ± SD between treated and non-treated HY eyes for VA, CS and MPOD 
over 3 visits. The shaded areas indicate statistical significance. 
 Visit 1 HY Visit 2 HY Visit 3 HY 
 Mean ± SD Mean ± SD Mean ± SD 
                                                   VA (logMAR units) 
Treated  -0.12 ± 0.08  -0.08 ± 0.09 -0.13 ± 0.08 
Non-treated  -0.13 ± 0.08  -0.09 ± 0.08 -0.13 ± 0.08 
                                                   CS (log units) 
Treated   1.95 ± 0.00 1.93 ± 0.08 1.95 ± 0.00 
Non-treated   1.95 ± 0.00 1.93 ± 0.08 1.95 ± 0.00 
                                                MPOD (optical density units) 
Treated  0.38 ± 0.12  0.43 ± 0.12  0.48 ± 0.12 
Non-treated   0.39 ± 0.16 0.40 ± 0.14 0.36 ± 0.15 
 
 
 
 
 
237 
 
Table 6.13: Dietary questionnaire analysis between visits 1 and 3 for the treated group of HY 
eyes using paired-samples t-tests. The shaded area indicates statistical significance. 
Dietary component t p 
Copper 0.935 0.419 
Zinc -0.488 0.659 
Vitamin E -0.745 0.510 
Vitamin C 0.125 0.909 
Retinol 0.245 0.823 
Carotene -5.706 0.011 
Lutein and zeaxanthin 0.640 0.568 
Omega 3  0.225 0.836 
 
 
Table 6.14: Dietary questionnaire analysis between visits 1 and 3 for the non-treated group of 
HY eyes using paired-samples t-tests. The shaded area indicates statistical significance. 
Dietary component t p 
Copper 0.916 0.456 
Zinc -0.516 0.657 
Vitamin E -1.033 0.410 
Vitamin C -0.032 0.977 
Retinol -4.919 0.039 
Carotene 0.626 0.595 
Lutein and zeaxanthin 0.516 0.657 
Omega 3  -0.173 0.878 
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Table 6.16: Mixed between-within ANOVA for mfERG N1P1 amplitude, N1 latency, P1 
latency and N2 latency over 3 visits for 5 areas of retinal eccentricity between treated and non-
treated groups for combined HY and HO eyes. The shaded areas indicate statistical significance. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
Ring 1 N1-P1 
amplitude 
0.311 0.736 0.617  0.440 0.067 0.935 
Ring 2 N1-P1 
amplitude 
1.642 0.216 0.058 0.812 0.034 0.966 
Ring 3 N1-P1 
amplitude 
1.659 0.213 0.112  0.741 0.063 0.939 
Ring 4 N1-P1 
amplitude 
1.408 0.266 0.212  0.650 0.068 0.934 
Ring 5 N1-P1 
amplitude 
0.007 0.993 1.894 0.182 0.193 0.826 
Ring 1 N1 latency 1.203 0.319 1.072 0.311 0.957 0.400 
Ring 2 N1 latency 0.579 0.569 1.868 0.185 0.253 0.778 
Ring 3 N1latency 0.196 0.823 0.280 0.602 0.513 0.606 
Ring 4 N1 latency 0.695 0.510 <0.001 0.998 0.101 0.905 
Ring 5 N1 latency 0.481 0.624 0.057 0.813 0.543 0.588 
Ring 1 P1 latency 3.172 0.062 1.973 0.174 1.294 0.294 
Ring 2 P1 latency 5.067 0.015 0.188 0.668 3.694 0.041 
Ring 3 P1 latency 1.401 0.268 0.365 0.552 0.118 0.889 
Ring 4 P1 latency 1.046 0.368 0.011 0.917 0.081 0.923 
Ring 5 P1 latency 1.495 0.246 1.430 0.244 1.319 0.288 
Ring 1 N2 latency 2.761 0.085 0.216 0.646 0.869 0.433 
Ring 2 N2 latency 3.622 0.044 0.191 0.666 0.095 0.910 
Ring 3 N2 latency 3.053 0.068 <0.001 0.999 1.042 0.369 
Ring 4 N2 latency 1.700 0.206 1.517 0.230 0.607 0.554 
Ring 5 N2latency 1.490 0.247 0.057 0.814 0.509 0.608 
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Table 6.17: Mean values ± SD for mfERG measures for 5 rings (R) of eccentricity for combined 
HO and HY treated and non-treated groups over 3 visits. The shaded areas indicate statistical 
significance. 
  Visit 1 HO & HY  Visit 2 HO & 
HY 
Visit 3 HO & 
HY 
  Mean ± SD Mean ± SD Mean ± SD 
R1 N1 latency Treated  15.17 ± 1.10  15.50 ± 0.93 15.44 ± 1.04 
(ms) Non-treated  15.28 ± 2.10  15.25 ± 1.18 14.58 ± 0.98 
R1 P1 latency Treated  29.05 ± 1.44 29.44 ± 1.63 29.17 ± 1.41 
(ms) Non-treated  29.33 ± 1.51 30.25 ± 1.76 30.25 ± 1.04 
R1 N2 latency Treated  43.61 ± 2.13 43.56 ± 1.88 44.72 ± 1.32 
(ms) Non-treated  44.00 ± 1.95  44.25 ± 2.68 44.50 ± 1.32 
R1 N1P1 amplitude Treated   167.35 ± 36.15 159.93 ± 47.92 159.00 ± 33.50 
(nV/deg
2
) Non-treated   153.93 ± 46.18 147.30 ± 47.00 151.10 ± 47.78 
R2 N1 latency Treated  15.50 ± 1.08 15.11 ± 0.88 15.28 ± 0.98 
(ms) Non-treated  14.92 ± 0.61 14.92 ± 1.55 14.75 ± 0.97 
R2 P1 latency Treated   28.56 ± 1.46 28.50 ± 1.48 27.89 ± 1.83 
(ms) Non-treated   28.25 ± 1.38 29.08 ± 1.33 28.33 ±1.24 
R2 N2 latency Treated  42.33 ± 1.84  43.06 ± 1.85 43.28 ± 1.65 
(ms) Non-treated  42.58 ± 1.73  43.42 ± 1.21 43.42 ± 1.33 
R2 N1P1 amplitude Treated   68.95 ± 18.72 61.93 ± 15.94 64.80 ± 12.42 
(nV/deg
2
) Non-treated  66.76 ± 17.12  61.40 ± 20.65 63.10 ± 21.97 
R3 N1 latency Treated  15.05 ± 0.97  15.28 ± 0.75  15.39 ± 0.82 
(ms) Non-treated  15.17 ± 0.66  15.09 ± 0.92 15.08 ± 0.47 
R3 P1 latency Treated  28.50 ± 1.76  28.89 ± 1.25  28.67 ± 1.66 
(ms) Non-treated  28.25 ± 1.59 28.67 ± 1.48 28.15 ± 1.46 
R3 N2 latency Treated  42.00 ± 1.40  42.39 ± 1.54 42.78 ± 1.47 
(ms) Non-treated  42.08 ± 0.98  42.67 ± 1.70 42.42 ± 1.07 
R3 N1P1 amplitude Treated  38.60 ± 12.40 35.33 ± 7.91 37.07 ± 7.26 
(nV/deg
2
) Non-treated  38.41 ± 10.14  33.60 ± 10.89 35.70 ± 11.03 
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Table 6.17 continued. 
 
 
  Visit 1 HO & HY  Visit 2 HO & 
HY 
Visit 3 HO & 
HY 
  Mean ± SD Mean ± SD Mean ± SD 
R4 N1 latency Treated  15.06 ± 0.86 15.28 ± 0.81 15.33 ± 0.88 
(ms) Non-treated  15.208± 0.61  15.34 ± 1.05 15.25 ± 0.97 
R4 P1 latency Treated  28.89 ± 1.16  29.17 ± 1.26 28.89 ± 1.29 
(ms) Non-treated  29.00 ± 1.41  29.25 ± 1.27 28.83 ± 1.37 
R4 N2 latency Treated  42.33 ± 1.27  41.67 ± 3.70 42.78 ± 1.36 
(ms) Non-treated  42.50 ± 1.11  43.25 ± 1.33 42.92 ± 0.71 
R4 N1P1 amplitude Treated  25.24 ± 8.50   23.47 ± 4.96 24.80 ± 4.83 
(nV/deg
2
) Non-treated  24.48 ± 6.17  21.90 ± 6.81 24.10 ± 8.72 
R5 N1 latency Treated  15.17 ± 1.01  15.11 ± 0.99  15.17 ± 0.96  
(ms) Non-treated  15.00 ± 0.68  15.33 ± 1.05 15.33 ± 0.98 
R5 P1 latency Treated  29.11 ± 1.07  29.45 ± 1.16 29.22 ± 1.28 
(ms) Non-treated  30.00 ± 1.11  30.00 ± 1.62 29.33 ± 1.40 
R5 N2 latency Treated  42.61 ± 1.44  42.72 ± 0.97 42.89 ±1.17 
(ms) Non-treated  42.50 ±1.11 43.08 ± 1.12 42.92 ± 0.59 
R5 N1P1 amplitude Treated  16.20 ± 5.91  16.13 ± 3.02 15.47 ± 4.17 
(nV/deg
2
) Non-treated  14.05 ± 3.59  13.90 ± 4.33 14.50 ± 5.56 
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Table 6.18: Mixed between-within ANOVA for VA, CS and MPOD over 3 visits between 
treated and non treated groups in HY and HO eyes. The shaded areas indicate statistical 
significance. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
VA 0.852 0.440 0.287 0.594 0.002 0.998 
 CS 1.615 0.209 0.425 0.517 0.144 0.866 
 MPOD 4.235 0.020 0.040 0.842 16.998 <0.001 
 
 
Table 6.19: Mean values ± SD between treated and non-treated combined HO and HY eyes for 
VA, CS and MPOD over 3 visits. The shaded areas indicate statistical significance. 
 Visit 1 HO & 
HY 
Visit 2 HO & 
HY 
Visit 3 HO & 
HY 
 Mean ± SD Mean ± SD Mean ± SD 
                                                   VA (logMAR units)  
Treated  -0.09 ± 0.09 -0.07 ± 0.08 -0.10 ± 0.09 
Non-treated  -0.12 ± 0.12  -0.06 ± 0.08 -0.10 ± 0.09 
                                                   CS (log units) 
Treated  1.88 ± 0.13  1.88 ± 0.13 1.89 ± 0.12 
Non-treated  1.89 ± 0.12  1.89 ± 0.12 1.92 ± 0.10 
                                                MPOD (optical density units) 
Treated  0.35 ± 0.16  0.40 ± 0.14 0.45 ±0.12 
Non-treated  0.42 ± 0.16  0.42 ± 0.16 0.39 ± 0.16 
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Table 6.20: Dietary questionnaire analysis between visits 1 and 3 for the treated group of HY 
and HO eyes using paired-samples t-tests. 
Dietary component t p 
Copper 1.702 0.133 
Zinc 0.221 0.831 
Vitamin E -0.011 0.992 
Vitamin C 1.137 0.293 
Retinol 1.107 0.305 
Carotene 1.058 0.325 
Lutein and zeaxanthin -0.155 0.881 
Omega 3  -0.543 0.604 
 
 
Table 6.21: Dietary questionnaire analysis between visits 1 and 3 for the non-treated group of 
HY and HO eyes using paired-samples t-tests. 
Dietary component t p 
Copper 0.519 0.617 
Zinc -0.841 0.422 
Vitamin E 0.053 0.959 
Vitamin C -0.265 0.797 
Retinol -1.113 0.295 
Carotene -0.191 0.853 
Lutein and zeaxanthin 0.102 0.921 
Omega 3  0.867 0.408 
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Table 6.23: Mixed between-within ANOVA for mfERG N1P1 amplitude, N1 latency, P1 
latency and N2 latency over three visits for five areas of retinal eccentricity between treated and 
non-treated groups for ARM eyes. The shaded areas indicate statistical significance. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
Ring 1 N1-P1 amplitude 3.470 0.134 0.666 0.452 0.432 0.677 
Ring 2 N1-P1 amplitude 3.188 0.149 0.774  0.419 1.778 0.280 
Ring 3 N1-P1 amplitude 11.963 0.021 0.599 0.474 1.768 0.282 
Ring 4 N1-P1 amplitude 13.957 0.016 1.273 0.310 4.785 0.087 
Ring 5 N1-P1 amplitude 1.363 0.354 0.378 0.566 0.871 0.303 
Ring 1 N1 latency 0.616 0.585 2.133 0.204 0.241 0.796 
Ring 2 N1 latency 0.441 0.671 0.019 0.896 0.116 0.894 
Ring 3 N1 latency 2.341 0.212 < 0.001 0.999 2.613 0.188 
Ring 4 N1 latency 0.420 0.683 0.732 0.431 0.080 0.924 
Ring 5 N1latency 1.548 0.318 0.627 0.464 0.032 0.969 
Ring 1 P1 latency 0.549 0.616 2.092 0.208 0.061 0.941 
Ring 2 P1 latency 0.317 0.745 0.099 0.766 1.333 0.360 
Ring 3 P1 latency 1.365 0.353  0.031  0.867 0.036 0.965 
Ring 4 P1 latency 0.922 0.469 0.086 0.781 0.768 0.522 
Ring 5 P1 latency 3.422 0.136 0.402 0.554 2.475 0.200 
Ring 1 N2 latency 0.245 0.794 3.018 0.143 0.135 0.878 
Ring 2 N2 latency 0.951 0.459 1.530 0.271 0.403 0.693 
Ring 3 N2 latency 0.990 0.447 0.052 0.828 1.000 0.444 
Ring 4 N2 latency 0.586 0.598 0.181 0.688 0.023 0.977 
Ring 5 N2latency 0.075 0.929 0.021 0.891 0.078 0.926 
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Table 6.24: Mean values ± SD for mfERG measures for 5 rings (R) of eccentricity for ARM 
treated and non-treated groups over 3 visits. The shaded areas indicate statistical significance. 
  Visit 1 ARM Visit 2 ARM Visit 3 ARM 
  Mean ± SD Mean ± SD Mean ± SD 
R1 N1 latency Treated   16.46 ± 1.42 15.42 ± 1.08 15.63 ± 0.80 
(ms) Non-treated  15.28 ± 1.74 15.00 ± 0.00 15.00 ± 2.21 
R1 P1 latency Treated  30.56 ± 1.47 31.11 ± 0.96 31.25 ± 1.99 
(ms) Non-treated  28.61 ± 2.09 29.72 ± 2.68 30.00 ± 1.67 
R1 N2 latency Treated  44.38 ± 1.05 45.00 ± 2.63 45.21 ± 1.25 
(ms) Non-treated  43.61 ± 2.41 43.33 ± 0.00 44.72 ± 2.68 
R1N1P1 amplitude Treated  115.52 ± 34.92  97.75 ± 16.13 125.75 ± 40.34 
(nV/deg
2
) Non-treated  111.19 ± 19.27 83.67 ± 24.79 100.00 ± 11.36 
R2 N1 latency Treated  15.21 ± 1.43 15.00 ± 0.68 15.42 ± 1.74 
(ms) Non-treated  15.00 ± 0.83 15.00 ± 0.00 15.83 ± 0.84 
R2 P1 latency Treated  28.96 ± 1.58 29.59 ± 0.83 28.75 ± 1.73 
(ms) Non-treated  29.44 ± 2.40 27.78 ± 0.48 29.17 ± 1.44 
R2 N2 latency Treated  43.96 ± 0.80 43.54 ± 1.05 44.59 ± 0.48 
(ms) Non-treated  43.06 ± 1.93 43.33 ± 0.00 43.61 ± 1.27 
R2 N1P1 amplitude Treated  47.52 ± 9.47 46.50 ± 9.15 53.00 ± 13.17 
(nV/deg
2
) Non-treated  50.08 ± 3.52 35.67 ± 1.53 47.00 ± 5.20 
R3 N1 latency Treated  15.21 ± 0.79 15.21 ± 0.42 15.42 ± 1.44 
(ms) Non-treated  16.39 ± 0.48 15.28 ± 0.48 14.16 ± 1.44 
R3 P1 latency Treated  28.13 ± 1.05 28.96 ± 1.05 28.96 ± 1.25 
(ms) Non-treated  28.34 ± 1.44 29.17 ± 0.84 28.89 ± 1.27 
R3 N2 latency Treated  42.71 ± 0.42 42.71 ± 0.79 42.71 ± 1.05 
(ms) Non-treated  42.78 ± 0.48 43.05 ± 0.48 41.94 ± 1.27 
R3 N1P1 amplitude Treated  29.58 ± 4.78 28.75 ± 5.91 36.25 ± 7.18 
(nV/deg
2
) Non-treated  30.00 ± 0.94 26.00 ± 1.73 31.00 ± 2.00 
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Table 6.24 continued. 
      
  Visit 1 ARM Visit 2 ARM Visit 3 ARM 
  Mean ± SD Mean ± SD Mean ± SD 
R4 N1 latency Treated  15.00 ± 0.00  15.21 ± 0.42 15.83 ± 1.17 
(ms) Non-treated  15.56 ± 1.27 15.28 ± 1.27 15.84 ± 1.44 
R4 P1 latency Treated  29.38 ± 0.80 29.79 ± 0.79 29.17 ± 0.00 
(ms) Non-treated  29.44 ± 0.96 29.72 ± 1.27 29.72 ± 1.27 
R4 N2 latency Treated  42.29 ± 0.42 43.13 ± 0.80 43.13 ± 1.42 
(ms) Non-treated  42.78 ± 2.10 43.33 ± 0.84  43.33 ± 1.67 
R4 N1P1 amplitude Treated  19.94 ± 4.17 19.25 ± 2.50 25.25 ± 4.50 
(nV/deg
2
) Non-treated  19.48 ± 0.48 17.33 ± 2.31 20.00 ± 2.00 
R5 N1 latency Treated  15.63 ± 0.80 15.21 ± 0.79 16.04 ± 1.05 
(ms) Non-treated  15.28 ± 0.48 15.00 ± 0.83 15.83 ± 0.84 
R5 P1 latency Treated  30.21 ± 1.43 30.63 ± 1.25 29.59 ± 0.48 
(ms) Non-treated  31.67 ± 1.44 30.56 ± 1.93 30.28 ± 2.41 
R5 N2 latency Treated  43.33 ± 1.80 43.34 ± 0.96 43.33 ± 0.68 
(ms) Non-treated  43.33 ± 0.84 43.05 ± 0.48 43.33 ± 1.67 
R5 N1P1 amplitude Treated  12.08 ± 2.70 12.50 ± 3.42 15.50 ± 2.65 
(nV/deg
2
) Non-treated  12.75 ± 1.69 11.67 ± 3.21 12.67 ± 2.08 
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Table 6.25: Paired-samples t-tests analysing mfERG measures in 8 ARM treated eyes between 
visit 1 and visit 3. The shaded areas indicate statistical significance. 
Visit 1 and 3 mfERG t p 
Ring 1 N1 latency 1.000 .350 
Ring 1 P1 latency -.513 .624 
Ring 1 N2 latency -.241 .817 
Ring 1 amplitude -.897 .399 
Ring 2 N1 latency .799 .451 
Ring 2 P1 latency -.148 .887 
Ring 2 N2 latency -1.819 .112 
Ring 2 amplitude -.318 .760 
Ring 3 N1 latency .753 .476 
Ring 3 P1 latency -.595 .570 
Ring 3 N2 latency -.801 .449 
Ring 3 amplitude -2.787 .027 
Ring 4 N1 latency -1.488 .180 
Ring 4 P1 latency -.757 .474 
Ring 4 N2 latency -1.985 .088 
Ring 4 amplitude -2.271 .057 
Ring 5 N1 latency -1.420 .199 
Ring 5 P1 latency -.142 .891 
Ring 5 N2 latency -1.221 .262 
Ring 5 amplitude -1.081 .316 
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Table 6.26: Independent-samples t-tests for differences between mfERG measures between 
visits 1 and 3 for treated and non-treated eyes. The shaded areas indicate statistical significance. 
Visit 1 and 3 mfERG t p 
Ring 1 N1 latency 0.299  0.770 
Ring 1 P1 latency -0.543 0.598 
Ring 1 N2 latency 1.226 0.246 
Ring 1 amplitude 0.265 0.796 
Ring 2 N1 latency 1.006 0.336 
Ring 2 P1 latency -0.086 0.933 
Ring 2 N2 latency 0.526 0.610 
Ring 2 amplitude -0.017 0.987 
Ring 3 N1 latency -2.970 0.013 
Ring 3 P1 latency -0.959 0.358 
Ring 3 N2 latency 0.146 0.886 
Ring 3 amplitude -0.498 0.628 
Ring 4 N1 latency -0.838 0.420 
Ring 4 P1 latency -0.347 0.735 
Ring 4 N2 latency -0.590 0.567 
Ring 4 amplitude -0.190 0.853  
Ring 5 N1 latency -1.069 0.336 
Ring 5 P1 latency -0.853  0.412 
Ring 5 N2 latency -0.593 0.565 
Ring 5 amplitude -0.034 0.973 
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Table 6.27: Mixed between-within ANOVA for VA, CS and MPOD over three visits between 
treated and non treated groups in ARM eyes. 
Outcome measure Main effect: time Main effect: group 
(treated/non-treated) 
Interaction effect 
 F p F p F p 
VA 0.564 0.584 0.843 0.377 0.174 0.843 
 CS 1.444 0.277 0.392 0.543 2.463 0.131 
 MPOD 1.383 0.291 1.395 0.260 0.519 0.609 
 
 
Table 6.28 Mean values ± SD between treated and non-treated ARM eyes for VA, CS and 
MPOD over 3 visits. 
 Visit 1 ARM Visit 2 ARM Visit 3 ARM 
 Mean ± SD Mean ± SD Mean ± SD 
                                                   VA (logMAR units) 
Treated  0.06 ± 0.08  0.07 ± 0.08 0.05 ± 0.10 
Non-treated  0.03 ± 0.02 0.06 ± 0.03 0.03 ± 0.08 
                                                   CS (log units) 
Treated  1.76 ± 0.16 1.69 ± 0.11 1.80 ± 0.16 
Non-treated  1.75 ± 0.15 1.70 ± 0.12  1.68 ± 0.15 
                                                MPOD (optical density units) 
Treated  0.36 ± 0.19 0.44 ± 0.20 0.39 ± 0.22 
Non-treated  0.52 ± 0.32 0.59 ± 0.18 0.48 ± 0.23 
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Table 6.29: ARM treated group dietary questionnaire analysis showing no difference between 
visits 1 and 3 using paired-samples t-tests. 
Dietary component t p 
Copper -1.462 0.218 
Zinc -0.949 0.396 
Vitamin E 0.264 0.805 
Vitamin C -0.914 0.413 
Retinol -1.642 0.176 
Carotene -0.330 0.758 
Lutein and zeaxanthin -1.047 0.354 
Omega 3  -0.040 0.970 
 
 
Table 6.30: ARM non-treated group dietary questionnaire analysis showing no difference 
between visits one and three using paired-samples t-tests. 
Dietary component t p 
Copper 0.794 0.485 
Zinc 0.406 0.712 
Vitamin E 0.783 0.491 
Vitamin C 0.797 0.483 
Retinol 0.260 0.812 
Carotene -0.182 0.867 
Lutein and zeaxanthin 0.565 0.611 
Omega 3  -0.501 0.651 
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Appendix 12 – Withdrawal results tables 
 
Table 7.1:  A summary of the change in each mfERG outcome measure for the HO group 
between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. Shaded areas 
show statistical significance. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
Ring 1 N1 latency (ms) 15.42 ± 1.09 15.73 ± 1.37 t = -0.436 0.676 
Ring 1 P1 latency (ms) 29.90 ± 1.13 28.79 ± 1.07 Z = -0.544 0.586 
Ring 1 N2 latency (ms) 44.69 ± 1.09 44.79 ± 1.88 t = -0.152 0.884 
Ring 1 N1P1 amplitude (nV/deg
2
) 151.38 ± 26.20 124.88 ± 29.33 t = 2.411 0.047 
Ring 2 N1 latency (ms) 15.00 ± 0.89 14.90 ± 1.04 Z = -0.414 0.679 
Ring 2 P1 latency (ms) 28.85 ± 1.17 28.33 ± 1.67 t = 1.174 0.279 
Ring 2 N2 latency (ms) 43.65 ± 1.17  43.54 ± 1.39 Z = -0.213 0.832 
Ring 2 N1P1 amplitude (nV/deg
2
) 60.50 ± 9.71 53.00 ± 9.13 t = 2.243 0.060 
Ring 3 N1 latency (ms) 15.52 ± 0.76 15.10 ± 0.53 Z = -1.000 0.317 
Ring 3 P1 latency (ms)  29.06 ± 1.50 29.17 ± 1.18 t =  -0.317 0.760 
Ring 3 N2 latency (ms)  43.13 ± 1.24 42.92 ± 0.77 t = 0.805 0.447 
Ring 3 N1P1 amplitude (nV/deg
2
) 35.75 ± 6.41 31.00 ± 7.25 t = 1.952 0.092 
Ring 4 N1 latency (ms)  15.52 ± 0.62 15.21 ± 0.86 Z = -0.530 0.596 
Ring 4 P1 latency (ms) 29.48 ± 0.88 29.90 ± 1.04 t = -1.183 0.275 
Ring 4 N2 latency (ms)  43.44 ± 1.22 42.81 ± 1.08 t = 1.657 0.141 
Ring 4 N1P1 amplitude (nV/deg
2
) 25.87 ±  5.69 22.50 ± 6.46 t =  1.863 0.105 
Ring 5 N1 latency (ms) 15.52 ± 0.62 15.52 ± 0.62 Z = 0.000 1.000 
Ring 5 P1 latency (ms) 29.70 ± 0.97 29.69 ± 0.76 Z = -0.137 0.891 
Ring 5 N2 latency (ms) 43.44 ± 0.94 43.33 ± 1.26  t =  0.244 0.814 
Ring 5 N1P1 amplitude (nV/deg
2
) 15.63 ± 4.44 14.75 ± 3.96 t = 0.665 0.527 
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Table 7.2:  A summary of the change in subjective outcome measures for the HO group between 
visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
 VA (logMAR units)  -0.06 ± 0.09  -0.02 ± 0.06 Z = -1.247 0.212 
 CS (log units) 1.80 ± 0.16 1.80 ± 0.16 Z = 0.000 1.000 
 MPOD (optical density units) 0.42 ± 0.13 0.42 ± 0.16 t = 0.056 0.957 
 
 
Table 7.3:  A summary of the change in dietary outcomes for the HO group between visit 3 (40 
weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
Dietary copper (mg) 1.31 ± 0.37 1.45 ± 0.66 t = -0.229 0.840 
Dietary zinc (mg) 9.27 ± 1.21 10.87 ± 1.16 t = -1.391 0.299 
Dietary retinol (µg) 350.00 ± 114.67 420 ± 103.59 t = -0.962 0.437 
Dietary carotene (µg) 1641.00 ± 1179.75 1880.67 ± 1099.55 Z = 0.000 1.000 
Dietary Vitamin E 
(mg) 
8.86 ± 5.56 7.13 ± 3.60 t = 0.461 0.690 
Dietary Vitamin C 
(mg) 
120.33 ± 64.03 114.00 ± 29.51 t =  0.152 0.893 
Dietary lutein and 
zeaxanthin (µg) 
1843.98 ± 996.67 1386.11 ± 669.07 t = 1.785 0.216 
Dietary Omega 3 (g) 0.21 ± 0.27 0.97 ± 0.44 t = -3.827 0.062 
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Table 7.4:  A summary of the change in each mfERG outcome measure for the HY group 
between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. Shaded areas 
show statistical significance. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
Ring 1 N1 latency (ms) 14.63 ± 1.03 15.55 ± 1.02 t = -1.752 0.118 
Ring 1 P1 latency (ms) 28.70 ± 1.03 28.33 ± 1.61 t = 0.594 0.569 
Ring 1 N2 latency (ms) 44.07 ± 1.21 43.33 ± 2.24 t = 0.948 0.371 
Ring 1 N1P1 amplitude (nV/deg
2
) 179.00 ± 29.00 165.11 ± 35.71 t = 1.060 0.320 
Ring 2 N1 latency (ms) 15.00 ± 1.02 14.44 ± 1.02 t = 1.206  0.262 
Ring 2 P1 latency (ms) 27.04 ± 1.11 27.50 ± 1.56 t = -0.679 0.516 
Ring 2 N2 latency (ms) 42.50 ± 1.25  41.85 ± 1.30 t = 1.075 0.314 
Ring 2 N1P1 amplitude (nV/deg
2
) 68.89 ± 10.14 62.33 ± 16.31 t = 1.485 0.176 
Ring 3 N1 latency (ms) 15.00 ± 0.72 14.72 ± 0.72 Z = -0.966 0.334 
Ring 3 P1 latency (ms) 28.06 ± 1.38 27.22 ± 1.32 Z = -1.975 0.048 
Ring 3 N2 latency (ms) 41.67 ± 0.83 41.48 ± 0.70 Z = -1.300 0.194 
Ring 3 N1P1 amplitude (nV/deg
2
) 39.56 ± 6.11 36.89 ± 10.81 t = 1.055 0.322 
Ring 4 N1 latency (ms)  14.91 ± 0.77 15.09 ± 0.50 Z = -0.707 0.480 
Ring 4 P1 latency (ms) 28.06 ± 1.18 28.43 ± 0.78 Z = -1.511 0.131 
Ring 4 N2 latency (ms) 41.85 ± 0.70 41.76 ± 1.28 Z = -0.333 0.739 
Ring 4 N1P1 amplitude (nV/deg
2
) 25.44 ±  3.61 24.11 ± 5.97 t = 0.669  0.522 
Ring 5 N1 latency (ms) 14.72 ± 0.93 14.91 ± 0.65 t = -0.390 0.707 
Ring 5 P1 latency (ms) 28.70 ± 1.11 27.97 ± 1.27 t = 2.198 0.059 
Ring 5 N2 latency (ms) 42.41 ± 0.97 41.95 ± 0.59  Z = -1.035 0.301 
Ring 5 N1P1 amplitude (nV/deg
2
) 16.67 ± 2.83 15.56 ± 3.81 Z = -1.053  0.292 
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Table 7.5:  A summary of the change in subjective outcome measures for the HY group between 
visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
 VA (logMAR units)  -0.14 ± 0.05  -0.14 ± 0.05 t = -0.223 0.828 
 CS (log units) 1.95 ± 0.00 1.95 ± 0.00 Z = 0.000 1.000 
 MPOD (optical density units) 0.44 ± 0.05 0.44 ± 0.05 Z = 0.061 0.952 
 
 
Table 7.6:  A summary of the change in dietary outcomes for the HY group between visit 3 (40 
weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test statistic p 
Dietary copper 
(mg) 
 0.90 ± 0.13 0.75 ± 0.00 Z = -1.342 0.180 
Dietary zinc (mg) 9.80 ± 0.28 7.3 ± 0.00 Z = -1.342 0.180 
Dietary retinol (µg) 357.00 ± 12.73 298.50 ± 3.54 Z = -1.342 0.180 
Dietary carotene 
(µg) 
1705.50 ± 191.63 2582.00 ± 9.90 Z = -1.342 0.180 
Dietary Vitamin E 
(mg) 
2.79 ± 0.45 3.40 ± 0.22 Z = -1.342 0.180 
Dietary Vitamin C 
(mg) 
39.50 ± 4.95 58.50 ± 3.54 Z = -1.342 0.180 
Dietary lutein and 
zeaxanthin (µg) 
1035.74 ± 566.43 1116.02 ± 34.87 Z = -0.447 0.655 
Dietary Omega 3 
(g) 
0.24 ± 0.05 0.41 ± 0.00 Z = -1.342 0.180 
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Table 7.7:  A summary of the change in each mfERG outcome measure for the HY and HO 
groups combined between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement 
withdrawal. Shaded areas show statistical significance. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test statistic p 
Ring 1 N1 latency (ms) 15.00 ± 1.10 15.64 ± 1.16 t = -1.476 0.159 
Ring 1 P1 latency (ms) 29.27 ± 1.21 29.02 ± 1.54 t = 0.621 0.544 
Ring 1 N2 latency (ms) 44.36 ± 1.16 44.02 ± 2.15 t = 0.674 0.510 
Ring 1 N1P1 amplitude (nV/deg
2
) 166.00 ± 30.37 146.18 ± 37.98 t = 2.323 0.034 
Ring 2 N1 latency (ms) 15.00 ± 0.93 14.66 ± 1.02 t =  1.166 0.261 
Ring 2 P1 latency (ms) 27.89 ± 1.45 27.89 ± 1.62 t = 0.000 1.000 
Ring 2 N2 latency (ms) 43.04 ± 1.32  42.65 ± 1.57 t = 0.926 0.368 
Ring 2 N1P1 amplitude (nV/deg
2
) 64.94 ± 10.55 57.94 ± 13.88 t = 2.561 0.021 
Ring 3 N1 latency (ms) 15.24 ± 0.76 14.90 ± 0.65 Z = -1.393 0.163 
Ring 3 P1 latency (ms) 28.53 ± 1.49  28.14 ± 1.57 Z = -1.244 0.214 
Ring 3 N2 latency (ms)  42.35 ± 1.26  42.16 ± 1.02 Z = -1.786 0.074 
Ring 3 N1P1 amplitude (nV/deg
2
) 37.76 ± 6.40 34.12 ± 9.52 t = 2.114 0.051 
Ring 4 N1 latency (ms) 15.20 ± 0.75 15.15 ± 0.67 Z = -0.100 0.921 
Ring 4 P1 latency (ms) 28.73 ± 1.18 29.12 ± 1.16 Z = -1.756 0.079 
Ring 4 N2 latency (ms) 42.60 ± 1.25 42.26 ± 1.28 Z = -1.372 0.170 
Ring 4 N1P1 amplitude (nV/deg
2
) 25.65 ±  4.55 23.35 ± 6.06 t = 1.714 0.106 
Ring 5 N1 latency (ms) 15.10 ± 0.88 15.20 ± 0.69 t = -0.335 0.742 
Ring 5 P1 latency (ms) 29.21 ± 1.16 28.78 ± 1.36 t = 1.730 0.103 
Ring 5 N2 latency (ms) 42.89 ± 1.07  42.60 ± 1.17 Z = -0.884 0.376 
Ring 5 N1P1 amplitude (nV/deg
2
) 16.18 ± 3.59  15.18 ± 3.78 Z = -1.071 0.284 
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Table 7.8:  A summary of the change in subjective outcome measures for the HY and HO 
groups combined between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement 
withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test statistic p 
 VA (logMAR units)  -0.10 ± 0.08  -0.08 ± 0.08 t = -1.466 0.157 
 CS (log units) 1.88 ± 0.00 1.88 ± 0.00 Z = 0.000 1.000 
 MPOD (optical density units) 0.43 ± 0.11 0.44 ± 0.14 Z = -0.201 0.840 
 
 
Table 7.9:  A summary of the change in dietary outcomes for the HY and HO groups combined 
between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test statistic p 
Dietary copper 
(mg) 
 1.15 ± 0.35 1.17 ± 0.60 Z = -0.674 0.500 
Dietary zinc (mg) 9.48 ± 0.91 9.44 ± 2.42 t = 0.034 0.975 
Dietary retinol 
(µg) 
352.80 ± 81.42 371.40 ± 98.98 t = -0.365 0.733 
Dietary carotene 
(µg) 
1666.80 ± 840.44 2161.20 ± 867.23 t = -.956 0.393 
Dietary Vitamin E 
(mg) 
6.43 ± 5.16 5.63 ± 3.27 t =  0.372 0.729 
Dietary Vitamin C 
(mg) 
88.00 ± 63.38 91.80 ± 36.91 t = -0.160 0.880 
Dietary lutein and 
zeaxanthin (µg) 
1520.69 ± 879.13 1278.07 ± 496.00 t = 1.033 0.360 
Dietary Omega 3 
(g) 
0.22 ± 0.19 0.75 ± 0.44 t = -2.918 0.043 
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Table 7.10:  A summary of the change in each mfERG outcome measure for the ARM group 
between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. Shaded areas 
show statistical significance. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
Ring 1 N1 latency (ms) 15.63 ± 1.32 15.49 ± 0.41 Z = -0.594 0.553 
Ring 1 P1 latency (ms) 29.86 ± 2.34 30.31 ± 1.26 Z = -0.853 0.394 
Ring 1 N2 latency (ms) 43.86 ± 2.04 44.13 ± 2.14 t = -2.084 0.076 
Ring 1 N1P1 amplitude (nV/deg
2
) 123.00 ± 29.94 107.88 ± 27.38 t = 1.191 0.272 
Ring 2 N1 latency (ms) 15.10 ± 1.21 15.52 ± 0.62 Z = -0.750 0.453 
Ring 2 P1 latency (ms) 28.23 ± 1.37 29.38 ± 1.88 t = -2.201 0.064 
Ring 2 N2 latency (ms) 43.54 ± 1.53  44.04 ± 0.67 t =  -0.810 0.444 
Ring 2 N1P1 amplitude (nV/deg
2
) 47.50 ± 11.26 50.00 ± 7.71 t = -0.514 0.623 
Ring 3 N1 latency (ms) 15.42 ± 1.00 15.73 ± 0.94 t = -0.708 0.502 
Ring 3 P1 latency (ms) 28.64 ± 1.41  28.75 ± 1.41 Z = -0.677 0.498 
Ring 3 N2 latency (ms) 42.61 ± 0.94  43.33 ± 0.77 t = -2.496 0.041 
Ring 3 N1P1 amplitude (nV/deg
2
) 32.25 ± 8.66 29.63 ± 3.66 t = 1.050 0.329 
Ring 4 N1 latency (ms) 15.73 ± 0.83 15.24 ± 0.86 Z = -1.033 0.302 
Ring 4 P1 latency (ms) 29.06 ± 0.54 29.90 ± 0.69 Z = -2.414 0.016 
Ring 4 N2 latency (ms) 43.13 ± 1.16 43.44 ± 1.21 t = -1.002 0.350 
Ring 4 N1P1 amplitude (nV/deg
2
) 22.00 ±  6.02 20.75 ± 3.20 t = 0.610 0.561 
Ring 5 N1 latency (ms) 16.04 ± 0.86 16.00 ± 0.71 Z = -0.141 0.888 
Ring 5 P1 latency (ms) 30.00 ± 1.18 29.90 ± 1.13 t = 0.160 0.878 
Ring 5 N2 latency (ms) 43.75 ± 1.09  43.65 ± 0.99 t = 0.206 0.842 
Ring 5 N1P1 amplitude (nV/deg
2
) 12.63 ± 3.66  12.88 ± 2.36 t = -0.251 0.809 
 
 
 
 
 257 
 
Table 7.11:  A summary of the change in subjective outcome measures for the ARM group 
between visit 3 (40 weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test 
statistic 
p 
 VA (logMAR units)  -0.10 ± 0.08  -0.08 ± 0.08 t = -0.060 0.954 
 CS (log units) 1.80 ± 0.16 1.73 ± 0.14 Z = -0.980 0.327 
 MPOD (optical density units) 0.40 ± 0.24 0.47 ± 0.20 t = -0.606 0.567 
 
 
Table 7.12:  A summary of the change in dietary outcomes for the ARM group between visit 3 
(40 weeks) and visit 4 (60 weeks) during supplement withdrawal. 
 Visit 3 
(mean ± SD) 
Visit 4 
(mean ± SD) 
Test statistic p 
Dietary copper 
(mg) 
 2.58 ± 1.89 0.91 ± 0.23 Z = -1.069 0.285 
Dietary zinc (mg) 7.93 ± 3.41 9.40 ± 2.15 t = -1.257 0.336 
Dietary retinol 
(µg) 
3309.33 ± 3001.13 260.33 ± 59.00 t =  1.779 0.217 
Dietary carotene 
(µg) 
3200.33 ± 2149.15 2607.33 ± 851.27 t = 0.635 0.591 
Dietary Vitamin E 
(mg) 
5.20 ± 0.87 4.36 ± 1.65 t =  0.973 0.433 
Dietary Vitamin 
C (mg) 
176.00 ± 19.67 149.33 ± 43.02 t = 1.648 0.241 
Dietary lutein and 
zeaxanthin (µg) 
2840.22 ± 2332.53 2304.62 ± 1247.67 t = 0.435 0.706 
Dietary Omega 3 
(g) 
0.07 ± 0.05 0.03 ± 0.06 Z = -0.816 0.414 
 
 
 
 
